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Resumen 1
I. Resumen
La célula, como estructura anatómica y funcional fundamental de la materia
viva, necesita llevar a cabo funciones esenciales para la supervivencia y el
desarrollo. Cualquier ambigüedad o tendencia a alejarse de su objetivo produce
graves efectos tanto en la célula como en el organismo del que forma parte. Por
esta razón, para el correcto funcionamiento y desarrollo a nivel uni y pluricelular, se
requiere de un control riguroso de la morfología, el crecimiento y la homeostasis
celulares. Todo ello depende de la estricta regulación de las respuestas a estímulos
extracelulares que modulan el nivel de activación celular.
La unión de factores o ligandos extracelulares a sus receptores provocan un
amplio repertorio de complejos multiproteicos altamente dinámicos. De esta forma,
la señal se amplifica y se traduce en cambios en el proteoma y el genoma celulares.
La mayoría de receptores de membrana producen señales positivas, y la
alteración de la intensidad y de la duración de estas señales provoca cambios en
las funciones de la célula. Para asegurar que se alcanzan y mantienen unos niveles
adecuados de señalización, las células han desarrollado mecanismos específicos
de señalización negativa.
Con el objetivo de atenuar rápidamente la transmisión de señales a la
célula, se produce una serie compleja de eventos en cadena. La naturaleza ha
desarrollado un mecanismo efectivo para asegurar de manera rápida y eficaz la
terminación de señales mediante la insensibilización a estímulos externos. Para
ello, se lleva a cabo la internalización de los receptores de membrana encargados
de transmitir las señales del exterior al interior de la célula.
El factor de crecimiento epidérmico EGF (del inglés: Epidermal Growth
Factor) y su receptor EGFR han sido identificados como componentes clave del
proceso de crecimiento y replicación celulares. El aumento en actividad del receptor
EGFR se ha visto directamente implicado en una serie de tumores sólidos como el
cáncer de colon, de mama, gástrico y ovárico. La unión de EGF al receptor EGFR
da lugar a su activación inicial y consecuente supresión tras una rápida eliminación
de la superficie celular mediante vesículas envueltas de clatrina. El estudio de este
proceso endocítico que modula la transducción de señales vía EGFR podría ofrece
nuevas oportunidades terapéuticas y elucidar mecanismos que contribuyan a la
eficacia de los tratamientos antitumorales existentes.
Para llevar a cabo la endocitosis del receptor, se requiere de la formación
de un complejo compuesto por endofilinas, la ligasa de ubiquitina Cbl y la proteína
adaptadora CIN85. Las proteinas Cbl conforman una familia ligasas de ubiquitina
que unen a receptores de membrana entre los cuales se encuentra el EGFR, y está
compuesta en mamíferos por c-Cbl o Cbl propiamente dicho, Cbl-b y Cbl-3. Por otro
lado, las moléculas adaptadoras son polipéptidos generalmente no catalíticos que
contienen uno o más dominios capaces de unir a otros ligandos tanto proteicos
como no proteicos. Estas moléculas controlan de manera selectiva el ensamblaje
espacial y temporal de complejos multiproteicos que transmiten señales
intracelulares involucradas en la regulación del crecimiento, la diferenciación, la
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migración y la supervivencia celulares. CIN85, junto con su homólogo CMS,
pertenece a una familia de moléculas adaptadoras que contienen tres dominios
SH3, una región rica en prolinas y un dominio coiled-coil.
La proteína adaptadora CIN85 interacciona con Cbl mediante la unión de
dominios SH3 (Src homology 3) a la región carboxi-terminal de Cbl. Todos los
dominios SH3 comparten un plegamiento conservado, en una conformación de
sandwich o barril-β constituido por dos láminas-β antiparalelas. Dentro de esta
estructura se encuentran dos lazos o loops variables, conocidos por lazos RT y n-
Src. Una de las caras de este sandwich contiene una superficie de unión al ligando
relativamente plana y de carácter hidrofóbico, que consta de 3 bolsillos poco
profundos definidos por residuos aromáticos conservados. Los dominios SH3
reconocen generalmente ligandos ricos en prolinas, de secuencia consenso PxxP.
Los grupos xP del motivo ocupan dos de los bolsillos hidrofóbicos formados por
residuos conservados en la mayoría de los SH3. Existe un tercer bolsillo de unión el
cual puede hospedar a una cadena lateral cargada positivamente, generalmente
arginina o lisina, que flanquea el motivo de unión.
El ligando adopta una conformación helicoidal levógira extendida
denominada como hélice poliprolina-2 (o PPII). El reconocimiento de esta estructura
se consigue por la inserción de los extremos de la hélice PPII en pares de surcos
complementarios en la superficie del SH3. Estos surcos se definen por una serie de
residuos aromáticos conservados dispuestos de manera casi paralela.
Dependiendo de su orientación relativa respecto al complejo que formen
con el dominio SH3, los ligandos de poliprolinas han sido clasificados como clase I
o clase II. Los ligandos de clase I se unen con su extremo amino terminal al
denominado lazo RT del dominio SH3, mientras que los ligandos de clase II se unen
con su extremo carboxilo terminal al lazo RT. Los péptidos que se unen en una
orientación de tipo I se ajustan al consenso +xφPxφP (clase I) (donde por lo general
+ es un residuo básico y φ es un residuo hidrofóbico), mientras que los péptidos que
se caracterizan por φPxφPx+ unen en la orientación opuesta. Sin embargo, la gran
cantidad de dominios SH3 identificados hasta la fecha, ha permitido el amplio
estudio de su diversidad estructural y funcional, seguramente por lo que se ha
podido identificar varios motivos de unión que no corresponden al consenso.
Se ha determinado en Cbl una región mínima de unión a CIN85 ausente en
Cbl-3. La unión de CIN85 a Cbl/Cbl-b parece estar mediada de forma independiente
a motivos PxxP, siendo en este caso el motivo de reconocimiento un nuevo motivo
poliprolina-arginina (PxxxPR), ya que las mutaciones de todas las secuencias PxxP
presentes en la región C-terminal del dominio mínimo de unión no impedían la unión
a CIN85.
Con la resolución de la estructura del primer dominio SH3 de CIN85
(CIN85-SH3A) en complejo con un péptido derivado de la secuencia natural de Cbl-
b que incluye el motivo atípico de unión PxxxPR, se ha puesto de manifiesto un
novedoso tipo de reconocimiento para esta clase de dominios. El complejo muestra
una estructura heterotrimérica compuesta de dos dominios SH3 unidos
simultáneamente al mismo péptido en orientaciones opuestas. El estudio estructural
de dicho complejo ternario permitió identificar residuos fundamentales para tanto la
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formación del heterotrímero como para la endocitosis y degradación del receptor
EGFR. Este tipo de reconocimiento supone un nivel inesperado de oligomerización
necesario para la regulación negativa del receptor.
Además, se ha podido resolver la estructura del SH3 homólogo en el
adaptador de la misma familia, CMS, en complejo con el mismo péptido derivado de
Cbl-b. Esto ha permitido revelar que la formación de un heterotrímero, similar en
líneas generales, supone un reconocimiento específico del motivo de unión
diferente al que ocurre en CIN85. El análisis detallado de las interacciones
esenciales para la formación de dichos complejos triméricos, muestra diferentes
residuos fundamentales en Cbl-b si la unión es a CIN85 o a CMS.
Estos hallazgos han permitido predecir el modo de unión a otros ligandos
naturales de CIN85. La resolución del complejo del mismo dominio SH3 unido a un
péptido derivado de CD2, confirmó aquellos residuos necesarios para la
heterotrimerización, los cuales habían sido identificados previamente en el complejo
con Cbl-b.
Asímismo, en el presente estudio se pretende descifrar las características
esenciales que modulan este tipo de reconocimiento mediante un estudio
comparativo con estructuras similares resueltas posteriormente.

INTRODUCTION
“The real purpose of introductions, of course, is to cite your own work, the work of
your advisor, the work of your spouse, the work of a friend from college, or even the
work of someone you've never met, as long as your name happens to be on the
paper.”
E. R. Schulman
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II. Introduction
Cells, as the smallest metabolically functional unit of life, need to perform
essential functions for survival and development. “Cells are required to stick
precisely to the point. Any ambiguity, any tendency to wander from the matter at
hand, will introduce grave hazards for the cells, and even more for the host in which
they live” (Lewis Thomas) (Thomas 1974).
Therefore, a rigorous control of cell morphology, growth and homeostasis, is
vital for a correct function and development of tissues in multicellular organisms, and
this depends on a very stringent regulation of responses to extracellular signals that
modulate the level of cell activation. As a result of the binding of extracellular factors
or ligands to their specific receptors, the formation of a broad repertoire of highly
dynamic protein complexes takes place. The signal is thus amplified and translated
into changes in the cellular proteome and genome (Crosetto, Tikkanen et al. 2005).
Most of the plasma membrane receptors elicit positive signals, and
variations in the strength and duration of such signals convey different instructions to
the cell. To ensure that proper signal thresholds are reached and maintained for the
appropriate length of time, cells have developed specific negative signaling
mechanisms. A delicate balance between positive and negative signals needs to be
established and its deregulation is often implicated in the development of human
diseases. An excess of positive signals that lead to excessive cell stimulation is
found in cancers and autoimmune diseases, whereas dominance of negative signals
is associated with various immune deficiencies (Dikic and Giordano 2003).
Consequently, regulation of signal activation and inactivation plays a critical role in
cell survival and development.
In order to attenuate the signal transmission, a number of highly complex
chains of events need to occur in the cell. Negative signaling can take place
transiently by regulating the strength and duration of the signal through multiple
mechanisms such as steric hindrance, effector compartmentalization,
posttranslational modifications (PTMs) or inhibition of catalytic activity (Dikic and
Giordano 2003). However, when the signal needs to be promptly blocked, the signal
inhibition must be irreversible.
Nature has consequently evolved a clever mechanism that ensures a rapid
signal termination of transmembrane-receptor-triggered signal transduction.
Membrane proteins cannot be redistributed in the cytosol, so that their internalization
and posterior degradation are necessary for the regulation of their quantity present
in the cellular membrane. Thus, to achieve prolonged cell desensitization to external
stimuli, such as growth factors, endocytosis of cellular receptors takes place, and
internalized receptors are then recycled or degraded.
8 Introduction
1. Epidermal Growth Factor Receptor (EGFR)
negative regulation
The Epidermal Growth Factor Receptor (EGFR) belongs to the family of
Receptor Tyrosine Kinases (RTKs) and, together with its natural ligand (the
Epidermal Growth Factor, EGF) has been identified as a key component of a wide
variety of important biological processes, such as cell proliferation, differentiation,
survival, migration, adhesion or apoptosis (Aaronson 1991; Schlessinger 2002; Dikic
2003).
As mentioned above, excessive cell stimulation by a prevalence of positive
signals leads to cancer and autoimmune diseases. Constitutive activation of
Receptor Tyrosine Kinases (RTKs) can take place by several mechanisms, among
which are gene amplification, overexpression, chromosomal translocation or
mutations (Finkel 2003; Normanno, De Luca et al. 2006). Therefore, it is not
surprising that overexpression of EGFR is frequently found in colon, breast, bladder,
cervical, ovarian, kidney, pancreatic and non-small cell lung cancer and it occurs
with very high incidence in squamous cell carcinomas of the head and neck
(Salomon, Brandt et al. 1995; Blume-Jensen and Hunter 2001; Schlessinger 2002;
Finkel 2003; Normanno, De Luca et al. 2006). Mutations that activate the kinase
activity of EGFR in the absence of ligand binding are as well often the main cause of
tumorigenic changes in EGFR activity (Finkel 2003). The best characterized EGFR
mutation is EFGRvIII, which includes deletions of exons 2 to 7 with consequent loss
of residues 6 to 276. Such mutation bears a constitutively active receptor that is not
regulated by endocitosis and is highly oncogenic (Nishikawa, Ji et al. 1994).
The establishment in 1984 of the relation between human cancer and the
viral oncogene v-Erb-B, a constitutively active truncated mutant of Erb2 (an EGFR
paralog), shed light to the knowledge that regulation of growth factor receptor
activation is crucial to avoid aberrant signaling critically involved in human
neoplasias (Downward, Yarden et al. 1984). Therefore, development of tyrosine
kinase inhibitors directed against EGFR have been widely sought and used for
treatment of certain cancers as advanced non-small-cell lung cancer (NSCLC) and
other aerodigestive carcinomas (ADCs), the leading cause of cancer related death
worldwide (Giaccone and Rodriguez 2005; Karamouzis, Grandis et al. 2007).
Down-regulation of EGFR, is hence a critical step in modulating receptor
activity. It has been shown that interruption of receptor endocytosis alters duration
and specificity of events that take place in this process and it has been proposed
that breakdowns in this process might be as well of oncogenic character (Peschard
and Park 2003; Crosetto, Tikkanen et al. 2005). Therefore, the study of the nature of
events that ensure a proper modulation of duration, specificity and strength of
receptor signal transduction stands out as a good target for cancer treatment.
This receptor down-regulation is mediated by endocytosis, receptor
ubiquitination, and subsequent lysosomal degradation (Waterman and Yarden
2001). Key to this endocytosis is the formation of large protein complexes (Dikic and
Giordano 2003) capable of removing activated receptors from the plasma
membrane via clathrin-dependent or -independent pathways (Vieira, Lamaze et al.
1996; Soubeyran, Kowanetz et al. 2002; Bonifacino and Traub 2003; Szymkiewicz,
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Shupliakov et al. 2004; Le Roy and Wrana 2005; Sigismund, Woelk et al. 2005). In
this process, c-Cbl and Cbl-b proteins play a crucial role by acting as ubiquitin
ligases as well as endocytic adaptor molecules (Sawasdikosol, Pratt et al. 2000).
Adaptor molecules are polypeptides with one or more domains able to bind
other proteic or non-proteic ligands and, in general (although not the case of Cbl
proteins), without enzymatic activity. They have the capability to connect proteins to
other proteins, to the plasma membrane or to intracellular organelles. This is how
large signaling multimeric complexes are formed, localizing signaling molecules to
specific subcellular localizations, and hence contributing to the specificity and
efficiency of cellular responses in a spatiotemporal manner (Pawson 2002; Csiszar
2006).
The same adaptors can act at different levels in different signalling
cascades. This requires lower numbers of molecules, saving the metabolic cost that
their delivery would suppose to the cell. More importantly, the multi-tasking capacity
of adaptors allows dynamic signaling networks and integration of independent
signaling events to happen through a limited number of unique proteins.
The negative regulation of the LET-23 receptor by SLI-1 (EGFR and Cbl
orthologs in C. elegans) was the first example described of the regulation of RTKs
((Ryan, Davies et al. 2006) from (Langdon 1995)). Upon cell stimulation, Cbl
proteins get translocated to activated RTKs and act as multifunctional adaptor
proteins. As adaptors, Cbl proteins are capable of recruiting additional endocytic
regulatory proteins such as CIN85(SH3KBP1)–endophilin complexes, which
facilitate receptor endocytosis. Once the receptor is stimulated upon ligand binding
receptor homodimerization and heterodimerization with receptors from the same
family are triggered. The receptor gets phosphorylated and Cbl can then bind to
specific phosphotyrosine motifs through its SH2 domain. Subsequently, Cbl multiple
monoubiquitination of RTKs takes place and sorts the receptor-containing vesicle to
a degradation route that leads to termination of the RTK signal (Dikic 2002; Haglund,
Di Fiore et al. 2003; Haglund, Sigismund et al. 2003; Mosesson, Shtiegman et al.
2003).
Cbl proteins are polypeptides from a highly conserved family that control
multiple essential cellular processes such as cell proliferation, differentiation and cell
morphology (Dikic, Szymkiewicz et al. 2003; Schmidt and Dikic 2005). The overall
domain structure of these proteins consists of an N-terminal Tyrosin Kinase Binding
(TKB) domain, a Ring Finger motif, a Proline Rich region and a C-terminal UBiquitin
Associated (UBA) domain that overlaps with a Leucine Zipper (LZ) motif (see Figure
II.1). There are three described mammalian isoforms: Cbl-c (or Cbl-3), c-Cbl and
Cbl-b. The first one is the shortest, lacking the C-terminal UBA/LZ domain and the
CIN8/CMS binding region, and it is mainly expressed in epithelial cells. The other
two are ubiquitously expressed, and hold a high degree of identity (47.4% overall
sequence identity), however, c-Cbl contains some phosphotyrosine and
phosphoserine regulatory sites that are absent in Cbl-b (Schmidt and Dikic 2005).
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Figure II.1. Schematic representation of the domain structure of human Cbl proteins. All Cbl
proteins share a high level of sequence conservation between their Tyrosine Kinase Binding (TKB)
domain (which consists of a four-helix bundle (4H), a calcium-binding EF hand and a variant SH2
domain), their linker (L) region and RING finger (RF) domains. c-Cbl and Cbl-b have extensive Proline-
Rich Regions (PRR) in their middle section that mediate interactions with numerous SH3-domain-
containing proteins. In the C-terminus of c-Cbl and Cbl-b there is a PxxxPR motif that binds the SH3
domains from the CIN85/CMS family of adaptor proteins (residues 824-849 in c-Cbl and 906-911 in Cbl-
b). Both c-Cbl and Cbl-b ligases have a UBA domain at the C-terminus that is lacking in the short Cbl-3.
Brown rhombuses represent phosphorylation sites. Modified from (Thien and Langdon 2001).
1.1. The family of adaptor proteins CIN85/CMS
The recruitment of the adaptor molecule CIN85 by Cbl is crucial for the
initiation of the early steps of the multistep process of EGFR downregulation (Dikic
2002; Petrelli, Gilestro et al. 2002; Soubeyran, Kowanetz et al. 2002). It was shown
that inhibition of the Cbl-CIN85-endophilin interaction was sufficient to block EGFR
endocytosis without affecting the ability of Cbl to ubiquitinate activated receptors
(Soubeyran, Kowanetz et al. 2002).
A grown interest in the study of this protein has arisen with discoveries on
the implication of CIN85 in the regulation of important processes such as cell
apoptosis, cytoskeletal arquitecture or receptor down-regulation (Chen, Borinstein et
al. 2000; Narita, Amano et al. 2001).
CIN85 (Cbl-Interacting protein of 85 kDa) was identified independently in
different laboratories, and it is known with different names such as Ruk (Regulator of
ubiquitous kinase) and SETA (SH3 domain-containing gene Expressed in
Tumorigenic Astrocytes) in rat, and SH3KBP1 (SH3-domain Kinase Binding Protein
1) in mouse. Its homolog CMS (Cas ligand with Multiple SH3 domains) (Kirsch,
Georgescu et al. 1999), also known as CD2AP (CD2 Associated Protein), shares an
identical overall domain organization and high sequence identity with CIN85, and
hence, it has been assumed to belong to the same family of adaptors and elicit
similar biological functions.
Both CIN85 and CMS are ubiquitously expressed, although with slight, but
important differences in their pattern of expression. Largest CIN85 expression levels
were found in skeletal muscle, and lowest in lung and pancreas (Take, Watanabe et
al. 2000). In contrast, CMS was observed to be expressed in high levels in the
pancreas, placenta, colon, kidney and thymus, and low expression levels were
detected in skeletal muscle, the aorta, bladder and uterus (Kirsch, Georgescu et al.
1999). This might suggest an overlapping role of these proteins with a specialized
location for each of them.
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Figure II.2. Schematic representation of the domain structure of CIN85 and CMS. CIN85 and CMS
contain three N-terminal SH3 domains, a centrally located proline-rich region (PRR) and a C-terminal
coiled-coil (CC) domain. Boundaries of each domain are indicated with corresponding residue numbers.
Four phophoserine sites are shown for CIN85 (Ser156 –putative-, Ser230, Ser509 and Ser511) and a
phosphotyrosine (Tyr88) and a phosphoserine (Ser510) for CMS. FxDxF motifs and putative actin binding
sites are indicated with grey and red rhombuses, respectively.
In the domain structure prediction of both adaptors there are three Src
homology 3 (SH3) domains in the N-terminal end (SH3A, SH3B and SH3C), a
central Proline-Rich Region (PRR), and a Coiled-Coil (CC) domain at the C-terminal
end through which they are capable homo- and heterodimerizing and hence
promote clustering (see Figure II.2). A region rich in serine and threonine residues,
which could be subject to phosphorylation, lies between the second and third SH3
domains. There are also three FxDxF sequences in the amino-terminus that may
serve as binding sites for the clathrin adaptor protein AP2 (Brett, Traub et al. 2002).
The only apparent difference in CMS sequence, compared to CIN85, is the
presence of four putative actin binding sites in its carboxyl-terminus that are similar
to the LKKTET motifs found in a number of actin binding proteins (Kirsch,
Georgescu et al. 1999).
The SH3 domains of these adaptors share higher similarity among
themselves than to any other SH3 domains, suggesting that they may have
overlapping specificities in binding. However, both CIN85 and CMS have been
reported to display differential SH3 domain usage in interactions with the different
binding partners which, suggested antagonistic activities for these adaptors (Tibaldi
and Reinherz 2003).
Complex formation between CIN85 and Cbl occurs via the selective binding
of SH3 domains of CIN85 to an atypical proline-arginine motif. This atypical motif is
present in the C-terminal region of c-Cbl and Cbl-b, outside their Proline-Rich
Region (PRR), and in other CIN85 effectors such as CD2 receptors (Dustin,
Olszowy et al. 1998; Borinstein, Hyatt et al. 2000), B-cell linker protein BLNK
(Watanabe, Take et al. 2000), apoptosis regulator AIP1 (Chen, Borinstein et al.
2000) and SETA binding protein SB1 (Borinstein, Hyatt et al. 2000; Take, Watanabe
et al. 2000; Kowanetz, Szymkiewicz et al. 2003; Kurakin, Wu et al. 2003).
Interestingly, it has been reported that deletion of the C-terminal end renders Cbl
oncogenic (Lupher, Andoniou et al. 1998).
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The closest homolog of CIN85-SH3A outside of the CIN85/CMS protein
family is β-PIX, which has 52% sequence identity. Recently, β-PIX/Cool-1 has been
described as another Cbl-interacting protein that modulates EGFR downregulation18.
It was shown that activated Cdc42–PIX complexes promote sequestration of Cbl
from the EGFR and consequently block EGFR endocytosis19. The crystal structure
of β-PIX in complex with a Cbl-b derived peptide and binding experiments show that
β-PIX binds to the same proline-arginine motif in Cbl that is recognized by CIN85
and hence may compete with CIN85 for binding to Cbl.
1.2. Molecular insights into the SH3 domain-mediated
interactions
The human proteome is estimated to contain Src homology 3 (SH3)
domains spread among over 600 proteins, according to the EBI InterPro database
{http://www.ebi.ac.uk/interpro/IEntry?ac=IPR001452}, some of which bear more than
one copy of SH3 domains (as seen for CIN85 and CMS). SH3 domains bind to
proline-rich recognition sequences and are protein modules of general importance in
many signalling processes of all organisms, suggesting that they regulate basic
aspects of cellular organization.
Most SH3 domain-mediated physiological interactions are of moderate
affinities. This facilitates the rapid response to activation or attenuation of cellular
signals by the formation and dissociation of specific signaling complexes. Therefore,
most protein-protein interactions occurring in cellular signal transduction are
transient, making it a very dynamic process (Jia, Nie et al. 2005).
The first SH3 3D structure was reported in 1992 and since then, several
hundred have been solved. They are generally composed of ~60-70 amino acids in
a β-barrel structure made up of five antiparallel β-strands, (generally named βa
through βe or β1 through β5; see Figure II.3). These β-strands form two β-sheets that
pack against each other at approximately right angles. β-strandb has a torsion in the
middle of about 90º known as a β-bulge, which allows it to participate in both β-
sheets simultaneously. As a result, the first β-sheet is made up of β-strands a, e and
the first half of b, and the second is composed of β-strands c, d and the second half
of b. There are three variable loops: the RT-loop, which owes its name to its high
content in arginine and threonine residues (located between β-strands a and b); the
n-Src loop, named after the first protein in which the SH3 3D structure was
described (between β-strands b and c); and the Distal loop, which is located in the
opposite site of the ligand binding interface (between β-strands c and d). The
variability in the length of the SH3 domains results generally from insertions or
deletions in the n-Src and Distal loops. The three residues separating β-strands d
and e are generally found in a 310 helix conformation (Larson and Davidson 2000;
Kishan, Newcomer et al. 2001).
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Figure II.3. “Schematic diagram of SH3 fold. The β-strands are labeled as B1 to B5 and are color
coded (blue and green), indicating the strands separated because of swapping. The N terminus, C
terminus, RT-loop, n-src loop, and distal loop are marked; the 310-helix is labeled as H1. The conserved
residues responsible for polyproline binding are shown and labeled.” Taken from (Kishan, Newcomer et
al. 2001).
Larson and Davidson identified several positions in the amino acid
sequences of 19 SH3 domains for which the structure was available at the time
(2000) that were highly conserved and constituted the hydrophobic core that
provides the protein domains with stability. Such hydrophobic core residues are
predominantly inaccessible to the solvent, given that they are packed in the interior
of the protein. These residues correspond in the first SH3 domain of CIN85 (SH3A)
to positions 4 (usually Val), 6 (frequently Ala), 18 (Leu), 20 (generally Phe), 26 (Ile),
28 (typically Val), 37 (Trp), 39 (Gly), 48 (Phe) and 53 (Val).
This arrangement forms a relatively flat and hydrophobic surface, consisting
of one acidic and two hydrophobic shallow pockets between the two β-sheets. This
surface is involved in the recognition and binding of proline-rich motifs (Larson and
Davidson 2000; Cesareni, Panni et al. 2002; Ferreon and Hilser 2004). The majority
of SH3 domains bind to a proline-rich sequence with a φPxφP motif (more
commonly denoted PxxP), where φ is usually a hydrophobic residue and x any
residue (Mayer 2001). The ligand adopts an extended, left-handed helical
conformation termed the polyproline type II (PPII) helix. Proline residues are in trans
conformation, and the helical structure shows precisely three residues per turn
(Adzhubei and Sternberg 1993) which makes this structure roughly triangular in
cross-section, and the base of this triangle sits on the surface of the SH3 domain.
The two hydrophobic ligand-binding pockets of the SH3 domain are occupied by two
hydrophobic-proline (φP) dipeptides, whereas the acidic pocket typically interacts
with a basic residue in the ligand distal to the φPxφP core (see Figure II.4). This
basic residue binds the acidic pocket in the SH3 domain, which has been thought to
provide the binding specificity and denoted as the “specificity pocket”.
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Figure II.4. Structure and binding
mechanism of SH3 domains. The structure of
the Sem5 SH3 domain in complex with a
proline-rich ligand is shown. A cartoon of the
proline-binding surface of these domains
docked with a ligand, showing the general
mechanism of recognition, is shown below. The
core recognition surface has two xP binding
grooves formed by aromatic amino acids,
shown in yellow, and the adjacent, less
conserved specificity pocket is designated in
green.” The polyproline peptide adopts a left-
handed helical conformation of a PPII helix with
a triangular cross-section (illustrated by the
prism formed by connecting peptide residues
parallel to the helix axis). Taken from
(Zarrinpar, Bhattacharyya et al. 2003).
Proline-rich peptide ligands potentially bind a given SH3 domain in either
one of two opposite directions governed by the location of such positively charged
residue, usually Arg, which often precedes or follows the PxxP core element (Feng,
Chen et al. 1994; Lim, Richards et al. 1994). According to this, the φPxφP (or PxxP)
motif is usually further classified into +xφPxφP (class I) and φPxφPx+ (class II)
(where + is generally a basic residue, usually arginine). Thereby, the φP dipeptides
occupy different positions on the surface of the hydrophobic grooves, depending on
the orientation of the ligand: this so that, relatively to the helix axis, class I binds
conserved prolines in the motif in the same side as the basic residue, while class II
does so in the opposite side (see Figure II.5).
Introduction 15
Figure II.5. “The structures of class I and class II peptide ligands
are depicted schematically. P and R indicate conserved proline and
arginine residues; q and X indicate variable amino acids”, q being
usually a hydrophobic residue. From (Mayer and Eck 1995).
Certain positions involved in peptide binding
have been shown to be highly conserved among the SH3 domain sequences and to
play an important role in binding preference. For instance, Musacchio and co-
workers identified three amino acid substitutions in the mouse Abl SH3 domain that
reversed binding specificity towards two proline-peptides (Musacchio, Saraste et al.
1994).
Structural analyses of different SH3-peptide complexes have helped identify
certain positions in the SH3 sequences that show preference to selected amino
acids. Almost totally conserved residues involved in peptide binding are amino acids
corresponding to Pro49 and Trp36 in CIN85. Furthermore, extreme conservation
observed at position of Tyr10 in CIN85 is explained by its location at the center of
the peptide binding cleft. Residues corresponding in CIN85 to positions 8 (Phe or
Tyr (Cesareni, Panni et al. 2002)), 35 (Gly), 51 (Asn) and 52 (Phe or Tyr (Cesareni,
Panni et al. 2002)) were found to have low positional entropy values (Larson and
Davidson 2000). Moreover, residues at the RT-loop, which, together with the n-Src
loop, forms the acidic pocket, have been considered to have a role in the specificity
of the binding, and positions 16 and 17 (CIN85 Asp16 and Glu17) are usually
observed to be acidic residues (75% of the time according to Larson and Davidson’s
study) (Larson and Davidson 2000). These acidic residues typically hydrogen bond
the arginine residue in the peptide motif, and hence explains the preference for
acidic residues at this position (Musacchio, Saraste et al. 1994).
In spite of the fact that the shallow binding surface of an SH3 domain bears
certain characteristics for the accommodation of the PPII helical structure, there are
no intricate features that allow this binding surface to distinguish subtle differences
between two proline-rich sequences. As a matter of fact, it has been shown that a
given SH3 domain can interact with a few to several dozens of different peptide
ligands (Li 2005). It is common in SH3-interacting proteins to contain multiple weak
to moderate binding sites. Computational methods have indeed been developed to
identify these putative canonical SH3 domain binding sequences within proline-rich
regions of such proteins to narrow down the size of peptide libraries used for
highthroughput analysis (as the recently published web server SH3-Hunter (Ferraro,
Peluso et al. 2007)) The SH3 domain may dissociate quickly from one site and can
subsequently be recaptured by a neighboring site in the same molecule. This way,
the presence of multiple binding sites together with the capability of SH3 domains to
recognize a collection of sequence motifs, effectively increases the local
concentration of the SH3 domain and thereby promotes binding (Jia, Nie et al.
2005). Therefore, the incidence of various SH3 binding motifs in the same molecule
may be a mechanism used by the cell to regulate SH3-mediated interactions (Li
2005).
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Despite these overlapping recognition profiles, selectivity is essential in the
SH3 domain-mediated interaction networks, given that the transduction of a defined
signal from one protein to another requires a high level of integrity. Indeed, it was
shown that substitution of the SH3 domain in Sho1 by other yeast SH3 domain
avoided binding to its proline-rich target peptide in Pbs2 (Panni, Dente et al. 2002).
Differences in binding motifs containing the sequence PxxP have been shown to
offer different levels of specificity. In particular, the basic residue of the motif as well
as additional interactions outside the motif, have played an important role at
enhancing specificity in SH3 domain-mediated interactions (Zarrinpar, Park et al.
2003).
The evolution of a non-canonical recognition mechanism has offered an
alternate solution to the need of the binding diversification of SH3 domains to
achieve the required specificity. Several SH3 domains recognize non-PxxP motifs,
as it has been shown for the SH3 domains of Eps8, which recognizes PxxDY
(Mongiovi, Romano et al. 1999); Gads, which recognizes RxxK (Berry, Nash et al.
2002); or Fus1, which recognizes Arg-Ser-rich sequences (Tong, Drees et al. 2002).
“Although SH3 domains share ~30% amino acid similarity, and a common
fold, the ability to predict the peptide recognition specificity of any given SH3 domain
has been challenging” (Panni, Dente et al. 2002). Several studies have attempted to
identify particular features in the SH3 sequences that would explain their specificity
and “despite tremendous progress made in the past decade (…), this age old family
of domains continues to generate surprises” (Jia, Nie et al. 2005).
1.3. Identification of a novel CIN85/CMS SH3
interacting motif in Cbl proteins
CIN85 interaction with Cbl proteins was intriguing in that its SH3 domains
can only recognize a novel proline-arginine motif (PxxxPR) present in the C-terminal
region of Cbl and Cbl-b (20, 21). In contrast to other SH3 domains, that are capable
of recognizing atypical binding motifs in addition to the canonical PxxP, CIN85 SH3
failed to bind any polyproline motif from the PRR region in Cbl proteins.
Mutagenic experiments revealed the importance to the proline and arginine
residues flanking the PxxxPR motif. Such motif indicated no correspondence to the
previously described atypical SH3 binding sequences. Most remarkably, CIN85
homolog CMS was reported to preferentially recognized this atypical polyproline
motif as well, while other SH3 containing proteins, such as Grb2, Src, Crk, Abl, CAP,
or ArgBP2 did not (Kowanetz, Szymkiewicz et al. 2003).
Additional cellular CIN85 and CMS interacting proteins, such as CD2
receptor (CD2), Pak, Disabled 1 and 2, SETA-binding protein 1 (SB-1), SLP-
65/BLNK, or Alg2-interacting protein (AIP1), and ASAP, contain the consensus
sequence PxxxPR (8, 20). However, although binding to either of these two
adaptors takes place at the same site, each interaction seems to elicit divergent
biological consequences (Tibaldi and Reinherz 2003).
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Identification of the consensus binding motif for the CIN85/CMS SH3
domains and structural determination of their interactions would provide a molecular
explanation for the mechanism by which CIN85 and CMS act as inducible
scaffolding proteins.
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III.Objectives
The appropriate balance of positive and negative signals is essential for the
cell to bring about the correct responses. The negative regulation of the epidermal
growth factor receptor (EGFR) signaling has been shown to be particularly
important.
In the past seven years, since its identification, numerous discoveries have
demonstrated the importance of CIN85 in processes that are crucial for the cell
survival and regulation. One of its main functions relays on its participation in the
EGFR endocytosis. The recruitment of CIN85 by Cbl seems to be necessary for the
initiation of the early steps of the EGFR downregulation.
The study of the interaction between CIN85 and the ubiquitin ligases c-Cbl
and Cbl-b raises a great interest not only in its global context but in the detail of the
minimum domains that participate in such interactions. It has been demonstrated
that these interactions are governed by the binding of CIN85 SH3 domains to an
atypical PxxP-independent SH3 binding motif. This may represent a novel
recognition mode that might explain the biological implications in the CIN85/CMS
signaling cascades in particular and in the SH3 repertoire of interactions in general.
Establishing the principles that govern ligand recognition by the SH3
domains is critical to the understanding of their diverse functions in the cell (Li 2005).
The broad knowledge on SH3 domain architecture and its interactions would allow
us to perform a detailed analysis of the interaction of the SH3 domains of the
CIN85/CMS family of adaptors with the c-Cbl/Cbl-b ubiquitin ligases, as well as a
meticulous comparison with proteins of similar structure and/or function.
With this premises, the following objectives were proposed for the present
study:
 To study, by means of structural analysis, the interaction between cin85 and
the cbl ubiquitin ligases, in order to contribute to the understanding of the
mechanism that controls the endocytic and degradation machinery of the
tyrosine kinase receptors.
 To describe at the structural level the uncharacterized interface involving
SH3 domains from CIN85 and the atypical PxxxPR motif in Cbl proteins.
 To characterize the structural differences of CIN85 and CMS SH3:Cbl
complexes that could shed light to their functional divergence.
 To analyze the recognition of the PxxxPR motif in other CIN85/CMS natural
partners and compare it with the recognition of Cbl proteins.

MATERIALS
AND METHODS
“Be aware that negative results can be just as important as positive results”
E. R. Schulman
“Un resultado negativo es un resultado”
J. Bravo
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IV. Materials and Methods
Several authors “have identified protein solubility (Yee, Chang et al. 2002)
and crystallization as the two major bottlenecks in the process towards the
determination of protein structures by X-ray diffraction” (Goulding and Perry 2003),
given that first, one third to one half of prokaryote, and probably more of eukaryote
proteins, cannot be expressed in soluble form in bacteria (Edwards, Arrowsmith et
al. 2000), and second, “there is no apparent relationship between a protein’s
properties and the conditions under which it will crystallize”, in which case, “one
must empirically sample the limitless number of crystallization conditions” (Goulding
and Perry 2003).
Only “~15–20% of small (<50 kDa) non-membrane proteins will be suitable
immediately for structural biology” (Edwards, Arrowsmith et al. 2000), and it is
known that even subtle changes in amino acid sequence can dramatically affect
protein solubility (Edwards, Arrowsmith et al. 2000); thus, a common strategy is to
clone and express many different constructs of different lengths or orthologs of the
same gene and select the clone with the best solubility properties. Therefore, in
order to guarantee a certain degree of success, an important portion of the time
needs to be spent in the design of such protein constructs and subsequently in the
acquisition of highly pure and soluble protein.
In order to do so, the protein sequence is inspected and a series of protein
constructs is designed. The DNA is cloned in different vectors for the expression
system of choice and effort is put on attempts for expression and solubilization of the
protein of interest for the crystallization trials.
1. Cloning
All the CIN85 DNA templates were obtained from DNA clones provided by
Ivan Dikic.
Enzymes, buffers and reagents used for DNA synthesis by PCR, DNA
restriction, DNA dephosphorylation, DNA ligation and DNA recombination are
described in the following table (Table IV.1).
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Table IV.1. Enzymes, buffers and
reagents used for DNA cloning.
Product Supplier Product code
PCR
Pfu
Polymerase Biotools 10.512
Pfu
Polymerase
Buffer
Biotools 10.502
Taq
Polymerase CNIO N/A (1 u/ml Taq Polymerase)
Taq
Polymerase
Buffer
CNIO N/A (10x concentrated)
dNTP Mix Fermentas R0192
DNA restriction
Nde I Fermentas ER0582
Xho I Fermentas ER0691
Buffer R
(Red) Fermentas BR5
Nde I Takara 1161B
Xho I Takara 1094S
Buffer K Takara Supplied with Enzymes
Product Supplier Product code
DNA restriction
Nde I NEB R0111S
XhoI NEB R0146S
Buffer 4 NEB B7004S
BSA NEB B9001S
Nhe I Fermentas ER0971
Buffer
Tango
(Yellow)
Fermentas BY5
Nhe I Takara 1162A
Buffer M Takara Supplied with Enzymes
DNA dephosphorylation
SAP Roche 1758250
Buffer Roche Supplied with Enzyme
DNA ligation
T4 DNA
ligase Fermentas EL0015
T4 DNA
ligase
Buffer
Fermentas Supplied with Enzyme
1.1. DNA amplicon generation
The acquisition of the CIN85 SH3 expression clones was accomplished via
the Polymerase Chain Reaction (PCR) using specific primers designed individually
for each open reading frame. Reactions were performed in volumes of 50l, with 10-
50ng of DNA template, 0.5μM of each oligonucleotide primer (see Table IV.2),
0.2mM dNTP mix, 1u high fidelity Pfu polymerase, and 1x Pfu polymerase buffer
(see Table IV.1).
The oligonucleotides used for the generation of the different gene constructs
either by PCR synthesis or by oligonucleotide hybridization were synthesized by
Sigma-Proligo. The characteristics of the oligonuclotides utilized for the cloning of
the gene constructs described here are summarized below (Table IV.2) (where the
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restriction enzyme (RE) site sequences are shown in purple, as well as hanging
bases for RE clamping and stop codons are shown in green lower case).
The melting temperature (Tm) shown in Table IV.2 was calculated for the
hybridizing region (HR), following Wallace rule for short oligonucleotides (Wallace,
Shaffer et al. 1979):
Tm = 4°C · (number of G’s and C’s) + 2°C · (number of A’s and T’s)
For the full sequence (FS) the web-based Sigma-Proligo oligo calculation tool was
used, for which calculation was based on the Nearest-Neighbor formula with
assumed salt concentration of 50mM and single strand concentration of 250pM
(Breslauer, Frank et al. 1986):
Tm = [ΔH/((A + ΔS) + Rln (Ct/4))] + 273.15 + 16.6 log [salt]
where ΔH (cal mole-1) is the sum of the nearest-neighbor enthalpy changes for
hybrid formation (<0); A (cal K-1mole-1) is a constant for helix initiation which is equal
to -10.8 cal K-1mole-1 for nonself-complementary sequences and = -12.4 for self-
complementary sequences); ΔS (cal K-1mole-1) is the sum of the nearest-neighbor
entropy changes for hybrid formation (<0), R is the molar gas constant (1.987 cal K-
1mole-1) and Ct is the total molar concentration of strands when oligonucleotides are
not self complementary or it is equal to 4 times this concentration in the case of self-
complementary sequences.
Table IV.2. Oligonucleotides used for the amplicon generation of the CIN85 SH3
constructs
Tm (ºC)Name Protein RE site
FS HR
Sequence 5’-3’
FwSH3A CIN852-6(Fw) NdeI 62 52 cgaCATATGGTGGAGGCCATAGTGG
RvSH3A CIN8553-58(Rv) XhoI 61 44 gggccCTCGAGTTTCTTTATTTCTCTTAC
RvStopSH3A CIN8553-58(Rv) XhoI 57 44 gggccCTCGAGtcaTTTCTTTATTTCTCTTAC
FwSH3B CIN85101-105(Fw) NdeI 77 62 gcgaCATATGCGCCGGTGCCAGGTGGC
RvSH3B CIN85153-157(Rv) XhoI 72 60 ccgCTCGAGCCCTGACAGCTCCTTGATG
RvStopSH3B CIN85153-157(Rv) XhoI 68 60 ccgCTCGAGtcaCCCTGACAGCTCCTTGATG
FwSH3C CIN85270-276(Fw) NheI 62 37 gcgGCTAGCGATTACTGCAAAGTAATATTT
RvSH3C007New CIN85324-328(Rv) XhoI 65 48 cggCTCGAGCGGTGGAAGTAACTTC
RvSH3C
DoubleStop
CIN85324-328(Rv) XhoI 61 48 gtcCTCGAGctattaCGGTGGAAGTAACTTC
Fwc-CblPeptide cCbl825-835
NdeI/
XhoI
91 91
gcgCATATG
CCCGAGAGGCCTCCAAAACCATTCCCGCGGAGA
tgaCTCGAGgcg
Rvc-CblPeptide cCbl825-835
NdeI/
XhoI
91 91
cgcCTCGAGtca
TCTCCGCGGGAATGGTTTTGGAGGCCTCTCGGG
CATATGcgc
Table IV.2. RE: Restriction Enzyme;Tm: Melting temperature; FS: Full Sequence; HR: Hybridizing
Region.
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Unless otherwise specified, the reactions were performed in a MJ Research
MiniCycler PTC150 thermal cycler, with an initial three minute denaturing step at
95ºC, followed by 30 cycles of three steps (denaturing step: 30’’ at 95ºC; annealing
step: 45’’ at a temperature 5ºC lower than the lowest primer melting temperature
(not lower than 45ºC); extension step: 2’ per kbp of DNA to be amplified (1’ minimun)
at 72ºC) and a final extension step of 10’ at 72ºC.
In the case of the pGATEV/c-Cbl820-830 clone, the dsDNA corresponding to
the c-Cbl CIN85 binding region was obtained by denaturation at 95ºC and posterior
annealing through slow cooling at room temperature (RT) of an equimolar mix of the
long complementary oligonucleotides Fwc-CblPeptide and Rvc-CblPeptide (see
Table IV.2).
1.2. DNA digestion and dephosphorylation
Amplified DNA and appropriate vector were digested with Nde I (Nhe I in the
case of CIN85-SH3C) and Xho I DNA Restriction Enzymes following the
manufacturer’s recommendations. When possible, simultaneous double digestions
were performed.
After digestion, in order to avoid re-circularization, the vector was
dephosphorylated with 1u of Shrimp Alkaline Phosphatase (SAP) in each of two
consecutive incubations of 30’ at 37ºC, as specified by the manufacturer. DNA was
subsequently purified as described in section IV.1.7.
1.3. DNA ligation
PCR and vector DNA concentrations were estimated by evaluation of
fluorescence intensity under UV light in samples separated by agarose gel
electrophoresis. Concentration ratios were calculated taking into account intensity
and size of the DNA fragments (see Figure IV.1).
Figure IV.1. Example of intensity calculation for a vector and an insert used
for DNA ligation. Same volume of Nhe I/Xho I cut pET-24d and CIN85-SH3C270-
328 TAA TAG were loaded in a 0.8% agarose-TBE gel. The intensity of the pET-24d
vector is calculated to be 10 times larger than that of the CIN85-SH3C270-328 TAA
TAG insert. Given that the vector is 30 times longer than the instert, we calculate a
1:3 insert:vector concentration ratio.
Approximately 100-200ng of vector were used for each DNA reaction and
different ratios of vector:insert DNA (1:5, 1:10, 1:15) were calculated for the 20l
reactions (when DNA insert was very diluted, 50l reactions were prepared). 1u of
T4 DNA ligase was used per reaction in 1x T4 ligase buffer at 22ºC. Ligation times
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varied from 2 hours to o/n. A ligation reaction without DNA insert was also set as a
negative control for posterior evaluation of vector re-circularization.
The characteristics of the plasmids used for the construction of the different
gene constructs are described in the following table:
Table IV.3. E. coli expression vectors.
Plasmid AntibioticResistance Tag Cleavage site Size Supplier (Cat. #)
pET-21a Amp
N-ter T7
C-ter His6
No 5.4 kb Merk1 (69740-3)
pET-29b Kan
N-ter S
C-ter His6
Thrombin 5.4 kb Merk1 (69872-3)
pET-24d Kan
N-ter T7
C-ter His6
No 5.3 kb Merk1 (69752-3)
pGATEV Amp
N-ter His6
N-ter GST
Tev 4.7 kb
Vector modified at the Max-Plank-Institute
for Molecular Physiology, Germany; and
the Institute of Protein Research, Russia
(Kalinin, Thoma et al. 2001)
1.4. DNA transformation
The ligation reactions were transformed into DH5α bacterial cells (see Table
IV.4) previously treated to make them electro or chemically competent for their
transformation with the different DNAs by electroporation or heat shock
transformation procedures (for transformation of ligation reactions the latter
procedure was preferred).
1.4.1. Preparation of transformation competent E.
coli cells
DH5α is an E. coli strain with a high transformation efficiency that is
recombination-deficient and thus very useful for plasmid DNA amplification. In order
to make them electrocompetent, a 1L culture is grown overnight and cells are
harvested by centrifugation at 4ºC and 4000xg for 20 minutes. They are then
resuspended in 1L ice-cold 1mM Hepes pH7. The cells are washed again with 0.5L
of Hepes and resuspended in 20ml 1mM Hepes pH7.0, 10% Glycerol for a final 20
minute centrifugation. They are finally resuspended in 3ml 10% Glycerol, frozen in
dry ice in 50l aliquots and stored at -80ºC.
To make cells chemically competent, Current Protocols procedure was
followed (Seidman 1997), except that final cell pellet was resuspended in 2.5 times
1 Previously Novagen
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less the recommended volume, and aliquots of 200l were made and subsequently
frozen in dry ice prior to storage at -80ºC.
Both procedures were carried out under sterile conditions, and
contamination controls were performed.
1.4.2. Transformation of E. coli cells by
electroporation or heat shock
Transformation of electrocompetent cells was carried out using 25l of,
already thawed under ice, electrocompetent cells and 0.2l of pure plasmid DNA (or
50l of cells and 1l of insert-plasmid ligation reaction) in a prechilled 0.2l gap
Gene Pulser/MicroPulser Cuvette from BioRad (Cat. # 165-2086). The Gene Pulser
II BioRad machine is set to give a pulse of 25F, 2.5kV with the pulse controller at
200ohms for 4msecs. Cells are quickly diluted into 1ml glucose containing SOC
medium (section IV.2) and incubated at 37ºC for a 30 to 45 minute recovery period
before plating into an antibiotic containing LB-Agar plate.
The procedure for transformation of chemically competent cells with plasmid
DNA was performed by means of heat shock reaction. Either 60l of CaCl2 treated
cells and 10ng of plasmid DNA or 90l of cells and the whole ligation reaction are
mixed and incubated on ice for 45 minutes or more. A 1.5 minute 42ºC heat shock is
applied to DH5α cells (45-50 seconds for expression strains) and bacterial cells are
incubated on ice for five more minutes. Cells are diluted with 200l of LB medium
and incubated at 37ºC for 30 minutes to 1 hour for recovery before plating them in
LB-Agar plates with appropriate antibiotic.
1.5. Confirmation of the DNA sequence
A number of colonies obtained by transformation and plating of vector:insert
ligation reactions into DH5α E. coli cells were selected and subjected to either
colony PCR analysis, restriction enzyme digestion of the extracted plasmid DNA, or
both.
Colony PCR was performed following the procedure described in section
IV.1.1, except that, instead of high fidelity polymerase, Taq polymerase was used
with its buffer and 2.5mM MgCl2, and the colony was used as DNA template with an
initial denaturing step of 5’ instead of 3’.
Plasmid DNAs extracted from positive hits were sequenced in the CNIO
facilities, in a multicapillary DNA analyzer ABI Prism 3700 (Applied Biosystems) to
confirm the integrity of the sequences.
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1.6. DNA detection
1.6.1. DNA electrophoresis
For DNA detection, 0.8% Agarose-TBE (89mM Tris, 89mM Boric Acid,
1.9mM EDTA) with 0.5mg/ml Ethidium Bromide gels were prepared by dilution of the
agarose in TBE buffer by boiling at 750W in a microwave oven. The Ethidium
Bromide is added when solution is warm, and solution polymerization takes place at
RT.
Electrophoresis of the DNA samples was performed at 20-90mA in TBE
buffer and DNA size was monitored by comparison to 1kb and 100bp DNA ladders
from Promega and Biotools, respectively (catalog numbers G5711 and 31.006).
Samples were prepared with 6x TriTrackTM Loading Dye Solution from
Fermentas (Cat. #R1161) or 2x home made Loading buffer (0.04% Bromophenol
Blue (Sigma B-0126), 0.04% Xylene Cyanol FF, 10% Glycerol) to a >1x final
concentration.
1.6.2. DNA quantification
The absorbance of the extracted DNA was measured at 230, 260 and
280nm wavelengths so that the purity could be evaluated with the double ratio
method (260/230nm2 and 260/280nm3 absorbance ratios) that give indication of the
presence of organic compounds or protein respectively. The concentration of the
DNA samples were calculated from the absorbance at 260nm assuming 1.0 OD260
per 50ng/l dsDNA.
1.7. DNA purification
DNA purification was achieved using different purification kits: for purification
of PCR products, RE, and ligation reactions, JetQuick PCR Purification Spin kit (Cat.
# 410050) was used; for plasmid DNA extraction from DH5 E. coli cells, Promega
Wizard Plus SV Minipreps kit (Cat. #A1460) was used for minipreps and Qiagen
Plasmid Midi/Maxi kits were used for large culture volumes; and for gel DNA
extraction both Qiagen Gel Extraction Kit (Cat. #28704) and JetQuick Gel Extraction
Spin Kit (Cat. #420050) were used indistinctively. In all cases, the manufacturers’
protocols were followed, except that for Qiagen Midipreps, DNA was more
extensively washed after precipitation (an extra washing step was performed with
1ml 96% Ethanol followed by a second washing step with 1.5ml 70% Ethanol).
2 Monitored to be near 2.0 OD for high purity DNA and low organic compounds content
(Warburg, O. and W. Christian (1942). "Isolierung und Kristallisation des Gärungsferments
Enolase (Isolation and crystallization of enolase)." Biochem. Z. 310: 384-421.).
3 Monitored to be beyond 1.8 OD for high purity DNA and low protein content.
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In all cases, DNA was eluted with 65-70ºC hot DNAse free water and
column membrane was let stand for at least one minute for proper hydration, in
order to achieve optimal DNA elution.
In some instances, standard DNA salt precipitation protocols were followed
to purify low concentrated DNA or small amounts of DNA from PCR reactions. Such
method consisted on precipitation of DNA with either 25/3 DNA volumes of 3M NaCl
or 1/10 DNA volumes of 3M Sodium Acetate, and 2-2.5 volumes of 96% Ethanol
which was left overnight at -20ºC (or incubated at -80ºC for 1-2hr). Precipitated DNA
was centrifuged 10-30 minutes at maximum speed at 4ºC and supernatant was
carefully removed by pipeting. DNA pellet was finally washed with 70% Ethanol,
vortexed and centrifuged 15 minutes at 4ºC at maximum speed. Ethanol traces were
evaporated by a 5 minute incubation at 37ºC and DNA was resuspended in 10l
water. Hydration of DNA was achieved by o/n incubation at 4ºC. DNA was
subsequently quantified and stored at -20ºC.
2. Heterologous protein over-expression and
solubilization
Once the sequences were inspected and no mutation was detected, the
plasmid DNAs were transformed in different E. coli expression strains by
electroporation or heat shock as described in section IV.1.4.2.
The bacterial E. coli strains used in this study are described in the following
table (for convenience, the strain DH5α, used for DNA amplification and not protein
expression, has been added to the same table).
Table IV.4. E. coli strains
Strain Genotype Comments Supplier
DH5α F– recA1 endA1 gyrA96 thi-1 hsdR17
supE44 relA1 AlacU169Φ80d lacZAM15
Used for DNA amplification
Highly transformation efficient
of unmethilated DNA and
recombination-deficient
Invitrogen
BL21 (DE3) F– ompT gal dcm lon hsdSB(rB
- mB
-)
λ(DE3 [lacI lacUV5-T7 gene 1 ind1
sam7 nin5])
Used for protein expression
T7 promoter driven expression
is repressed until IPTG
induction.
Invitrogen
BL21 (DE3) pLys S F– ompT gal dcm lon hsdSB(rB
- mB
-)
λ(DE3) pLysS(cmR)
Used for protein expression
Reduces and almost eliminates
expression from transformed
T7 promoter containing
plasmids when not induced.
Invitrogen
Rosetta (DE3) pLys S F– ompT hsdSB (rB
- mB
-) gal dcm (DE3)
pLysS/RARE (argU, argW, ilex, glyT,
leuW, proL) (cmR)
Used for protein expression
Expresses rare tRNAs
facilitating expression of genes
that encode rare E.coli codons.
Novagen
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Strain Genotype Comments Supplier
TG1tr D(lac-pro) glnV44(AS) thi hsdD5 F0a Used for protein expression
T phage resistant.
Modified from TG1
strain at the University
of Cambridge (Wang, Lo
et al. 2005)
{http://openwetware.org/wiki/E._coli_genotypes#BL21.28DE3.29}
F- = Does not carry the F plasmid, recA1 = For reduced occurrence of unwanted recombination in cloned DNA; cells UV sensitive, deficient
in DNA repair, endA1 = For cleaner preparations of DNA and better results in downstream applications due to the elimination of non-specific
digestion by Endonuclease I, gyrA96 = mutation in DNA gyrase; conveys nalidixic acid resistance, gyrA462 = mutation in DNA gyrase;
conveys resistance to ccdB colicin gene product, thi = requires thiamine, hsdR = For efficient transformation of cloned unmethylated DNA
from PCR amplifications, supE = glnV: suppression of amber (UAG) stop codons by insertion of glutamine; required for some phage growth,
relA = relaxed phenotype; permits RNA synthesis in absence of protein synthesis, (φ80) = Cell carries the lambdoid prophage φ80. A
defective version of this phage carrying lacZM15 deletion is present in some strains, lacZΔM15 = partial deletion of the lacZ gene that allows
α complementation of the β-galactosidase gene; required for blue/white selection on XGal plates. Deletes the amino portion of lacZ (aa 11-
41), DE3 = T7 polymerase promoter, ompT = mutation in outer membrane protein protease VII, reducing proteolysis of expressed proteins,
gal = galactose loss of function, dcm = cytosine methylation at second C of CCWGG sites abolished, lon = lon protease loss of function,
hsdS = Both restriction and methylation of certain sequences is deleted from the strain. If you transform DNA from such a strain into a wild
type strain, it will be degraded, rB
- mB
- = The B defines the strain lineage. The - indicates the strain hasn't got the restriction system (rB
-) nor
the modification (methylation) system (mB
-), lacI = overproduction of the lac repressor protein, pLysS = contains pLysS plasmid carrying
chloramphenicol resistance and phage T7 lysozyme, effective at attenuating activity of T7 RNA polymerase, for better inhibition of expression
under non-induced conditions, cmR = resistance to Chloroamphenicol.
Colonies obtained from DNA transformed E. coli cells were selected on LB-
agar with proper antibiotic (LB medium with 4% agar). Selected colonies were
subsequently grown o/n at 37ºC in LB medium (see below). Short scale, 20ml,
expression tests were performed by diluting the o/n cultures 20-50 times in different
expression strains, at different temperatures (16, 20, 30 and 37ºC).
Different rich media supplemented with appropriate antibiotic (100g/ml
Amp, 50g/ml Kan or 34g/ml Chloroamphenicol) were tested for protein
expression: Lysogeny Broth (more commonly known as Luria Broth) (LB) (10g/L
Tryptone, 5g/L Yeast extract, 170mM NaCl, pH7.2); Two times Tryptone-Yeast
extract (2xTY) (16g/L Tryptone, 10g/L Yeast extract, 85mM NaCl, pH7.2); SOC
(20g/L Tryptone, 5g/L Yeast extract, 8.55mM NaCl, 0.25mM KCl, 2M MgCl2, 1M
Glucose, pH7); and Terrific Broth (TB) (12g/L Tryptone, 24g/L Yeast extract, 0.4%
Glycerol, 0.17M KH2PO4, 0.72M K2HPO4) (all these media were prepared by the
CNIO services).
When the optical density at 600nm (OD600) of the cell culture reached 0.6-
1.0 (corrected for turbulence by a factor of 2), expression was induced with different
concentrations of Isopropyl β-D-1-thiogalactopyranoside (IPTG), 0.1-1mM. Samples
were collected every two hours and protein samples were prepared as described in
section IV.4.1 for SDS electrophoresis analysis.
Cell cultures were pelleted 15’ at 6000xg and resuspended in different lysis
buffers (see Table IV.5), sonicated in a Branson 250 Sonifier at a 10% intensity for
2’ and centrifuged 15’-30’ at 16000xg. Amount of soluble fraction was evaluated by
gel electrophoresis of the supernatant (s/n) and the pellet of the cell lysates.
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Table IV.5. Solubilization buffers used for cell lysis.
Solubilization/Lysis Buffers
Name Composition Proteins
High [NaCl] 50mM Tris pH 7.5 at 4ºC, 400mM NaCl, 15mM
Imidazole
CIN85-SH3B101-157His6
Medium [Imidazole] 50mM Tris pH 8.0 at 4ºC, 200mM NaCl, 50mM
Imidazole
CIN85-SH3C270-328His6
PBS (Phosphate
Buffer Saline
solution)
137mM NaCl, 10mM Na2HPO4-2H20, 2.7mM KCl, 2mM
KH2PO4 at pH 7.4
CIN85-SH3C270-328 TAA TAG:His/GST/cCbl820-830
Low [NaCl] 50mM Tris pH 8.0 at 4ºC, 100mM NaCl, 15mM
Imidazole
CIN85-SH3A2-58His6
Tris 100mM Tris pH 7.5, 200mM NaCl, 1mM EDTA CIN85-SH3A2-58 tga, CMS-SH3A1-62 tga
Once a suitable amount of protein expression and solubilization was
achieved, the expression protocol was established for large scale 1L cultures. A
glycerol stock was frozen in dry ice (1.5ml of o/n culture was centrifuged at 5000xg
at 4ºC and resuspended in 1ml 15% Glycerol-LB) and stored at -80ºC for posterior
use for initiation of o/n cultures.
Large scale cultures were grown in incubator shakers (New Brunswick
scientific Innova 4430) at the indicated temperature (see Results section) with a
shaking speed of 200rpm. After standard times of expression of 4-6hr (o/n for
expression at 16 or 20ºC), cells were harvested by pelleting in 1L bottles using a
Beckman Coulter Avanti J-20 XP centrifuge in a JLA-8.1000 rotor for 15min at
5000xg. Total cell pellets were washed with PBS buffer (Table IV.5), frozen under
liquid nitrogen, and stored at -80ºC until used for protein purification.
3. Protein purification
Thorough purification is very important for protein crystallization, as
contaminants can hamper crystallization. Thus, multiple step purification was
undertaken for each protein.
For the purification of the already expressed protein, appropriate total cell
pellets corresponding to 1-3L cultures (depending on the expression level achieved),
were thawed in ice and resuspended in 5-10ml of the indicated solubilization/lysis
buffer per gram of cells.
Cell lysis was achived by mechanical methods such as homogenization
(with an Avestin Emulsiflex-C5) or sonication. Sonication was the lysis standard
method of choice and was carried out on ice, in 10-15 mins. with short pulses of 0.5
sec. with resting periods of 2 seconds in between, at 40% intensity in a Bioblock
Scientific Vibracell 75042, which was located inside a 4ºC room.
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Membrane traces were discarded by high speed centrifugation at 16100xg
in a Beckman ultracentrifuge with a Ti 45 rotor at 4ºC for 40 minutes. The cleared
lysate was filtered through a 0.45m membrane prior to loading into a previously
equilibrated affinity column.
3.1. His-tagged and GST-tagged protein
purification
The purification protocol followed for His-tagged proteins consisted on the
loading of the 4ºC or ice cold filtered proteins in a HiTrap GE Healthcare4 column at
5ml/min with a MiniPuls 3 peristaltic pump (Gilson) or with an AKTA Purifier (GE
Healthcare). The columns were previously equilibrated with the lysis buffer (with the
NTA resin previously charged with 100mM NiSO4).
Once the protein was bound to the column, the sample was washed with
specific washing buffers at 5ml/min in an AKTA Purifier (GE Healthcare) and eluted
in a 5-10 column volume gradient to 100% elution buffer, which contained 500mM
Imidazole or 100mM EDTA (10mM L-Glutathione reduced (GSH) in the GST co-
purification of the CIN85-SH3C270-328 TAA TAG:His/GST/cCbl820-830 complex). A final 5
column volume wash was carried out to guarantee complete protein elution.
If the purity of the protein sample was not satisfactory, it was subjected to a
second purification step in an anion exchanger sepharose column (HiTrapTM Q HP
or FF, GE Healthcare Cat. #17-1154-01 and 17-5156-01, respectively). Sample was
diluted to 50-100mM NaCl and/or 20mM Imidazole concentration, and loaded in the
column to be eluted in a NaCl gradient.
Elute fractions were analyzed by SDS-gel electrophoresis (section IV.4.1)
and pure fractions were subsequently concentrated by ultracentrifugation with
Amicon Ultra or Vivaspin filter devices to a final volume of 1-2ml. The concentrated
fraction was then centrifuged at 14000xg for 10-15 minutes to bring down any
particle or aggregate present in solution and loaded into a HiLoad Superdex 75
16/60, Superdex 75 26/60 or Superdex 30 16/60 gel filtration column for a size
exclusion separation, using an AKTA Prime system at at 0.5ml/min for the 16/60 and
2.5ml/min for the 26/60.
Purification steps and buffers used for each protein are specified in the
following table.
4 Previously Amersham. Columns: HiTrapTM Chelating HP (Cat. #17-0409-03), HisTrapTM HP
or FF (Cat. # 17-5248-02 or 17-5255-01), GSTrapTM FF (Cat. #7-5131-02).
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Table IV.6. Purification schemes for CIN85-SH3 constructs and CMS-SH3A.
Protein Column Wash buffer Elution buffer Superdex Buffer
HiTrap
Chelating
Wash 1:
50mM Tris pH 7.5 at 4ºC
400mM NaCl
15mM Imidazole
Wash 2:
50mM Tris pH 8 at 4ºC
400mM NaCl
0.1% Triton x-100 v/v
2mM Imidazole
50mM Tris pH 8.0 at 4ºC
1% Ethylene Glycol v/v
500mM Imidazole
CIN85-SH3B101-157His6
HiTrap Q FF Wash:
20mM Hepes pH 8.0 at 4ºC 20mM Hepes pH 8.0 at 4ºC
1M NaCl
20mM Hepes pH 8.0
at 4ºC, 100mM
NaCl, 4% Glycerol
HiTrap
Chelating
Wash:
50mM Tris pH 8.0 at 4ºC
200mM NaCl
50mM Imidazole
50mM Tris pH 8.0 at 4ºC
1% Ethylene Glycol v/v
500mM Imidazole
CIN85-SH3C270-328His6
Q FF Wash:
20mM Hepes pH 8.6 at 4ºC 20mM Hepes pH 8.0 at 4ºC
2M NaCl
20mM Hepes pH 8.0
at 4ºC
100mM NaCl
4% Glycerol
CIN85-SH3C270-328 TAA
TAG: His/GST/cCbl820-830
GSTrap FF Wash 1:
50mM Tris pH 8.0 at 4ºC
500mM NaCl
Wash 2:
50mM Tris pH 8.0 at 4ºC
100mM NaCl
50mM Tris pH 8.0 at 4ºC
100mM NaCl
10mM GSH
25mM Tris pH 8.0 at
4ºC
HiTrap
Chelating
Wash 1:
50mM Tris pH 8.0 at 4ºC
400mM NaCl
15mM Imidazole
Wash 2:
50mM Tris pH 8.0 at 4ºC
2mM Imidazole
50mM Tris pH 8.0 at 4ºC
1% Ethylene Glycol v/v
100mM EDTA
CIN85-SH3A2-58His6
Q HP Wash:
50mM Hepes pH 8.0 at 4ºC 50mM Hepes pH 8.0 at 4ºC
500mM NaCl
20mM Hepes pH 7.0
at 4ºC
100mM NaCl
4% Glycerol
CIN85-SH3A2-58 tga
CMS-SH3A2-62
HiTrap
Phenyl FF
(high sub)
Wash:
100mM Tris pH 7.5
200mM NaCl
1mM EDTA
50% (NH4)2SO4
100mM Tris pH 7.5
200mM NaCl
1mM EDTA
20mM Tris pH 7.5 at
4ºC
150mM NaCl
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3.2. Untagged CIN85 and CMS SH3A purification
For the purification of CIN85-SH3A2-58 tga and CMS-SH3A2-62, the total cell
pellets of 3L cultures were resuspended with 5ml of Tris buffer (see Table IV.5) per
gram of cells, sonicated and ultracentrifuged as described previously. The clear
lysate proteins were precipitated with Amonium Sulfate in two steps at 4ºC for 15
minutes and centrifuged at 13000xg for 15 minutes. The first precipitation step was
of 50% w/v Amonium Sulfate, followed by a second step in which the salt
concentration was increased to 70% w/v Amonium Sulfate.
The soluble fraction was then diluted to 50% ammonium sulfate Tris buffer
to avoid any trace of precipitated protein, and filtrated through a 0.45m membrane.
The sample was then loaded into a hydrophobic interaction chromatography HiTrap
column from GE Healthcare (HiTrap Phenyl (high sub) FF, Cat. # 17-5193-01)
(previously equilibrated with 50% (NH4)2SO4/Tris buffer) and the protein was eluted
with a 50 to 0% (NH4)2SO4 gradient. Protein obtained from this step was very pure,
so that it was concentrated with an Amicon 5kD filter to a volume between 1.5 and
2ml and loaded into a Superdex 75 16/60 column, which was run with 20mM Tris pH
8.0, 200mM NaCl at 0.5ml/min. To decrease the concentration time, the sample was
diluted to a calculated Amonium Sulfate concentration of 25-50% prior to protein
concentration.
4. Protein detection
4.1. SDS-PAGE
The purity and relative molecular mass of protein samples as well as the
progress of the purification procedure was followed by separation of proteins by
Sodium Dodecyl Sulfate PolyAcrylamide Gel Electrophoresis (SDS-PAGE).
SDS-polyacrylamide gel electrophoresis (PAGE) was performed according
to the Laemmli method (Laemmli 1970) using gels of uniform or gradient density in a
MiniProtean 3 system from BioRad.
Uniform density polyacrylamide gels were prepared as described in the
“Maniati’s Laboratory Manual” (Sambrook and Russell 2001). Polyacrylamide
gradient gels were prepared with a Model 485 Gradient Former from BioRad,
following BioRad’s protocol with the following modifications: 41.5ml of the 4%
polyacrylamide Light Solution, and 55ml of a 23% polyacrylamide Heavy Solution.
Protein samples were diluted with with 5x Protein Loading Sample Buffer
(10% SDS, 312mM Tris pH 6.8, 50% Glycerol, 0.05% Bromophenol Blue (Sigma B-
0126), 712.5mM -Mercaptoethanol (-MeOH)) and boiled at 99ºC for 3-10 minutes.
In the case of total cell pellet (TCP) protein samples, the OD600 of the cell cultures
were measured, 0.5ml of cell culture was pelleted and resuspended in 2x Protein
Loading Sample Buffer (4% SDS, 125mM Tris pH 6.8, 20% Glycerol, 0.02%
Bromophenol Blue, 285mM -MeOH) accordingly to their cell content for their
normalization (either 50 or 100x OD600 l of Protein Loading Buffer; i.e. for a
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0.6OD600, 30 or 60μl of loading buffer is added). They were subsequently boiled 10
to 15 minutes in order to break totally the cell membrane.
4.2. Protein quantification
Protein concentration was calculated using the Beer-Lambert Law, A280 = εlc
(where A280 = Absorbance at 280nm, ε = Extiction coefficient, l = path lenght, c =
Concentration). The protein absorbance was measured with a Nanodrop ND-1000
spectrophotometer, and the extinction coefficients were calculated from the amino
acid composition using the EXPASY algorithm of denatured proteins (±5%)
(Edelhoch 1967; Gill and von Hippel 1989). No difference in the concentrations were
quantified when the SH3 proteins were denatured with 6M Guanidinium Chloride,
therefore, regular measurements were performed without denaturing the protein. All
the proteins were kept at 4ºC for short term usage, and at -80ºC for long term
storage.
Alternatively, protein concentration was estimated with the Bradford (BioRad
500-0006) and BCA (Pierce 23227) standard assays, following the protocols
provided by the manufacturers.
5. Crystallography
"Si la proteína no cristaliza a temperatura ambiente, no es interesante para la
ciencia”
Macromolecular X-ray crystallography is a powerful tool for solution of
protein structures since, provided that adequate ordered crystals are available, there
is almost no limit to the complexity of the structures that can presently be
determined by X-ray diffraction. It is though, a relatively young area of research,
given that it was only five decades ago that Max Perutz and John Cowdery Kendrew
were awarded with the Nobel Prize in Chemistry for the solution of Sperm Whale
myoglobin by X-ray crystallography. Since then, the number of protein structures
solved has grown exponentially with more than 5000 proteins released to the Protein
Data Bank (PDB) public database in the last year (4451 already in the present year).
This growth is due not only to the improvement of the technical devices, but to a
better understanding of the technique and crystallization process and to the
development of new data processing software. The contribution of X-ray
crystallography to the structural biology is especially important, given that from the
45865 structures in the database (44052 of them being of protein structures), 85%
have been solved by this technique, while Nuclear Magnetic Resonance (NMR) has
contributed with >14% of them, and electron microscopy with 154 structures (data
obtained from the PDB, September 2007).
The reason we use X-ray diffraction to solve protein structures is because in
order to visualize objects by electromagnetic radiation, incoming radiation needs to
have a wavelength comparable to the smallest features that you wish to resolve.
The distance of carbon bonded atoms falls into the X-ray wavelength range in the
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electromagnetic spectrum, so that by radiating a protein crystal with X-rays we
obtain a diffraction pattern with information on the distribution of the electrons in the
molecule, which will allow us to build a model of the protein structure in the crystal.
A single molecule in solution has not enough scattering power alone and
would be masked by the scattering of water and air. Crystals arrange huge numbers
of molecules in the same orientation, so that scattered waves can add up in phase
and increase the signal to a measurable level. And this is the reason why we need
to obtain protein crystals for the use of this technique.
5.1. Protein crystallization
“A lot of protein crystallization is dumb luck”
Bob Cudney
Crystallization of macromolecules is not trivial and it is the least understood
step in the X-ray structural analysis of a protein (Drenth 1994). As mentioned
previously, there is no apparent relationship between a protein’s properties and the
conditions under which it will crystallize.
Protein crystallization occurs when the concentration of protein in solution is
greater than its limit of solubility and so the protein is in a superstaturated state.
Traditional methods of crystallising inorganic molecules have been modified to be
gentle enough for proteins, which are sensitive to temperature and high
concentrations of organic solvents. Many methods exist to crystallise proteins, but
the two most successful methods are the microbatch and vapor diffusion techniques.
Concentrated solutions of the protein are mixed with various solutions, which
typically consist of a buffer to control the pH of the experiment, a precipitating agent,
to induce supersaturation (typically Poly ethylene glycols (PEGs), Salts such as
Ammonium sulphate or organic alcohols) and other salts or additives, such as
detergents or co-factors.
Both microbatch and vapor diffusion methods allow the protein solution to
concentrate over time, feature that favors nucleation of the protein. Two common
vapor diffusion methods for crystallisation are hanging and sitting drop. In the
hanging method, a small drop of concentrated protein- and precipitant-containing
solution is applied to a glass coverslip which is then inverted so as to suspend the
drop above a larger reservoir of a similar solution lacking protein but containing a
higher concentration of precipitant, and the chamber is then sealed (Figure IV.2). In
the sitting drop method the drop is placed in a pedestal above the reservoir solution
(Figure IV.3). Over time, the drop containing protein equilibrates with the larger
reservoir beneath it as water in the drop leaves the drop and transfers to the
reservoir, effectively increasing the precipitant concentration in the protein drop.
Supersaturation of protein is favored only in some solutions that cannot be predicted
and are specific for each protein construct, and it is then that crystal nuclei form,
leading to crystal growth. Typically, hundreds or thousands of conditions are
screened before a suitable condition is found that leads to a crystal of suitable
quality; therefore, most of the effort for the solution of a protein structure is put into
the crystallization of such protein.
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Figure IV.2. Diagram of hanging drop method. Reservoir solution
(blue) usually contains buffer and precipitant. Protein solution (red)
contains the same compounds, but in lower concentrations. The protein
solution may also contain trace metals or ions necessary for
precipitation of particular proteins (taken from
{http://www.bio.davidson.edu/courses/MolBio/MolStudents/spring2003/K
ogoy/protein.html}).
Figure IV.3. Diagram of sitting drop method. In this method, the
protein drop sits on a pedestal above the reservoir solution, as opposed
to hanging (taken from
{http://www.bio.davidson.edu/courses/MolBio/MolStudents/spring2003/K
ogoy/protein.html}).
Our first approach for initial search of chemical conditions that would deliver
diffraction-quality crystals began with sitting drop vapor diffusion crystallization trials
with sparse matrix screens, Polyethylene Glycol (PEG) matrices or home made
screens (see Table IV.7): the Classics (Cat. #130901 & 130701), PEGs Suite (Cat.
#130904), Cryos Suites (Cat. # 130903) and pHClear (Cat. #130909) suites from
Qiagen; Crystal Screens I & II (Cat. # HR2-110 and HR2-112) and Index (Cat. #
HR2-134) from Hampton Research; JBScreen Classic I and II (Cat. # CS-101L &
CS-102L), Wizard Screens I + II (Cat. #EBS-WIZ-F) and Wizard CryoTM I + II (EBS-
CRYO-F) from Jena Bioscience.
Table IV.7. Crystallization screens used for
inicial search of crystallization conditions.
Screen Company Cat. #
NeXtal Classics Suite Qiagen 130901 & 130701
NeXtal PEGs Suite Qiagen 130904
NeXtal Cryos Suite Qiagen 130903
NeXtal pHClear Suites Qiagen 130909
Crystal Screens I & II Hampton Research HR2-110 & HR2-112
Index Screen Hampton Research HR2-134
JBScreen Classic I and II Jena Biosciences CS-101L & CS-102L
Wizard Screens I + II Jena Biosciences EBS-WIZ-F
Wizard CryoTM I + II Jena Biosciences EBS-CRYO-F
A (PEGs) Home Made N/A
B (Various) Home Made N/A
C (Salts) Home Made N/A
Different 96-well sitting drop crystallization plates were used from different
companies for initial screenings: Innovaplate, Corning, and Costar. 24-well hanging
and sitting drop plates were used for grid screening for crystal optimization.
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Table IV.8. Crystallization plates used for crystal growth.
Company Description Cat. #
96-well plates
Hampton
Research 96x1 well sitting drop plate, Low Profile, Polystyrene, Greiner, 80 plates HR3-093G
Hampton
Research 96x3 wells sitting drop plate, hydrophobic surface, Greiner, 40 plates HR8-149
Hampton
Research 96x1 wells sitting drop plate, untreated, Greiner, 80 plates HR3-304
Corning CrystalEX™ 96 Well Flat Bottom Protein Crystallization Microplate, Advanced Polymer, 25/Bag,Hydrophilic Treated, Nonsterile 3785
Innovadyne Innovaplate™ SD-2 Crystallography Plate, Package of 100 11978-1
24-well plates
Qiagen 100 x 24-well plates each with 24 crystallization supports 132025
Hampton
Research Cryschem Plate, 24 well sitting drop, 100 plate case HR3-160
Hampton
Research Hanging drop, 24 well VDX™ Plate, 100 plate case HR3-140
Hampton
Research Hanging drop, 24 well VDX™ Plate with sealant, 100 plate case HR3-170
Often, the initial screens were as much a test of protein concentration as of
crystallization conditions. If approximately 30% of the conditions yielded a
precipitate, we consider the protein concentration to be appropriate for further trials.
If not, the concentration of the protein was adjusted accordingly. For identification of
optimal initial protein concentration, Hampton Pre-Crystallization Test (Cat. #HR2-
140) and Nextal EasyXtal Pre-Screen Assay were occasionally used as a guide.
The use of nanodroplet high-throughput crystallization allows for numerous
conditions to be sampled while keeping the requirements of protein quantities to a
minimum (Stevens 2000) and therefore, reduces the burden on protein production.
We used a medium high-throughput system in which either 0.5+0.5l or 0.8+0.8l
protein+reservoir solution drops were set manually with a multi-channel pipette or
100+100ng protein+reservoir solution drops were set with the Cartesian MycroSys
synQUAD liquid handling robot in 96-well crystallization plates. Plates were
incubated at 22ºC or 4ºC temperature monitored rooms.
Drops for crystallization complexes of SH3 domains with synthetic peptides
were set with a protein-peptide mixture of 1.5 to 3 times peptide molar excess. The
peptides were diluted in 100mM Tris pH 8 and the mixture was incubated 10 to 15
minutes at RT for proper complex formation. Prior to drop setting, the sample was
centrifuged at 14000xg for 10-15 minutes to bring down any particle or aggregate
present in solution.
All Cbl derived peptides used for crystallization and binding assays were
synthesized from C to N-terminus by Sigma-Genosys using Fmoc chemistry and
solid support resin, with >90% purity guaranteed.
Peptide sequences are summarized in the following table (Table IV.9).
Mutations of native sequences are shown in red, and residues from the CIN85/CMS
binding motif are aligned and highlighted in bold letters. An N-terminal tyrosine was
added to some peptides for accurate quantification of peptide concentration for the
ITC binding assays.
42 Materials and Methods
Table IV.9. Polyproline peptides used for
co-crystalization and binding studies.
Peptide Sequence
CIN85 binding motif
RxPx PxPR
c-Cbl811-834
TNVTEGSQVPERPPKPFPRRINSE
c-Cbl816-834
GSQVPERPPKPFPRRINSE
c-Cbl820-830
PERPPKPFPRR
Clb-b893-914
PSCSDGSQAPARPPKPRPRRTA
Cbl-b898-914
GSQAPARPPKPRPRRTA
Cbl-b902-912
PARPPKPRPRR
Cbl-b902-912R911A PARPPKPRARR
YCbl-b903-912 YARPPKPRPRR
YCbl-b903-912R904A YAAPPKPRPRR
YCbl-b903-914 YARPPKPRPRRTA
CD2324-333 KGPPLPRPRV
YCD2325-335 YGPPLPRPRVQP
5.2. Crystal cryo-cooling
Protein crystals, as well as living tissues, undergo radiation damage if
exposed to X-rays. Radicals are formed in the crystals upon exposure to high-
energy X-ray photons. These radicals lead to subsequent chemical reactions that
gradually destroy the crystalline order and as a consequence the information that
can be obtained from a single crystal is limited. Radiation damage is proportional to
dose and might be structurally specific. It has been calculated that each absorbed
8keV photon disrupts ~70 molecules and disorders another 90. Colin Nave and
Elspeth F. Garman reported that diffraction at 100ºK usually prolongs the crystal
lifetime by a factor of ~70 (Nave and Garman 2005), normally long enough for a
complete dataset to be collected from a single crystal.
Among the consequences of radiation damage are the decrease of
diffraction intensity and resolution, the increase in the unit cell volume, and site-
specific damage. The latter occurs in a well-defined order, starting with the breakage
of disulphide bonds, followed by decarboxylation of aspartates, glutamates and the
C-terminus, and then loss of the hydroxyl group from tyrosines. Active sites and
metal centres appear to be particularly vulnerable and, thus, they must be inspected
carefully when assigning structural or functional significance (Nave and Garman
2005; Ravelli and Garman 2006).
This is why nowadays X-ray data collection from biomacromolecular crystals
is usually performed at cryogenic temperatures. However, crystal cryo-cooling needs
to be carefully undertaken. Slow cooling allows water inside and surrounding the
crystal to form hexagonal ice, disrupting the order of the protein lattice and creating
ice rings that obscure its diffraction. The protein conformation might even be altered
upon formation of ice within the crystal. To avoid water contained in the solvent to
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transform into ice, a rapid or `flash' cooling of the crystal is usually performed so that
any water content is transformed into an amorphous (vitreous) form and its
redistribution within the crystal is prevented. This procedure generally improves the
diffraction results (Kriminski, Kazmierczak et al. 2003).
Transforming pure water to amorphous ice requires cooling from room
temperature to below water glass transition temperature in less than 10-4s. The use
of penetrating cryoprotectants such as glycerol or ethylene glycol and non-
penetrating cryoprotectants such as large molecular weight polyethylene glycols
(PEGs) (commonly present in the crystallization mother liquor as precipitants) can
increase cooling times required for vitrification of internal and external solvent.
Protein itself can be an excellent cryoprotectant at specific concentrations usually
found in protein crystals (Kriminski, Kazmierczak et al. 2003).
We used glycerol or ethylene glycol-containing cryoprotectant solutions to
wash the protein crystals and ensure collection of single crystals with no precipitate
content. When components of the crystallization solution itself acted as
cryoprotectants, crystals were washed in reservoir solution.
Protein crystals are usually flash-cooled by inserting a crystal into a nitrogen
or helium cold gas stream, or by plunging into liquid nitrogen at 77ºK or liquid
propane at 86ºK. We flash-cooled the crystals of this study under a nitrogen gas
source using an Oxford Cryosystem device.
5.3. Crystal data collection
Once the crystal is ready for the experiment, it can be exposed to an X-ray
beam. Structural information is obtained from crystal diffraction.
X-rays are scattered in all directions upon interaction with the electrons
contained in the protein crystal. Depending on the distance traveled by the scattered
rays, their relative phases will differ or not. When scattered X-rays are in phase, they
add up with a resulting amplitude that is the sum of the individual amplitudes. On the
other hand, when they are out of phase, their amplitudes cancel out.
When the angle of incidence is the same as the angle of reflection, incident
and scattered light rays are in phase. Such condition in crystallography is true only
for Bragg planes. The crystal lattice defines the distance that separates these Bragg
planes, and only electrons situated on this theoretical plane contribute to the
scattering of the incident X-ray. Given that X-rays are scattered in all directions,
there is an infinite number of Bragg planes (see Figure IV.4).
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Figure IV.4.
Representation of pairs
of Bragg planes. The
large black arrow
represents the incoming
radiation. Coloured arrows
represent different
diffracted rays, and a pair
of Bragg planes is shown
in the same colour (taken
from the Macromolecular
Crystallography course of
1999-2000, University of
Cambridge and the MRC-
LMB:
http://images.google.es/i
mgres?imgurl=http://www-
structmed.cimr.cam.ac.uk/Course/Basic_diffraction/Ewald_planes.gif&imgrefurl=http://www-
structmed.cimr.cam.ac.uk/Course/Basic_diffraction/Diffraction.html&h=259&w=600&sz=13&hl=es
&start=9&um=1&tbnid=bDDovWxsvq5VTM:&tbnh=58&tbnw=135&prev=/images%3Fq%3Dewald%2
Bsphere%26svnum%3D10%26um%3D1%26hl%3Des%26client%3Dfirefox-
a%26rls%3Dorg.mozilla:es-ES:official%26sa%3DN).
In order for the unit cells to diffract in phase, the Bragg planes must pass
through the same points in all the unit cells in the crystal. The easiest case to
imagine is when the planes are separated by one unit cell edge, or an integral
fraction of a unit cell edge. On the other hand, if the planes divide the unit cell edge
by a non-integral number, the different unit cells will all diffract out of phase and the
waves will cancel out.
In order to help visualise which Bragg planes are in the correct orientation to
diffract we can construct the Ewald sphere of radius 1/λ. In such sphere, only
scattered rays from the Bragg planes that cross the Ewald sphere will be in phase
(see Figure IV.5). The diffraction pattern of a crystal thus, can therefore be used to
extract information about its symmetry and arrangement of its electrons.
Figure IV.5. The Ewald sphere construction. The X-ray beam is along
the X axis and the Z axis is the rotation axis. The origin of the reciprocal
lattice lies at the point that the X-ray beam exits the Ewald sphere (Q)
and the crystal is located at the centre of the sphere (O). The crystal is
oriented so that the a axis lies along the X axis. The reciprocal-lattice
plane h = 1 is shown. Each diffraction spot on the detector can be
mapped back to the equivalent scattering vector in reciprocal space.
One such scattering vector is shown as a bold line from the reciprocal-
lattice origin (Q) to the surface of the Ewald sphere. Taken from (Leslie
2006).
A common experimental setting used to collect the crystal diffraction pattern
is such in which the crystal is positioned to be directly exposed to the incident X-ray
beam, and a detector is located in the other side of the incident beam to record the
diffraction pattern. In order to collect all the atomic information contained in the
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crystal, either the detector needs to be rotated around the Ewald sphere or the
crystal needs to be rotated around itself. For technical ease, it is usually the latter
that is used.
We collected the diffraction images of CIN85-SH3C270-328His6 and CIN85-
SH3A2-58His6 crystals on a Bruker F530 rotating anode X-ray source at 110ºK,
1.54179Åλ, with a Mar345 image plate, which is a photosensitive detector. In the
case of the CIN85-SH3A2-58:Cbl-b902-912 crystal a Bruker-Nonius generator was used
for collection at 100ºK, and a Kappa2000 CCD detector.
Crystals from CIN85-SH3A2-58:CD2324-333 and CMS-SH3A1-62:YCbl-b903-914
complexes were collected under the more powerful synchrotron radiation source at
the European Synchrotron Radiation Facility (ESRF) beamlines ID23-1 and ID14-1,
respectively, with CCD detectors.
5.3.1. Data reduction
Once the data is collected, it needs to be processed to obtain the
unit cell parameters and the orientation of the crystal, which may indicate
the symmetry of the crystal. With that information, the images can be
integrated to predict the positions of the Bragg reflections on each image
and obtain an estimate of the intensity of each reflection and its
uncertainty (Leslie 2006). There are several programs available to carry out such
data reduction.
We used Denzo (Otwinowski 1997) program for the processing of CIN85-
SH3A2-58His6 and CIN85-SH3A2-58 tga:Cbl-b902-912 data, and the program Mosflm
(Collaborative Computational Project 1994) for all the other data sets.
There are several physical factors that affect the measured diffraction
intensities, such as variations in the crystal rotation rate, variation in incident-beam
intensity (in synchrotron radiation), radiation damage or errors from the detector.
Therefore, the diffraction data need to be scaled to put them on a consistent scale.
After such scaling, intensities can be analysed to establish the real resolution of the
data set, to detect bad regions, to analyse radiation damage and to assess the
overall quality of the data set (Evans 2006).
In our study, hkl-Scalepack (Otwinowski 1997) was used to scale CIN85-
SH3A2-58His6 and CIN85-SH3A2-58 tga:Cbl-b902-912 data, and Scala (Collaborative
Computational Project 1994) to scale data that was reduced with Mosflm.
5.3.2. Structure solution by Molecular Replacement
(MR)
The diffraction pattern we measure in the diffraction experiment is
essentially the result of a count of the number of X-ray photons in each spot. These
spots depend directly on the phase of the scattered wave, since, as already
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mentioned, amplitudes of scattered waves that are in phase will add up, and the
amplitude of scattered waves that are out of phase will cancel out. However, there is
no practical way of measuring the relative phase angles for the different diffracted
spots experimentally. The number of photons gives the intensity, which can be
turned into amplitudes. But the phase has been lost.
The diffraction pattern is related to the object diffracting the waves through a
mathematical operation, the Fourier transform. Diffraction patterns gives us
information of the “reciprocal space”, which, calcultating the inverse Fourier
transform, gives information of the “real space”. To compute the inverse Fourier
transform we need the amplitude and the phase of the diffracted waves (see Figure
IV.6).
Figure IV.6. A particularly dramatic illustration of the importance
of phase. On the top are photographs of Jerome Karle (left) and Herb
Hauptman (right), who won the Nobel Prize for their work on solving the
phase problem for small molecule crystals. The photographs are
treated as density maps and their Fourier transforms are calculated to
get amplitudes and phases. When the phases from the picture of
Hauptman with the amplitudes from the picture of Karle are combined,
we get the picture on the bottom left. The bottom right picture combines
the phases of Karle with the amplitudes of Hauptman. Clearly the
phases are dominating what we see (http://www-
structmed.cimr.cam.ac.uk/Course/Fourier/Fourier.html#phase).
One way to solve the phase problem is to possess an atomic model, from
which estimates of the phases can be computed. Such a model can be obtained
when the structure of a related protein is known, or even the same protein from a
different crystal form. But to build up an atomic model of the new crystal form, it is
necessary to work out how the model should be oriented and positioned in the new
cell. Molecular replacement is the technique used to solve that problem.
Molecular replacement can be used to solve a structure when a good model
is available for a reasonably large fraction of the structure in the crystal. As the
number of solved structures in the database increases, this method will be useful for
a larger fraction of new structures. Of course, it is also useful for binding studies or
studies of complexes formed from previously-determined proteins.
The level of resemblance of two protein structures usually correlates well
with the level of sequence identity, which means that it can be speculated whether
or not molecular replacement will succeed before even trying it. As a rule of thumb,
molecular replacement will probably be moderately straightforward if the model is
reasonably complete and shares at least 40% sequence identity with the unknown
structure. It becomes progressively more difficult as the model becomes less
complete or shares less sequence identity.
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This technique was particularly appropriate for the solution of the SH3
structures, since all SH3 domains have essentially the same overall structure. For
the first SH3 domain that was solved in this project (CIN85-SH3C), SEM5 C-terminal
SH3 domain (PDB code 1SEM) was used as a search model, since they have a
sequence identity of 47%. For posterior structures, CIN85 and CMS SH3 domains
were chosen as search models. Molecular replacement was performed using the
programs AmoRe (Navaza 1994) and Molrep (Collaborative Computational Project
1994).
In the case of CIN85-SH3C and CIN85-SH3A:CD2, after the theoretical
phases were assigned automatic model building was carried out using the program
ARP/wARP (Zwart, Langer et al. 2004).
5.3.3. Model refinement
Once the structure solution is found, a model can be generated either by
automatic model building or, alternatively, model building can start directly from the
MR solution. The parameters of this model need to be changed to be optimized so
that it agrees with the observed data. Refinement of a structure model consists on
the optimization of a function of a set of observations.
In refinement programs, several properties are taken into account, such as
crystal symmetry, stereochemical properties of the atoms in the molecule, the
atoms’ vibrations about their central positions (which estimates are indicated by the
B factors), or the internal energy of the molecule, among others.
A diffraction data set at 2Å resolution of a medium-sized protein with about
2500 atoms contains around 22000 reflections. This means that in order to be able
to handle the data, the number of parameters to be refined need to be minimized.
There are a number of programs available for structure model refinement.
Each of them makes their own set of assumptions, with certain distribution of errors
and different consequences of such errors. Therefore, one may work better than
another in a particular problem.
Two main statistical methods are used for model refinement: least squares
and maximum likelihood. The latter does not need to make the assumptions
required for the least squares method (which have been shown to be incorrect in
many refinement problems), and it is more broadly used nowadays (Tronrud 2004).
For the CIN85-SH3A2-58His6 model, automatic refinement was carried out
with CNS software (Brunger, Adams et al. 1998), combined with manual model
building in Xfit (McRee 1999).
All the other models were refined by cycles of positional and restrained
individual B-value automatic refinement with Refmac5 software (Collaborative
Computational Project 1994) and manual model building using Coot (Emsley and
Cowtan 2004) software. In the case of CIN85-SH3A:CD2 complex, final refinement
was carried out with Shelxl software (Sheldrick, Schneider et al. 1997).
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5.4. Protein characterization
5.4.1. Fluorescence Spectroscopy
Proteins are the only biomolecules that have an intrinsic fluorescence useful
and measurable, in contrast to lipids, membranes and saccarides that are in
principle non fluorescent, or DNA, which fluorescence is too weak to be useful. The
three aromatic residues (phenylalanine, tyrosine and tryptophan) contribute to the
protein ultraviolet fluorescence, and, to our advantage, they are uncommon in
protein sequences. Particularly, tryptophan absorbs at the longest wavelength and
displays the largest extinction coefficient so that it dominates the emission of
proteins. Tryptophan is especially sensitive to its local environment, and thus,
changes in its emission spectrum in response to conformational transitions,
substrate binding or denaturation, among others, can be observed. All of these
processes can affect the local environment of the indol ring of the tryptophan. In
addition, tryptophan has a tendency to donate electrons from the indol group when it
is in an excited state, which gives it a unique sensitivity to collisional quenching5.
The decrease in fluorescence, or quenching, can be caused by either an external
molecule, such as a protein substrate, or by nearby groups in the protein (Lakowicz
1999).
To measure the change in fluorescence emission upon peptide addition, a
1-2μM protein solution and a 1.5-2.5mM peptide solution were prepared in the
Superdex elution buffer. The lyophilized peptides were weighted in an analytical
balance and corresponding buffer volume was added for their solubilization. Protein
concentration was calculated by measurement of absorbance at 280nm using the
Beer-Lambert Law as described in section IV.4.2. Samples were mixed and
temperate in a Peltier stirring block to 20ºC. Excitation and emission slits were open
2 and 4mm, respectively and the photomultilplier set to 1000V.
5ml cuvettes were filled with 2.5ml of protein solution, and samples were
excited at 290nm to avoid contribution of the emission of phenylalanine and tyrosine.
Emission spectra were measured from 310 to 370nm in 1nm steps. Between each
spectrum measurement, 0.3μl of peptide was pippeted in manually, and incubated
under continuous stirring at 500rpm for 15 minutes at 20ºC. A tryptophan bleaching
control was taken by measuring protein against buffer emission spectra and the
same was done with buffer against buffer for dilution correction.
Buffer measurement was substracted to the raw data to correct for dilution.
Subsequently, an average of the five maximum points was calculated (335-340nm)
and tryptophan bleaching correction was applied (Di Stasio, Bizzarri et al. 2004). For
the latter, dilution correction and average of the peak was calculated for control data,
time-spots vs. relative fluorescence (normalized) was plotted to calculate the
parabolic equation which was then applied to each point in the spectra. Every point
5 The decrease in intensity of fluorescence is referred as quenching. Collisional quenching
occurs when the excited-state fluorophore is deactivated upon contact with some other
molecule in solution (which can be referred as the quencher).
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of the corrected data was divided by the calculated tryptophan bleaching
contribution and a fit curve could be calculated with Origin software applying the
single-site binding model equation (Frel=(1+K[L]FML)/(1+K[L]), where Frel= Relative
Fluorescence, normalized to F0); K= association constant, for which the published
data (14M KD) was used as a temptative value; [L]= ligand concentration, FML=
Fluorescence of the complex) (Eftink 1997).
5.4.2. Isothermal Titration Calorimetry (ITC)
Almost all physical or chemical processes have an associated heat effect. In
most biological binding events, heat is absorbed or generated, and this can be used
as the basis for a number of analytical techniques as well as for the determination of
absolute thermodynamic quantities for the study of biomolecular interactions.
Microcalorimetry is a good biophysical method for non-invasive, non-destructive
analysis of biomolecular stability and interactions, since no tagging or immobilization
of binding components is needed (http://www.microcal.com/index.php?id=312).
Titration calorimetry is the most direct method to measure the heat change
on formation of a complex at constant temperature. In a typical Isothermal Titration
Calorimetry experiment a ligand is titrated into a solution of protein (or vice versa),
and the association constant, KA, and the stoichiometry, n, of the complex are
obtained (Jelesarov and Bosshard 1999). After each addition of a small aliquot of
ligand, the heat released or absorbed in the sample cell is measured with respect to
a reference cell filled with buffer so that the quantity of heat absorbed or released is
in direct proportion to the amount of binding occurring. When the system reaches
saturation, the signal diminishes and only heats of dilution are observed.
The setup of our experiment in a VP ITC Calorimeter from MicroCal
consisted on titration of a peptide solution in the protein buffer concentrated 10 times
more than the protein. Protein and peptide solutions were degassed and taken to
18ºC temperature in a Thermovac apparatus from Microcal. Protein concentration
used varied from 1 to 2 μM, and peptide was titrated in 2 and 5μl volumes in 30
second intervals. Heat measurements were taken at 18ºC.
Control measurements were taken with titrations of buffer into buffer and
buffer into protein, so that heat emission of solvent dilution could be substracted to
the raw data. Data were fit by least-squares procedures assuming a one-site binding
model using Microcal Origin software version 7.0 (function itcfun32.2).
5.4.3. Circular Dichroism (CD)
Circular dichroism measures the wavelength dependence of the differential
absorption of right and left circularly polarized light. The right and left components of
a polarized beam of light interact differently with the chiral centers of an optically
active chromophore. This interaction results in a decrease of the velocity of wave
propagation and its absorption, which depends on the wavelength. This fenomena
results in a difference in phase of each component of the polarized light so that the
sum of the vectors of the two components rotates following a helical path.
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Measurement of the differences in reflected light gives an idea of the chirality of the
molecule and its structure.
Because of the multiple conformations adopted by the peptide bond (the
principal element detected by CD), the CD spectrum is the result of an average of
the various conformation parameters. Therefore, the precise structure of a protein
cannot be constructed from its CD spectrum. Nevertheless, this technique is broadly
used for comparison with spectrums of proteins with already known structures and
gives an idea of the structural features of the molecules (Freifelder 1982).
The different secondary structure elements display characteristic spectra, so
that we can predict which of them prevails: antiparallel β-sheets, turns or helices.
Measurements were taken for individual His-tagged SH3 domains from
CIN85 in a Jasco J810 apparatus. The system was purged with liquid nitrogen to
evacuate all the oxygen, and gas speed were set to 15-20 L/min.
The concentration of the protein was adjusted so that the signal was lower
than 800AU (~21μM). 2mm cuvettes were used with 0.4ml of protein solution. 20
cycle measurements were taken at 20ºC.
A temperature denaturing curve was collected at the maximum peak, at
1ºC/min. Subtraction of the buffer baseline was not needed since the protein had
been diluted 300 to 1000 in water and the buffer spectra showed values very close
to zero.
5.4.4. Chemical shifts in monodimensional Nuclear
Magnetic Resonance (NMR)
As seen for circular dichroism spectrometry, 1-D nuclear magnetic
resonance (NMR) can be used to identify secondary structure elements of a protein.
Comparison of empirically measured chemical shifts of a protein in
monodimensional NMR spectra with those of known-three dimensional structures
allows the assignment of secondary structure elements such as β-sheets, α-helix or
random coils.
In a molecule, each nucleous of the same type will have a resonance
frequency that depends on the chemical group in which it resides, which means that
shifts in chemical resonance (chemical shifts) of backbone atoms in proteins are
extremely sensitive to local conformation. Advanteously, homologous proteins show
similar patterns of secondary chemical shifts that can be used to assign secondary
structure features to proteins of unknown structure.
Purified CIN85 SH3 samples were diluted to 0.1mM in PBS buffer and
dialysed against PBS to get rid of any Hepes traces from the Superdex buffer.
Deuterium was added to a 10% final concentration.
One dimensional NMR experiments were performed at 25ºC in a 600MHz
Bruker Avancer spectrometer and analized by Dr. Daniel Padró and Dr. Francisco J.
Blanco from the NMR group at the CNIO. XWinNMR version 3.5 (Bruker) was the
software used for the acquisition, processing and analysis of all spectra.
RESULTS
“Be aware that negative results can be just as important as positive results”
E. R. Schulman
“Un resultado negativo es un resultado”
J. Bravo
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V. Results
1. CIN85
1.1. Individual CIN85 SH3 domains
In our attempt to study the interactions that take place in the signalosomes
required for EGFR endocytosis, we successfully cloned and purified several CIN85
and c-Cbl fragments, in addition to wild type human Ubiquitin. Each clone was
designed with GST and hexahistidine affinity tags at different positions, as well as
un-tagged: full length CIN85, CIN851-607, CIN851-600, CIN85-SH3ABC, CIN85-
SH3AB, CIN85-SH3BC, c-Cbl808-906, c-Cbl816-906, c-Cbl816-895, c-Cbl820-830 and full
length Ubiquitin. Expression of all of them was endeavored in different systems and
they were purified to be combined to form different multimeric complexes which
interactions were confirmed by different methods; nevertheless, crystals obtained in
this approach, if any, were not suitable for structural determination.
It is widely known in the field that proteins with multiple domains, such as
CIN85, are difficult targets for structural studies for several reasons: “First, multi-
domain proteins are difficult to express in E. coli”, which is a low cost, fast and easy
to handle expression system. “Second, these proteins exhibit conformational
heterogeneity, which decreases the probability of crystallization” (Edwards,
Arrowsmith et al. 2000).
SH3 domains are generally very stable and globular domains, thus, as an
alternative and in order to simplify the crystallization problem and focus on the study
of the direct interaction between CIN85 and Cbl, we expressed and purified the SH3
domains individually.
Characterization of the CIN85 SH3 domains both individually and
complexed with synthetic peptides derived from the Cbl-b and c-Cbl CIN85 binding
sequences should provide specific information regarding the differences among the
CIN85 SH3 domains. It should also offer some clues regarding SH3 differential or
redundant functionality within the CIN85 molecule, a recurrent issue expossed in the
literature. Their characterization would allow us to compare binding of other SH3
domains to different polyproline motives, and thus, be able to elucidate the
relevance of the described novel binding motif (Kowanetz, Szymkiewicz et al. 2003;
Kurakin, Wu et al. 2003) in comparison to the typical xPxxP motif and other already
reported atypical SH3 binding motifs (Lewitzky, Harkiolaki et al. 2004);(Mongiovi,
Romano et al. 1999);(Berry, Nash et al. 2002);(Tong, Drees et al. 2002).
1.1.1. Design of SH3 constructs and the Cbl peptides
SH3 domains provided by I. Dikic were designed so that 22 residues
reminiscent from the vector sequence, which represent a ~37% of the construct
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sequence length, were expressed (see Figure V.1). This fact should not represent a
problem for interaction and cell biology studies, yet it might certainly be an obstacle
for protein crystallization. Crystallisation trials of these constructs did not yield any
crystals suitable for any further structural characterization so that we proceeded to
the design of new CIN85 individual SH3 constructs.
Figure V.1 Multiple cloning site (MCS) of pET-21a from Novagen. Nucleotide sequence of the MCS is
transcribed in the bottom line. On the upper part, sequence sections corresponding to the differentent
restriction enzyme (RE) sites and expression tags are indicated. On the lower part, the amino acids
corresponding to the DNA translation are annotated. The hexahistidine tag is expressed when in frame
with the Xho I site. Vector aminoacids expressed in the clones provided by Ivan Dikic are indicated in red.
As an alternative to increase the chances of obtaining suitable crystals, we
proceeded to the recloning of the SH3 constructs, mainly to avoid the expression of
extra residues coded into the vector sequence. Expressed residues foreing to the
protein sequence do not provide any relevant structuctural information inherent to
the protein; however, they can provide the protein constructs with flexible fragments.
Flexibility is an attribute that plays against crystal formation, given that in a crystal,
the molecules must pack together in a regular, periodic, and continuous manner.
Flexible fragments might thus grant conformation variability to the protein sample,
and thus, do not allow formation of the periodic arrangement that builds up a protein
crystal. As a matter of fact, it has been found that removal of mobile elements from a
protein by proteolysis or by molecular biology methods, allows the prompt
crystallization of proteins that had not been possible to crystallize by all means prior
to exclusion of such elements (McPherson 1999).
We compared the CIN85 SH3 domains with the sequence of a highly
identical SH3 domain of which the structure was known. This comparison would
allow us to evaluate whether the extension of the domains was appropriate and
hence allow us to limit it to the residues strictly necessary to fold into an SH3
domain. A BLAST search in the Protein Data Bank (PDB) database with the CIN85
SH3 domains was performed, and we found that, among the SH3 domains with a
known structure, the C-terminal domain of SEM5 (1SEM; SEx Muscle abnormal
family member, GRB2 worm homolog -Caenorhabditis elegans-) was the one with
the highest sequence identity (43%) with an expected value (E) of 0.47. Such
relatively high E-value is due to the short sequence length. Comparison of the
aligned sequences by ClustalW and analysis of the structure of 1SEM helped us
design new constructs with an extension similar to the SEM5 SH3, avoiding flexible
extremes (Figure V.2).
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Figure V.2. Overall structure of the C-
terminal SH3 domain of SEM5 bound to
a polyproline rich Sos derived peptide
(PDB code 1SEM). Cartoon representation
of the β-barrel structure of the C-terminal
SH3 domain of SEM and a stick
representation of the peptide with carbons
in white, nitrogens in blue and oxygens in
red. Conserved aromatic residues from the
binding core are highlighted in yellow, and
the RT and n-Src loops that form the acidic
pocket are colored in green (Figure
modified from (Zarrinpar, Bhattacharyya et
al. 2003)).
We cloned the new sequences into the pET-21a vector using Nde I and Xho
I restriction sites that would allow the expression of a minimum number of residues
foreign to the protein (Nde I codes for the initial methionine, and Xho I allows
expression of only two extra residues apart from the hexahistidine tag, see Figure
V.1), residues that would not provide any structural information intrinsic to the
protein. In the case of CIN85-SH3C, the DNA could not be cloned into the pET-21a
vector with Nde I, since such restriction site is present into the natural CIN85-SH3C
cDNA sequence. Therefore, the amplicon of CIN85-SH3C was flanked by Nhe I and
Xho I (this cloning causes the expression of only three extra residues in the N-
terminal end, plus eight residues in the C-terminus).
In the structure of 1SEM, we observed that only the first three amino acids
had a flexible character, since the first β-sheet was stabilized by a hydrogen bond
established between phenylalanine 158 and the last expressed residue, asparagine
212. To be in the safe side, we limited the extension of the new designed constructs
to be one residue longer in each terminus, according to the sequence alignment to
SEM-SH3C-term (see Figure V.3). Therefore, new residue boundaries were set to
residues 2 to 58 in SH3A, 101 to 157 in SH3B and residues 270 to 328 in SH3C.
Figure V.3. Alignment of the newly designed SH3 construct sequences from CIN85 and the C-
terminal SH3 of SEM5. The residues disordered in the SEM SH3 structure are indicated with a red box.
The sequence alignment of the new constructs with SEM5 SH3C-term
individually shows an identity of around 41% with a ~22% of strong similarity and
~15% of weakly similar residues (43% identity with SH3A, 36% with SH3B and 45%
with SH3C, specifically, according to the program Clustal) (see Figure V.3).
56 Results
Another observation we made from the published structure of the SEM5
SH3 domain in complex with the Sos derived polyproline peptide, is that only seven
of the nine amino acids in the peptide were observed in the electron density, which
seemed to be the only ones contributing to the interaction. We initially had been
using for crystallization trials Cbl peptides that included the sequence of those
peptides previously shown to interact in vivo with CIN85 (Kowanetz, Szymkiewicz et
al. 2003). Those extra amino acids might indeed hamper the crystallization of the
complexes by providing flexibility to the peptide structure. Therefore, we decided to
design new peptides with short extensions, decreasing the number of residues from
22 and 23 (in Cbl-b893-914 and c-Cbl811-834, respectively) to 11 (see Table IV.9 in
Materials and Methods).
Figure V.4. Overexpression of CIN85-SH3B101-157His6 in E. coli
strains at 37ºC. 17% SDS-PAGE gels of total cells, lanes 1 and 4:
molecular weigth markers; lanes 2 and 5: uninduced (u); lanes 3, 6 and
7: induced (i); lane 3: overexpression of SH3B in BL21(DE3) with TB
broth; lane 6: overexpression of SH3B in Rosetta(DE3)pLysS with
2xTY broth; lane 7: overexpression of SH3B in Rosetta(DE3)pLysS
with SOC medium. The gel was stained with Coomassie Brilliant Blue.
We first pursuited the expression and purification of the new construct of
SH3B. We achieved adequate overexpression of CIN85-SH3B101-157His6 in
Rosseta(DE3)pLysS and BL21(DE3) E. coli strains with SOC, 2xTY and LB media at
37ºC (Figure V.4). Imidazole was included in low concentration in the lysis buffer to
avoid competition of contaminants in binding to the nickel charged sepharose resin.
An Imidazole gradient was performed in the elution segment of the affinity
chromatography to selectively elute the His-tagged protein. In the final size
exclusion step, we obtained a pure protein sample of an apparent molecular weight
of 9.2kD, according to the gel filtration column calibration, which is close to the
sequence calculated weight of 7.6kD of a monomeric protein (Figure V.5).
Figure V.5. Pure CIN85-SH3B101-157His6. Analysis of the elution peak in an SDS-PAGE
shows high purity of the eluted sample. It can be observed that low molecular weight
proteins run as broader bands in high percentage polyacrylamide gels.
The acquisition of suitable crystals for structural studies
requires not only a chemically highly pure sample but also a
structurally homogeneous protein. The SH3B protein sample was
analyzed by mass spectrometry. The homogeneity of the sample was
confirmed by a spectrum with a single peak of a molecular weight of
7.6kD that differed from the theoretical one in only 5Da.
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In order to analyze the folding state of the protein we also performed some
circular dicroism (CD) studies and monodimensional nuclear magnetic resonance
(NMR) experiments. Figure V.6 shows the far UV spectrum of CIN85-SH3B101-
257His6, in which we observe negative peaks around 206 and 228nm (Figure V.6A).
Compared to other SH3 domain CD spectra in the literature (Figure V.6B and C), the
CIN85-SH3B spectrum displays a typical pattern for SH3 domains. Additionally, the
experiment was repeated after thermal denaturation to confirm total recovery of the
folding state. This indicates that the thermal denaturation of the SH3 domain is
totally reversible (Figure V.6A).
Figure V.6. Circular Dichroism (CD)
spectra of CIN85-SH3B101-257His6 and
other SH3 domains. (A) The green
spectrum corresponds to the measurement
taken previous to thermal denaturation,
while the purple one represents the
measurement after thermal denaturation.
Both show negative peaks near 206 and
228nm. (B, C) Circular Dichroism (CD)
spectra of (B) Fyn-SH3 wild type and
mutants of the core domain and (C) SH3
domains from Abl, Fyn, c-Src, n-Src and
Spectrin, studied by Di Nardo et al. (Di
Nardo, Larson et al. 2003) and Viguera et
al. (Viguera, Arrondo et al. 1994),
respectively. The far UV spectrum of all SH3
shown, except for Abl, show similar
characteristics as the one measured for
CIN85 SH3B domain, with minimums
around 206 and 228nm, and maximum
around 222nm.
The thermal denaturation of CIN85-SH3B101-257His6 yielded a sigmoidal
transition at a wavelength of 206nm. A cooperative process of denaturation occurred
between 40 and 60ºC, with a melting temperature of approximately 50ºC (see Figure
V.7).
Figure V.7. Thermal
stability curve of CIN85-
SH3B101-257His6 monitored
by far-UV CD. Mean
residue weight ellipticity at
206nm, with normal two
folding state behavior with a
melting temperature of
around 50ºC.
Figure V.8. Detail of the Monodimesional Nuclear Magnetic Resonance
(NMR) spectra of the CIN85-SH3B101-157His6 protein construct between 6
and 5.5 ppm. Peaks in this region indicate the presence of β-sheet folding
structure.
In the NMR experiment we observed chemical shifts between 6 and 5.5ppm
characteristic of antiparallel β-sheet pattern in the NMR monodimensional spectrum
of CIN85-SH3B101-157His6 (Figure V.8), which would correlate with the correct folding
of the protein (Viguera, Arrondo et al. 1994; Viguera, Martinez et al. 1994). The
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SH3B was tested for Cbl-b binding by comparison of monodimensional spectra of
samples of SH3 alone, and with the peptide; however, only subtle changes were
observed and results were inconclusive.
The protein sample was concentrated to 7.9mM (60mg/ml) and Wizard HT
screen was set at 22ºC with drops of 0.8+0.8μl (protein+reservoir solution).
Crystallization of the complex was attempted as well by sparse matrix screening of a
mixture of the CIN85-SH3B protein and the long Cbl-b peptide (Clb-b893-914) in a
1:1.5 ratio and at a calculated final protein concentration of 6.6mM (50mg/ml). We
did not obtain any crystals in these conditions. However, we did not succeed in the
acquisition of crystals suitable for structural determination.
1.1.2. Purification, crystallization and structure of CIN85-
SH3C270-328His6
As mentioned before, CIN85 SH3 domains have been shown to associate
with several intracellular signaling proteins containing different PxxxPR motifs.
Interestingly, variations in these motifs can also lead to modulation of CIN85-SH3
domain binding affinities, as reported in various studies. Several authors have
claimed to observe overlapping but not identical specificities of the domains.
Specifically, peptides selected by the SH3C domain can host a proline (which can
exclusively be substituted by a valine) in the position preceding the arginine of the
core PxxxPR motif, whereas the other SH3 domains can tolerate polar and charged
residues (Kurakin, Wu et al. 2003). This differential binding has also been observed
not only with peptides but with natural partners as well, as it has been shown by pull-
down or assays where different authors have noticed the lowest affinity to c-Cbl to
be displayed by SH3C, as well as no appreciable binding between BLNK or CD2
and SH3C (although there was clear binding to SH3A and SH3B) (Kurakin, Wu et al.
2003; Tibaldi and Reinherz 2003). Another feature that distinguishes SH3C from the
other CIN85 SH3 domains is that it is the least cross-reacting toward peptides
selected by the other two domains, supporting the idea of overlapping but distinct
specificities of CIN85 SH3 domains.
Figure V.9. Overexpression of CIN85-SH3C270-328His6. The CIN85-SH3C
construct was expressed in E. coli BL21(DE3) strain at 25ºC, induced with 0.1mM
IPTG. 17% SDS-PAGE of total cells: lane 1, molecular weight marker; lane 2, pre-
induced and lane 3, induced. Gel was stained with Coomassie Brilliant Blue.
The SH3C270-328 construct was successfully expressed in
E. coli/BL21(DE3) with LB broth at 25ºC for 7 hours of 0.1mM
IPTG induction (Figure V.9). It was purified following a similar
strategy as followed for SH3B. No addition of protease inhibitors in
the lysis buffer was used since the SH3 domains are predicted to
be globular and their short sequence length is not expected to
contain many exposed sites susceptible for bacterial proteolysis.
However, as a precaution and to avoid activation of proteases, the
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cell lysate was kept on ice or at 4ºC at all times prior to His-tag selection, which was
carried out inmediately after cell lysis.
Briefly after sonication, the clear lysate was subjected to a His-tag selection
in a nickel charged HiTrap chelating column, and bound protein was washed with a
buffer containing 50mM imidazole so that waste proteins readily separated from the
target protein (first eluted peak in the chromatogram, see Figure V.10). For protein
elution a 50 to 500mM Imidazole gradient was performed. We recovered a large
amount of a partially clean sample of SH3C, which eluted in a broad peak starting at
109mM Imidazole (Figure V.10).
Figure V.10. Purification of -SH3C270-328His6 in a nickel charged Chelating HiTrap column. The blue
spectrum indicates the UV280 absorption of eluted sample, and the green line indicates the elution buffer
percentage (which, indirectly indicates the imidazole concentration from 50 to 500mM). The SH3C eluted
in a broad peak between 109 and 266mM Imidazole concentration. The indented 15% polyacrylamide
Coomassie Brilliant Blue stained SDS gel shows collected fractions of the elution peak where the SH3C
protein was eluted together with some high molecular weight contaminants.
In order to further purify the sample, a second anion exchange
chromatography step was performed. Given that imidazole contributes to increase
the ionic strength of the solution, we diluted the collected sample to a calculated
imidazole concentration of 20mM, previously to loading into the Q FF HiTrap column
so that sample would bind to the resin. Most of the middle molecular weight
contaminants did not bind to the column, and the SH3C protein eluted in a broad
peak between 18 and 49mS/cm of conductivity (see Figure V.11).
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Figure V.11. Purification of CIN85-SH3C270-328His6 in a Q FF HiTrap column. The blue spectrum
indicates UV280 absorption of the eluted sample, and the green line shows the elution buffer percentage
(which indirectly indicates the NaCl concentration, from 0 to 1M). CIN85-SH3C270-328His6 elutes in a broad
peak starting at 18.2mS/cm. The indented 15% polyacrylamide SDS-PAGE stained with Coomassie
Brilliant Blue, shows elution peak corresponding to SH3C elution.
The slightly purer sample was then subjected to a size exclusion
chromatography in a Superdex75 column. A very pure protein sample that behaved
as a monomer was collected. CIN85-SH3C displayed an apparent molecular weight
of 8.6kD (Figure V.12), which is in agreement with the sequence calculated weigth
(8.1kD).
Figure V.12.
Purification of CIN85-
SH3C270-328His6 by size
exclusion. Elution of
CIN85-SH3C270-328His6
in a Superdex 75 26/60
gel filtration column at a
volume of 219.93ml,
which corresponds to a
molecular weigh of
8.6kD that agrees with
the theoretical weight of
the monomeric SH3C
(8.1kD). Analysis of the
elution peak in a 15%
SDS-PAGE shows high
purity of the eluted
sample.
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Mass spectrometry analysis showed a spectrum similar to the one obtained
for SH3B. The molecular weight measured differed from the calculated one in
140Da. The initiation methionine (formyl-methionine) has a theoretical weight of
161Da. This weight difference could be accounted for the loss of the formyl-
methionine, as it has been previously described in the literature (Sherman, Stewart
et al. 1985; Ben-Bassat, Bauer et al. 1987), together with the addition of a sodium
atom (23Da) present in the buffer.
Circular dichroism studies in SH3C displayed a spectrum similar to the one
observed for the SH3B, correlating with published CD spectra of correctly folded
SH3 domains (Figure V.6B and C, and Figure V.13A). Apart from measuring the
ellipticity changes at the far UV spectrum, a thermal denaturation curve at a 222nm
wavelength was performed. CD is extraordinarily sensitive to changes in
conformation. Hence, conformational changes upon ligand binding, or protein
denaturation, for instance, can be followed. The denaturation of proteins is always
accompanied by CD changes that indicate the loss of secondary structure and the
enhancement of the random-coil spectral components. By plotting ellipticity at a
particular wavelength as a function of the denaturing conditions, in this case
temperature, one can follow denaturation of the protein.
Thermal denaturation of CIN85-SH3C270-328His6 yielded a sigmoidal
transition reflecting loss of secondary structure when monitored by far-UV CD, as
seen in Figure V.13B. A wavelength of 222nm was chosen to monitor the thermal
melts because maximum differences in CD signal were seen at this wavelength. A
cooperative process of denaturation occurred between 35 and 60ºC, with a melting
temperature of approximately 45ºC (Figure V.13B).
Figure V.13. Circular
Dichroism (CD) spectra
of CIN85-SH3C270-
328His6. (A) The
spectrum corresponds to
ellipticity changes along
the far UV spectrum. (B)
Thermal stability curve of
CIN85-SH3C270-328His6,
with normal two folding
behavior monitored by
ellipticity at 222nm,
where we observe the
melting temperature at
around 45ºC.
Previous knowledge of SH3 domain structure, allows us to search for
specific secondary structure elements in the NMR spectrum of CIN85-SH3C270-
328His6. As mentioned previously, SH3 domains fold into a β-barrel build of two
antiparallel β-sheets. The presence of such antiparallel β-sheets was inferred in the
62 Results
NMR analysis, with chemical shifts between 6.5 and 5.0 ppm characteristic of such
structural elements (Figure V.14.) (Viguera, Arrondo et al. 1994; Viguera, Martinez
et al. 1994).
Figure V.14. Detail of the Monodimesional Nuclear Magnetic
Resonance (NMR) spectra of the CIN85-SH3C270-328His6 protein
construct between 6 and 5.5 ppm. Peaks in this region indicate the
presence of β-sheet folded structure.
Provided that results from Mass spectrometry, CD and NMR analysis
indicated evidence for the correct folding state of the SH3C construct in a
homogesneous sample, the pure protein was used for crystallization trials.
1.1.2.1. CIN85-SH3C binds to c-Cbl peptides
In order to evaluate the biological activity of the newly designed SH3C
construct and c-Cbl peptide, we wanted to verify their binding by fluorescence
spectrometry and compare it with the published data.
To our convenience, there are only two tryptophans in the CIN85-SH3C
sequence, which are located consecutively, and one of them (Trp307) is predicted to
be directly involved in SH3:polyproline binding. Changes in Trp307 environment
upon interaction with the ligand are thus expected to be reflected in fluorescence
emission.
Fluorescence was hence used as a spectroscopic probe to monitor the
change in environment of tryptophan 307 from the binding core domain and its
adjacent tryptophan, Trp306, upon peptide binding. The affinity of CIN85-SH3C273-
326His6 for the synthetic peptide c-Cbl810-834 reported by Kowanetz and co-workers
was of 14μM (Kowanetz, Szymkiewicz et al. 2003). When binding affinities of our
CIN85-SH3C construct to both a long (c-Cbl810-834) and a short (c-Cbl820-830) c-Cbl
peptide were measured, we obtained measurements of a dissociation constant six
times lower than the published data in the case of the long peptide (2.4 ± 0.3μM),
and 23-fold lower with the newly designed peptide (0.6 ± 0.06μM) (Figure V.15).
Calculation of binding stoichiometry and affinity depends directly on sample
concentration. Hence, accurate measurement of the protein and peptide sample
concentration is critical for data interpretation. The polyproline c-Cbl derived peptide
sequences do not include any aromatic amino acid, so that any precise calculation
of the peptide concentration cannot be achieved by spectrometric absorvance
measurement at 280nm wavelength. Instead, the lyophilized peptide was weighted
in an analytical balance and appropriate buffer volume added to achieve the desired
stock concentration. This method accumulates a series of experimental errors in
each step, such as weighting errors and pipetting. Therefore, this is the most
plausible explanation for the affinity differences observed in c-Cbl810-834 and c-Cbl820-
830 binding to CIN85-SH3C.
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Figure V.15. Binding of c-Cbl peptides to CIN85-SH3C273-326His6 construct monitored by collisional
quenching of CIN85-SH3C fluorescence. Change in the fluorescence intensity of CIN85-SH3C as a
function of c-Cbl820-830 (left) and c-Cbl810-834 (right) concentration, corrected for the effect of dilution on
addition of the buffer. The solid red line is the calculated curve using the best-fit parameters to equation
Frel=(1+K[L]FML)/(1+K[L]). The best values for stoichiometry, binding constant, and enthalpy are shown in
the box. A decrease in the relative fluorescence is observed upon peptide addition in both cases. To
better illustrate the different affinities between these two titrations the x and y axes are shown on the
same scale.
It is important to highlight the observation that most of the published
fluorescence spectrometry studies of SH3 domain binding to polyproline sequences
show an increment in the fluorescence when the peptide binds to the SH3, as shown
by De Filippis and co-workers and Kaneko and co-workers (Figure V.16).
Surprisingly, in our case there is a quenching effect upon peptide binding.
Figure V.16. Published fluorescence data of other SH3 domains binding to polyproline peptides.
(A) Myo3-SH3 binding to IF analogs: P2IF1 (•-•), P2IF13 ( - ) and an unmodified P2 peptide ( - ).
Continuous lines represent the best fit of the data points to ΔF=Fº-F=(ΔFmax·[L])/(KD+[L]) (De Filippis,
Draghi et al. 2007) and (B) fluorescence change of STAM2 SH3 domain by poly-L-proline peptide binding
(Kaneko, Kumasaka et al. 2003). The change in fluorescence upon peptide binding in both examples
increases, as opposed to CIN85-SH3C binding to c-Cbl peptides.
Additionaly, we were able to co-purify a His/GST-tagged c-Cbl peptide
(His/GST/c-Cbl820-830, in pGATEV vector) with an untagged SH3C CIN85 construct
(CIN85-SH3C270-328 taa tag, in pET-24d vector) by means of binding of the c-Cbl
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peptide to a GSTrap column and then the SH3C to the peptide.
Presence of both proteins in sample solution was confirmed by SDS-
PAGE (Figure V.17) and mass spectrometry. From this result we could
conclude that binding of both proteins was possible, although no affinity
constant or stoichiometry can be estimated from such experiments.
Crystallization experiments were set with this sample and crystals were
obtained. Crystal diffraction was very poor and no data processing was
possible.
Figure V.17. Purified CIN85-SH3C270-328 taa tga (middle band) and c-Cbl820-830 after tag
cleavage (lower band). A small fraction of the Tev protease used for tag cleavage is
present in this sample (top band).
1.1.2.2. Structure of CIN85-SH3C270-328His6
Un-complexed CIN85-SH3C270-328His6 was
crystallized at 4ºC by the vapor diffusion method, in 1μl
drops of a 1:1 mix of protein solution at 11.4mM
(92.7mg/ml) and three different crystallization
solutions: 0.1M Acetate pH 4.5, 20% PEG 3000; 0.1M
Citrate pH 5.5, 2.0M (NH4)2SO4 and 0.1M CHES pH
9.5, 30% PEG 3000 (Figure V.18).
Crystal formed in the second condition
appeared to be the best candidate for its reproduction.
Optimization of the crystal was carried out with
different (NH4)2SO4 concentrations and different citrate
pH’s (100mM final concentration). Crystals used for the
X-ray diffraction were produced in 1.8M (NH4)2SO4,
100mM Sodium Citrate pH 6.0 and stepped soaked
prior to crystal diffraction into a cryo solution of
reservoir solution containing 15 and 20% Glycerol. A
total of 80 images of 1º rotation with 15 minute
exposure each were collected with a maximum
resolution of 2.0Å.
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Aigure V.18. CIN85-
H3C270-328His6 protein
rystals. (A) Needle
haped crystals grown in
.1M Acetate pH 4.5,
0%PEG 3000. (B) Single
rystal of CIN85-SH3C270-
28His6 grown in 0.1M
itrate pH 5.5, 2.0M
NH4)2SO4.
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A resolution range of 26.8-2.2Å was used all throughout the molecular
replacement process. The integration radius for the rotation function was 20.16Å,
corresponding to 60% of the longest dimension of the model (model dimensions:
33.8 x 31.0 x 26.5Å) and it is 1.9 times larger than its radius of gyration (10.4Å).
A good correlation factor of 43 and low R-factor of 58.2% with a contrast of
4.4 to the next molecular replacement solution indicated the correct solution. Rigid-
body refinement of the top solution resulted in a correlation coefficient of 42 and an
R value of 50.5%.
Automated model building was carried out with the program ARP/wARP
(Zwart, Langer et al. 2004) included in the CCP4 program suite (Collaborative
Computational Project 1994), with which 98% of the sequence was covered, (only
the first alanine residue and the last four histidine residues from the vector sequence
were missing). A high quality model was obtained with an R-factor (which measures
the agreement between the crystallographic model and the experimental X-ray
diffraction data) of 21% and 24% of R-free (which is used to validate the R-factor
value) for a random 5% of all data.
Because the resolution of the data obtained by X-ray crystallography is not
high enough to define the atomic positions of a macromolecule with enough
precission, the structure models need to be optimized. Different programs have
been developed to subject models from the experimental data to sophisticated
refinement procedures that apply constrains based on prior knowledge about the
chemical and conformational properties of the atoms and the molecule.
Table V.1. Crystallographic data collection and refinement analysis
of CIN85-SH3CHis structure
CIN85-SH3CHis
Space group P3121
Unit Cell Dimensions (Å) a=b=47.83, c=70.23
α=β=90º; γ=120º
Data range (Å) 26.8-2.0
Observations (unique) 19366 (5991)
Completeness (%) (last shell) 95.4 (90.6)
Rsym
a (last shell) 0.054 (0.032)
Reflections F>0 (cross validation) 5715 (275)
Non-hydrogen atoms (solvent molecules) 606 (58)
Rcryst
b (Rfree
c) 0.197 (0.248)
R.m.s. bond length (Å) 0.023
R.m.s. bond angles (o) 1.674
a Rsym is the unweighted R value on I between symmetry mates.
b Rcryst = Σhkl[[Fobs(hkl)]-[Fcalc(hkl)]]/Σhkl[Fobs(hkl)]
c Rcryst is the crossvalidation R factor for 5% of reflections against which
the model was not refined.
The model of CIN85-SH3C generated with ARP/wARP was subjected to
cycles of manual and automatic refinement with the programs Coot V0.1.2-Pre-1
(Emsley and Cowtan 2004) and Refmac5 (Collaborative Computational Project
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1994) (from the CCP4 program suite (Collaborative Computational Project 1994)),
respectively. Inspection of electron density map in the program Coot allowed
building of the initial alanine and two more histidine residues in the His-tag, as well
as the addition of water molecules up to a total of 58. Repetitive cycles of positional
and isotropic thermal factor restrained refinement resulted in an R-factor of 19.7%
and an R-free of 25.1% for data at 2.0Å resolution (see Table V.1).
Figure V.19. Structure of CIN85-SH3C270-328His6. This cartoon representation shows a β-barrel structure
characteristic of SH3 domains. Main structural elements, such as β-strands (a through e), 310 helix, RT-
loop, n-Src loop and binding pocket are indicated. Residues belonging to the vector sequence are shown
in red.
The structure determination and refinement procedures might have biases
that prone the structure models to systematic errors. Therefore, it is necessary to
validate the quality of such models. There are a variety of tools available that
measure the deviation of the geometric and conformational parameters of the model
from those of other small molecules or high-quality structures of other
macromolecules.
Figure V.20. Ramachandran plot of CIN85-
SH3CHis6 structure validation in MolProbity
webtool. There are no residues in disallowed regions
and 100% of them are in the favored regions.
We analyzed our CIN85-SH3C
structure model with the web-based tool
MolProbity (Lovell, Davis et al. 2003) (at
http://molprobity.biochem.duke.edu).
Evaluation with this tool showed all
residues in the favored regions of the
Ramachandran plot, which compares the
backbone φ, ψ angle distribution with that
of high-quality structures (See Figure V.20).
No serius steric overlaps were detected,
and correct geometry was confirmed.
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The structure of CIN85-SH3C clearly displayed the characteristic β-barrel
fold of SH3 domains formed by two antiparallel β-sheets perpendicular to each other
(Figure V.19). This arrangement forms a hydrophobic pocket in the surface between
the two β-sheets, where the polyproline peptide binds. The first β-sheet is formed by
β-strands a (residues 270-274), e (residues 323-325) and first half of b (residues
293-295), while the second is comprised of β-strands c (a.a. 306-311), d (a.a. 314-
319) and the second half of b (a.a. 296-298). It is worth mentioning that one of the
most conserved positions in SH3 domains is a glycine (Gly316 in CIN85-SH3C)
located in the middle of β-strand d. This fact is not common in β-strands, since
glycines are usually unfavored. It has been proposed that the reason why this
glycine is present at this position is because a bulkier residue would collide with side
chains of residues from the RT-loop, although Larson and Davidson observe that
position of this glycine adopts uncommon Φ/ψ6 angles (Larson and Davidson 2000).
A torsion in β-strand b, known as a β-bulge, is what allows this strand to
participate in both β-sheets. These β-bulges are secondary structures that occur
mostly as irregularities in antiparallel sheets (only 5% of them have been found in
parallel sheets) (http://65.54.170.250/cgi-
bin/linkrd?_lang=EN&lah=10c153948089623929c773ea6ff7b706&lat=1086808043&
hm___action=http%3a%2f%2fwww%2end%2eedu%2f%7etlin%2fprotein%2ehtm).
The bulge in this sheet is due to hydrogen bond formation between one amino acid
from one sheet and one from the other. This β-bulge is conserved in SH3 domains
at a position corresponding to isoleucine 297 in CIN85-SH3C. Conserved hydrogen
bonds are present between amido groups of this residue and the following and the
carbonile oxygen of residue corresponding to Glu308CIN85. Another bond between
the amido hydrogen of the latter and the carboxylic oxygen from residue
corresponding to Asn298CIN85 is also present (Larson and Davidson 2000) (Figure
V.21).
Figure V.21. Detail of the β-bulge in the CIN85-
SH3C270-328His6 structure. Hydrogen bonds are
represented by pink lines. Carboxylic oxygen from
Glu308 main chain hydrogen bonds amide groups
from Iso297 and Asn298 main chains and amide
group of Glu308 with carboxylic oxygen of Asn289.
6 Φ refers to the angle around Cα-N and ψ the angle aroundCα-Co. Positive values correspond
to a clockwise turn of the angle (viewed from the Cα). (Φ,ψ)=(0,180), two carbonile oxygens
are too close; (Φ,ψ)=(180,0), two amide groups are superposed; (Φ,ψ)=(0,0), one carbonile
oxygen is superposed with an amide group. Glycines allow a broader angle range than other
residues.
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Several hydrogen bonds in the RT-loop (located between β-strands a and b)
give a distinctive irregular antiparallel structure with β-sheet character observed in
most SH3 domains (Gmeiner and Horita 2001). A number of recurrent interactions
are observed in all SH3 domains analyzed by Larson and Davidson (Larson and
Davidson 2000) that stabilize this loop, such as hydrogen bonds between
Glu285CIN85 and Tyr278CIN85, and carbonyl oxygen from Thr287CIN85 and the amido
hydrogen from Ala280CIN85. The hydrogen bond commonly found between the
residue located five amino acids prior to Glu285CIN85 (usually a lysine) and the
residue 13 positions prior to it (occupied 60% of the time by an asparagine) (Larson
and Davidson 2000) is not present in CIN85-SH3C, given that instead of the
conserved asparagine, we find a proline (Pro277), and a glutamic acid (Glu290) in
position of the conserved lysine. Proline is not a hydrogen donor, so that this
hydrogen bond cannot be formed.
The point in which the first β-strand changes direction is where the RT-loop
starts. Here, a hydrogen bond formed by a highly conserved residue is widely
present in SH3 domains (Larson and Davidson 2000). In CIN85-SH3C, this
hydrogen bond is estabilised between conserved residues Iso275 and Phe322 (see
Figure V.22). It has been postulated that even though the residue corresponding to
isoleucine in CIN85-SH3C is not directly implicated with the recognition of the
polyproline motif, it can play a functional role in the context of full length protein
complexes (Larson and Davidson 2000). In the case of CIN85, this position is
occupied by a glutamic acid in SH3A and an alanine in SH3B.
Figure V.22 Detail of the RT loop in the CIN85-SH3C270-
328His6 structure. Hydrogen bonds are represented with
pink lines. Conserved hydrogen bond between Ile275 and
Phe322 is shown. Phenylalanines 276 and 322 that are
predicted to interact directly with the polyproline peptide
are labeled.
Although SH3 sequences are variable, all of them share a highly conserved
common fold. In order for this to happen, certain residues need to be preserved.
Many of them form a hydrophobic nucleus critical for the protein stability, which is
comprised of a series of hydrophobic side chains particularly inaccessible to the
solvent. Almost ten positions that are conserved in the SH3 domains have
hydrophobic character and are packed in the center of the structure. These
correspond to the following in the SH3C of CIN85: Val274, Leu286, Iso288, Val294,
Leu296, Trp307, Phe318 and Val323, and also Lys273. Glycine 309 is considered
as part of the nucleus, even though it does not have a hydrophobic character, given
that it is always completely buried and contacts are established with side chains of
the rest of the residues in the nucleus.
Other conserved hydrophobic residues are present in these structures,
generating two hydrophobic pockets that, together with an acidic pocket located
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between the RT and n-Src loops, are critical for the protein recognition. Aromatic
residues Trp306 and Tyr278, and Pro319 in SH3C are the positions most conserved
in SH3 domains and play an essential role in the binding to the peptide, given that
they are situated in the center of the interaction. Residues corresponding to
phenyalanines 276 and 322, glycine 305 and asparagine 321 interact directly with
the peptide and thus are also determinant for the binding.
Analysis of the arrangement of the symmetric molecules in respect to the
asymmetric unit shows that the histidine tag packs directly against the acidic pocket
of the crystallographic symmetry related molecule, where the peptide was expected
to bind (Figure V.23). There is a hydrogen bond between the amide groups of the
first histidine and the conserved tryptophan 306, and between the hydroxyl group
from the aspartic acid 303 side chain and the carboxylic oxygen of the same
histidine. The second histidine forms four hydrogen bonds with Tyr278, Glu285 and
Gln281 from the symmetric molecule (Figure V.23). All these residues are predicted
to be essential for the binding of the ligand, so that the histidine tag could be
competing with the peptide for the binding site and thus interfering in the
crystallization of the complex.
Figure V.23. Surface
representation of the
CIN85-SH3C270-328His6
structure. A symmetry
related molecule
surface is shown in
sticks. Residues from
the binding core,
predicted to be involved
in the peptide binding,
are colored in yellow.
The fraction of the
histidine tag that could
be modeled, shown in
from the symmetrically
related molecule, is
pointing towards the
binding surface.
We also set crystallization experiments of the different SH3C CIN85
constructs in presence of Cbl peptides of different lengths. We were able to obtain
crystals at 4ºC that took over a year to appear, and were neither reproduceable nor
big enough for X-ray diffraction (Figure V.24).
Figure V.24. Crystals obtained with
a protein mix of CIN85-SH3C270-
328His6 and Cbl-b902-912 at 4ºC. Crystals were grown in (A)
30% PEG 4000, 100mM Na Citrate pH5.6, 200mM
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Amoniumm Acetate and (B) 25% PEG
4000, 8% Isopropanol, 100mM
Acetate.
1.1.3. Purification, characterization, crystallization and
structure of CIN85-SH3A2-58
In parallel to the SH3C structural studies, we tried the crystallization of the
CIN85-SH3A.
High overexpression of the soluble CIN85-SH3A protein was achieved in
Rosetta(DE3)pLys E. coli at 37ºC with 2xTY or SOC broth, induced with 1mM IPTG
for 4hr (see Figure V.25).
Figure V.25. Overexpression of CIN85-SH3A2-58His6 in E. coli
Rosetta(DE3)pLysS strain. Expression was achieved at 37ºC in LB,
2xTY and SOC broths and induced with 1mM IPTG. 17% SDS-PAGE
gel of total cells; lane 7, molecular weight marker (M); lanes 1 and 2:
expression in LB, uniduced (u) and induced (i); lanes 3 and 4:
expression in 2xTY, uniduced (u) and induced (i); lanes 5 and 6:
expression in SOC, uniduced (u) and induced (i). Gel was stained with
Coomassie Brilliant Blue.
The purification protocol used was modified
slightly from the previous ones. Low concentration of
imidazole (15mM) was also used in the sonication buffer
to avoid binding competition of contaminants when
loading the sample in the nickel charged chelating
column.
In this case, two washing steps were performed: a first wash with 15mM
imidazole and 400mM NaCl, which were reduced to 2mM Imidazole and no sodium
chloride in the second washing step. The protein was subsequently eluted at 261mM
Imidazole in a 2 to 500mM imidazole gradient (Figure V.26). The SH3A protein
came out very concentrated but contaminated with high molecular weight proteins,
so that an anion exchage step was required. As mentioned before, the sample
needed to be diluted to a calculated Imidazole concentration of 20mM, prior to
loading into the Q sepharose column. The protein was eluted at 17.5mS/cm
conductivity in the anion exchange chromatrography step, which indicated similar
global electrostatic properties as observed for CIN85-SH3C (Figure V.27). After a
final purification step in gel filtration separation, maximum purity was achieved, and
the protein was recovered at an elution volume of 70.72ml (Figure V.28),
corresponding to a monomeric state (7.0kD) according to the column calibration
(theoretical weight calculated to be 7.8kD).
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Figure V.26. Purification of CIN85-SH3A2-58His6 in a nickel charged Chelating HiTrap column. The
blue line indicates UV280 absorption of eluted sample, and the green line represents the percentage of
buffer in pump B, which indirectly indicates the EDTA concentration (0-100mM). The SH3A is eluted in a
broad peak with 261mM average Imidazole concentration. The indented polyacrylamide Coomassie
Brilliant Blue stained SDS-PAGE gel, shows collected fractions of the elution peak where the SH3A
protein was eluted together with some high molecular weight contaminants.
Figure V.27. Purification of CIN85-SH3A2-58His6 in a Q HP HiTrap column. The blue line indicates
UV280 absorption of eluted sample, and the green line shows the elution buffer percentage, which
indirectly indicates the NaCl concentration (0 to 0.5M). CIN85-SH3A2-58His6 elutes in a broad peak starting
at 17.5mS/cm, which indicates that this SH3A construct has similar superficial electrostatic characteristics
as CIN85-SH3C270-328His6. The indented SDS-PAGE gel stained with Coomassie Brilliant Blue, shows
elution peak corresponding to SH3A elution.
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Figure V.28. Pure CIN85-SH3A2-58His6. Elution of CIN85-SH3A2-58His6 in a Superdex 30 16/60 gel
filtration column at a volume of 70.72ml, which corresponds to a molecular weigh of 7.0kD and
approximates to the theoretical weight of the monomeric SH3A (7.8kD). Analysis of the elution peak in an
SDS-PAGE shows high purity of the eluted sample.
Spectrometry analyses were carried out for the pure sample as described
previously for SH3B and SH3C. Mass spectrometry assay revealed a molecular
weight 135Da lower than the theoretical weight of the CIN85-SH3A2-58His6 construct,
which, as discussed for CIN85-SH3C270-328His6, could be accounted for the loss of
the initiation methionine.
Figure V.29. Circular Dichroism (CD) spectra of CIN85-SH3A2-58His6 (A) and detail of the
Monodimesional Nuclear Magnetic Resonance (NMR) spectra of the CIN85-SH3A2-58His6 protein
construct between 6 and 5.5 ppm. Peaks in this region indicate the presence of β-sheet folding
structure (B).
CD and NMR 1-D spectra showed similar patterns as shown previously for
SH3B and SHC (Figure V.6, Figure V.8, Figure V.13, Figure V.14, and Figure V.29), so
that homogeneity and folding state of the sample was also confirmed. This protein
sample seemed to show appropriate conditions to be used for crystallization assays,
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since the homogeinity and purity of the sample is crucial for the acquisition of well-
ordered crystals.
We also aimed to characterize the binding of the SH3A domain to the Cbl-b
peptide by means of energetic terms. We wanted to obtain data on the stoichiometry
of the binding, for which purpose we used titration microcalorimetry method to do the
binding measurements.
To achieve accurate calculated affinity and stoichiometry values, we used
the YCbl-b903-912 peptide, which was tagged with a tyrosine residue in the N-
terminus, so that concentration could be empirically determined by means of UV280
absorvance measurement (see Materials and Methods section 4.2).
CIN85-SH3A2-58His6 domain showed a clear binding to the Cbl-b peptide,
with an affinity of 11.06μM (K = 9.04E4  9.4E3M) (Figure V.30), which differs by
more than four times with the results obtained in the fluorescence studies of
SH3C:c-Cbl binding. This may indicate a higher affinity of SH3C to c-Cbl than that of
SH3A to Cbl-b. In spite of that, the affinity values are in agreement with results
published by Kowanetz and co-workers (Kowanetz, Szymkiewicz et al. 2003) so that
a more plausible explanation to such difference could be that values are more
reliable in this assay, given that the peptide concentration could be measured with
higher precission.
Figure V.30. Isothermal titration calorimetry
measurements of complex formation between CIN85-
SH3A (50μM) and the Cbl-b peptide (545μM). The upper
panel shows the raw data of each titration. The optimal fits for
these two titrations give a KD of 11.6μM and an N of 0.75 in a
one-site binding model.
We repeatedly obtained a non-equimolar
stoquiometry, of 1:0.75 protein to peptide when
data were analyzed in a one site system (Katrin
Rittinger’s lab reported a 1:0.61 soichiometry in
the same experiment). This result opened a new
door for the recognition of polyproline peptides by
SH3 domains.
The fact that the proteins were able to
bind the Cbl peptides also increased our hope on
the acquisition of crystals of the SH3:Cbl peptide
complexes.
Subsequently, the pure CIN85-SH3A protein sample was concentrated by
ultracentrifugation with Amicon Ultra or Vivaspin filter devices with a 3000 or 5000Da
membrane pore. Crystallization assays of the uncomplexed protein were set at
10.3mM (81mg/ml) protein concentration in 96-well plate format under the sitting
drop vapor diffusion method. All crystallization commercial screens available in the
laboratory were set at 22ºC and 4ºC with 1.6μl drops and initial crystal hits were
observed at D4 and B9 Hampton conditions (0.1M Citrate pH 5.6, 20% PEG 4000,
20% Isopropanol and 0.2M Magnesium Acetate tetrahydrate, 0.1M Sodium
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cacodylate pH 6.5, 30% 2-Methyl-2,4-Pentanediol) and at C9 Wizard I condition
(0.2M Lithium sulfate, 0.1M CAPS pH 10.5, 2M Ammonium sulfate).
No crystal optimization was needed, and a single crystal from original
Hampton condition B9 was used for solution of the structure. The crystal was
washed in stabilization solution with 20% Ethylene Glycol (20% Ethylene Glycol,
80mM Citrate pH5.6, 16% PEG 4000, 16% Isopropanol) and immediately flash
cooled under a nitrogen gas stream source. A dataset of 331 images of 0.5º rotation
each, with 2 minutes of exposure was collected.
Probably due to some crystal cracking during manipulation, two crystal
lattices could be distinguished in the diffraction patterns, and a high mosaicity (1.5º)
was observed when the data was processed (Figure V.31). The crystal showed
symmetry of a primitive tetragonal crystal, P43212 and maximum resolution of 2.2Å.
CIN85-SH3C coordinates were used as a search model for obtaintion of the
theoretical phases. With a cell volume of 166814Å2, only one molecule in the
asymmetric unit could be fit (Mathew’s coefficient of 2.81 and a calculated solvent
content of 56%). The correlation coefficient for a single solution from AmoRe after
rigid body refinement from the translation search was 35.6 and the R value was
51.4%.
Figure V.31. Image of CIN85-SH3A2-58His6 crystal
diffraction. This image corresponds to a diffraction
exposure of 2 minutes in a 0.5º oscillation in phi, with
maximum resolution at 2.2Å. A very mosaic diffraction
pattern was detected as well as two crystal lattices
diffraction patterns from the crystal cracking.
The structure showed the same β-
barrel folding described for the SH3C, where
the hydrophobic nucleus has isoleucines in
place of Lys273, and Val294 in SH3C (Iso5
and Iso26 in SH3A), and an asparagine
instead of Leu296 (Asn28). All residues from
the binding core are conserved in SH3A
(Figure V.32).
Figure V.32. Alignment of CIN85 SH3A and SH3C sequences. Conserved residues from the
hydrophobic nucleous are indicated with pink boxes and conserved residues in the binding core are
indicated with green boxes.
Nevertheles, in this crystal, electron density for the His-tag could only be
detected for the first histidine residue, probably owing to its flexible nature. The
beginning of the tag did not seem to be pointing towards the direction of any of the
binding pockets of the crystallographically symmetry related SH3 domains though.
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1.1.3.1. Structure of CIN85-SH3A2-58:Cbl-b902-912 complex
c-Cbl had been shown to bind preferentially to the N-terminal SH3 domain of
CIN85 (Kowanetz, Szymkiewicz et al. 2003; Tibaldi and Reinherz 2003). Thus, the
structure of CIN85-SH3A in complex with a Cbl peptide did seem as a good
objective to pursuit.
Observations obtained from the crystallization of the constructs of the CIN85
SH3C and SH3A domains, and data obtained in the laboratory in related projects,
allowed us to infer that the decrease in the number of residues foreign to the original
protein sequence, together with the increase in the protein concentration favors its
crystallization.
In order to avoid the possible interference of the histidine tag and the
process of removal of any affinity tag used for the purification process, we decided
to express the protein untagged and purify it by the traditional ammonium sulfate
step precipitation method. For that purpose, the CIN85-SH3A was cloned in the
pET-29b vector with a stop codon at the end so that the Open Reading Frame
(ORF) did not include the His-tag.
Figure V.33. Overexpression of CIN85-SH3A2-58 tga. The CIN85-SH3A2-58 tga was grown
in E. coli Rosetta(DE3)pLysS strain at 37ºC in 2xTY broth and induced with 1mM IPTG. A
4-22% SDS-PAGE of total cells is shown; lane 1: molecular weight marker (M); lane 2,
uninduced (u) and lane 3: induced (i). Gel was stained with Coomassie Brilliant Blue.
Optimal expression of the pET29b/CIN85-SH3A2-58 tga clone
was achieved in 4 to 6 hours in Rosetta(DE3)pLysS E. coli cells
induced with 1mM IPTG, in 1L cultures with 2xTY medium (see Figure
V.33). Cell pellets were resuspended in Tris buffer (see Table IV.5) with
5ml of buffer per gram of cells, and frozen under liquid nitrogen. These
cell pellets were thawed under ice and sonicated for five minutes and
membrane traces were discarded by high speed centrifugation (16100 xg). Due to
the extremely high solubility of the protein, we were able to salt-out the majority of
the protein contaminants at 70% w/v ammonium sulfate concentration (see Figure
V.34). The soluble fraction was further purified and partially desalted in a
hydrophobic interaction chromatography step with a 50 to 0% (NH4)2SO4 gradient
(Figure V.35). A very pure fraction was collected and subsequently concentrated
with an Amicon 5kD filter to a volume between 1.5 and 2ml for loading into a
Superdex 75 16/60 column. The protein behaved as a monomer in the gel filtration
chromatography (Figure V.36).
Figure V.34. 4-23% polyacrylamide gradient SDS-PAGE shows the
(NH4)2SO4 precipitation of CIN85-SH3A2-58 tga. Lane 1: Molecular weight
marker (M); Lane 2: sample precipitated (ppt) with 50% ammonium sulfate;
Lane 3: supernantant (s/n) from 50% ammonium precipitation; Lane 4: sample
precipitated (ppt) with 70% ammonium sulfate; Lane 5: supernantant (s/n) from
70% ammonium precipitation. Sample recovered after salting out with 70%
ammonium sulfate is visibly pure.
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Figure V.35.
Purification
of CIN85-
SH3A2-58 tga
by
hydrophobic
interaction
chromatogra
phy. The blue
line in the
chromatogra
m indicates
UV280
absorption of
eluted
sample, and
the green line
represents
the
percentage of
buffer, from
which the
ammonium sulfate concentration can be inferred. The SH3A is eluted in a broad peak starting at 40%
(NH4)2SO4 concentration. The indented 4-23% polyacrylamide Coomassie Brilliant Blue stained SDS-
PAGE gel, shows main collected fractions of the elution peak where the SH3A protein was eluted
together with some high molecular weight contaminants.
Figure V.36. Pure CIN85-SH3A2-58 tga. Elution of CIN85-SH3A2-58 tga in a Superdex 75 26/60 gel filtration
column at a volume of 227.62ml, which corresponds to a molecular weigh of 10.6kD and approximates to
the theoretical weight of the monomeric SH3A (6.8kD). Analysis of the elution peak in 4-23%
polyacrylamide gradient SDS-PAGE shows high purity of the eluted sample.
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It is worth mentioning that a large amount of the expressed SH3 protein
precipitated with the E. coli contaminants in the bulk salt precipitation step, and
therefore we obtained a much lower yield compared to the affinity chromatography
purifications, with a final harvested amount of aproximately 2mg of protein per
culture Litre. However, the high purity of the sample was optimal for macromolecular
crystallization.
Pure protein was concentrated to more than 7.4mM (50mg/ml) and mixed
with the different proline rich peptides in ratios that varied from 1:2 to 1:3.
Commercial crystallization screens were set at 22ºC for crystallization trials.
Crystals of CIN85-SH3A2-58 tga:Cbl-b902-912 complex were obtained with a
mixture of the pure protein and the peptide in a 1:2.5 protein:peptide ratio. Final
concentration of the protein in the 1μl drops (0.5:0.5μl protein:reservoir solutions)
was calculated to be of 7mM (47mg/ml).
In the initial crystallization Wizard screening by the sitting drop vapor
diffusion method, 18 conditions were found to give crystals (Figure V.37). The large
number of crystallization conditions allowed us to select for the best alternative, so
that reproduction of crystals was attempted for those conditions that gave well
structured crystals. Fine screening conditions were selected based on the
crystallization solution composition (avoiding difficult to handle compounds, such as
volatile agents) and geometric structure of the crystals grown in such conditions
(aiming for those crystals big enough for X-ray diffraction and with stable visual
appearance). Like so, we aimed to work on crystals with high probability of being
protein crystals and not salt crystals and avoided possible space groups
corresponding to the ones in which uncomplexed CIN85 SH3 domains had
previously crystallized.
Figure V.37. Crystals of of
CIN85-SH3A2-58 tga obtained at
22ºC. Crystallization conditions
were: (A) 2.0M (NH4)2SO4, 0.1M
Tris pH 7.0, 0.2M Li2SO4 ;(B)
20% (w/v) PEG-3000, 0.1M
Citrate pH 5.5; (C) 1.0M Sodium
Citrate, 0.1M Cacodylate pH 6.5;
(D) 1.2M NaH2PO4/0.8 M
K2HPO4, 0.1M CAPS pH 10.5,
0.2M Li2SO4; (E) 2.0M (NH4)2SO4
CAPS pH 10.5, 0.1M Li2SO4; (F)
1.0M Sodium Citrate, 0.1M
Imidazole pH 8.0; (G) 1.26M
(NH4)2SO4, 0.1M Tris pH 8.5,
0.2M Li2SO4; (H) 30% (w/v) PEG-
3000, 0.1M CHES pH 9.5; (I)
1.0M K/Na Tartrate, 0.1M CHES
pH 9.5, 0.2M Li2SO4; (J) 20%
(w/v) PEG-8000, 0.1M Tris pH
8.5, 0.2M MgCl2; (K) 2.0M
(NH4)2SO4, 0.1M Cacodylate pH 6.5, 0.2M NaCl; (L) 20% (w/v) PEG-3000, 0.1M Tris pH 7.0, 0.2M
Ca(OAc)2; (M) 1.0M Sodium Citrate, 0.1M CHES pH 9.5; (N) 1.26M (NH4)2SO4, 0.1M HEPES pH 7.5; (O)
1.0M Sodium Citrate, 0.1M Tris pH 7.0, 0.2M NaCl, (P) 0.8M NaH2PO4/1.2 M K2HPO4, 0.1M Acetate pH
4.5; and (Q) 1.0M K/Na Tartrate, 0.1M Tris pH 7.0, 0.2M Li2SO4.
A B C D E
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78 Results
Crystals used for the solution of the protein complex structure were grown at
22ºC by the hanging drop vapor diffusion method in 0.8M Sodium Citrate, 0.1M Bis-
Tris pH 7.5 and 0.2M NaCl (Figure V.38). Prior to flash cooling under a nitrogen gas
stream, crystals were transferred to a stabilization solution of 10% (v/v) Ethylene
Glycol, 0.54M Sodium Citrate, 0.09M Bis-Tris pH 7, and 0.18M NaCl.
Figure V.38. Crystals of of CIN85-SH3A2-58 tga used for structure determination. Crystals were
obtained at 22ºC in 0.8M Sodium Citrate, 0.1M Bis-Tris pH 7.5 and 0.2M NaCl.
A 2.0Å resolution was achieved in the diffraction of the crystal and a dataset
was collected at 100ºK on a rotating anode with 180 seconds exposure and a 0.75º
rotation per image. Diffraction data were reduced using the HKL package, DENZO
and SCALEPACK. Crystals of CIN85-SH3A2-58 tga:Cbl-b belong to space group P65.
Unit cell parameters were as follows: a = b = 51.158, c = 97.472, α = β = 90º, γ =
120º and a completeness of 99.7%.
Initial phases for CIN85-SH3A:Cbl-b were calculated from a single AMoRe
molecular replacement solution with correlation coefficient of 24.1% and R-factor of
47.6% by using the previously solved isolated CIN85-SH3A2-58His6 structure as
search model. A resolution range of 15-3.5Å was used all throughout the molecular
replacement process. The integration radius for the rotation function was 22.84Å,
corresponding to 51% of the longest dimension of the model (model dimensions:
44.54 x 18.01 x 39.64Å). For both the rotation and translation functions the 20
orientations/translations with at least one half the highest correlation coefficient of
the search value were used. The correct molecular replacement solution was found
for the primitive hexagonal P65 space.
With a Mathew’s coefficient of 2.34 and a calculated solvent content of
47.42% for two molecules in the asymmetric unit, a model of the solution found was
generated with the program AMoRe. The correlation coefficients after rigid body
refinement of the solutions from the translation search were 32.4 and 30.4, and the
R values were 51.1 and 50.4%, respectively.
Analysis with SFcheck software from the CCP4 program suite allowed us to
detect a twinning fraction of 31.3% in the cumulative intensitive distribution graph
(see
Figure V.39).
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Figure V.39. Statistic analysis of the intensities of twinned
data obtained with the Sfcheck tool. The experimental
distribution for CIN85-SH3A:Cbl-b is plotted as a dotted line and
the expected cumulative distributions of the parameter H, which is
a fuction of the two twin-related intensity measurements in
hemihedral twinning. Cumulative distributions for non-
centrosymmetric reflections with twinning fractions of 0.0, 0.1, 0.2,
0.3, and 0.4 are represented as solid lines. The experimental
distribution deviates from the theoretical for untwined data (0.0),
and it resembles the most to the expected cumulative distribution
of data with a twinning fraction of 0.3.
The twinning effect in crystallography refers to a disorder in the crystal
growth that is composed of different crystal domains in different orientations but
related in a particular and well defined manner. Most of the time, this change in the
domain orientation does not have an effect in the crystal that can be recognized
macroscopically. Usually, this twinning effect prevents the right determination of the
structure, unless it is detected and avoided or corrected.
There are essentially two categories of twinning, the epitaxial and the
merohedral. In the first case, twinning can be detected in the diffraction pattern,
given that each domain in the crystal has a different diffraction pattern, and so, data
from the predominant domain can sometimes be integrated by rejecting reflections
of the other domain.
In the case of the merohedral twinning, which was our case, it refers to the
special cases where crystal lattices7 from the different domains superpose in three
dimensions (Figure V.40). In our case, the unit cell of the space group to which the
crystal belongs to, has two equal size sides and two equivalent angles so that these
sides can be interchanged without deforming the crystal and allowing an organized
crystal growth. However, the internal symmetry is changed (the asymmetric unit
would not be oriented in the same way in both domains). The most common case of
merohedral twinning is the hemihedral twinning, which includes only two orientations
of the domains.
Figure V.40. “A hypothetical example of merohedral
twinning in which separate domains with P3 symmetry are
related by a 180° rotation about an axis parallel to the
threefold crystallographic axis. The arrows represent
individual molecules. The twinning is hemihedral, having two
distinct domain orientations. The domain boundaries are
indicated by bold lines.” Taken from Yeates, T.O. (1997) (Yeates
1997).
As a result of a hemihedral twinning, the observed diffraction pattern
appears to be normal, but each of the observed intensities contains contributions
from two reflections that are related by the twinning operation but are
crystallographically independent. In order to be able to correctly handle these data it
7 Regular geometrical arrangement of points or particles over a 2 or 3 dimension periodic
pattern.
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is necessary to know the twinning fraction contained in the crystal (Yeates
1997){http://www.doe-mbi.ucla.edu/Services/Twinning/intro.html}. There are several
tools that can be used nowadays for the calculation and application of this fraction
for the processing of the data and solution of the structure. We used the approach of
estimating the proper partitioning of each observed intensity into the two
components from the separate domains. For each pair of twin-related observations
the true crystallographic intensities can be calculated and recovered from the
measured values (Yeates 1997).
To correct the amplitudes of the CIN85-SH3A:Cbl-b .mtz data file we used
the Detwin program included in the CCP4 program suite applying a twinning fraction
of 30% to generate a new reflection data file for the refinement cycles. We first
attempted the refinement with Refmac cooperative software (Collaborative
Computational Project 1994), but unsatisfactory statistics were obtained. We then
proceeded to the refinement of the model with CNS (Brunger, Adams et al. 1998),
with which the statistics were notably improved. The final model was obtained by
combining cycles of rigid-body refinement and simulated annealing, and temperature
factors in CNS considering a twinning fraction of 0.305 for the operator k, h, -l,
alternating with manual model building using the programs Xfit and Coot V0.1.2-Pre-
1. Electron density was detected for only one molecule of the peptide in between the
two SH3 molecules. The peptide molecule was modeled manually using the
program Xfit (McRee 1999). Of the total 125 residues, residue 58 in one of the SH3
molecules (SH3AI) of CIN85-SH3A2-58 tga was disordered, and a total of 82 water
molecules were added to the final model.
Crystallographic refinement of the complexed structure against all data to
2.0Å resulted in R-factor of 22.1% and Rfree of 27.1% (for a random 5% subset of
all data). This cross-validation represents acceptable values, since the Rfree/R ratio
is close to unity (Tickle, Laskowski et al. 1998) (see Table V.2).
Table V.2. Crystallographic data collection and refinement statistics
of CIN85-SH3A2-58 tga:Cbl-b902-912 structure
CIN85-SH3A2-58 tga:Cbl-b902-912 (PDB 2BZ8)
Space group P65
Unit Cell Dimensions (Å) a=b=51.158, c=97.472
α=β=90º; γ=120º
Data range (Å) 20.0-2.0
Observations (unique) 18888 (9776)
Completeness (%) (last shell) 99.7(98.9)
Rsym
a (last shell) 0.062 (0.430)
Reflections F>0 (cross validation) 9742 (746)
Non-hydrogen atoms (solvent molecules) 1027(82)
Rcryst
b (Rfree
c) 22.1. (27.1)
R.m.s. bond length (Å) 0.007
R.m.s. bond angles (o) 1.334
a Rsym is the unweighted R value on I between symmetry mates.
b Rcryst = hklFobs(hkl)Fcalc(hkl)hklFobs(hkl)
c Rcryst is the crossvalidation R factor for 5% of reflections against which
the model was not refined.
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Unexpectedly, we observe a structure of a ternary complex that is
composed of two SH3 domains and a single Cbl-b peptide, as mentioned previouly.
Both CIN85-SH3A domains adopt the typical SH3 domain fold, a five stranded β-
sandwich, and overlap with one another with r.m.s. deviations between Cα atoms of
0.5Å. In this heterotrimeric complex, two SH3 domains contact the Cbl-b peptide,
which itself adopts a classical PPII helical conformation, through their conserved
ligand-binding surfaces (Figure V.41). However, one SH3 engages the peptide
resembling a class I interaction (defined as SH3 I), whereas the other binds on the
opposite side of the peptide ligand resembling a class II orientation (defined as SH3
II). Recognition of the peptide does not correspond to a canonical class I or class II
SH3-peptide binding in either case, since none of them binds the prolines from the
motif in the same way required for a canonical SH3:PPII binding. This is such that
the RT loop from SH3 I recognizes the N-terminal arginine in the Cbl-b polyproline
motif, and SH3 II does so with an arginine in the Cbl-b C-terminus, but none of the
SH3 molecules recognize proline residues with their hydrophobic pockets in the
canonical mode.
Figure V.41. Overall structure of the CIN85-SH3A:Cbl-b heterotrimeric complex. The electron
density map around the peptide is contoured at 2.5σ. The secondary structural elements and position of
the RT, n-Src and distal loops are indicated. The SH3A that binds the peptide in a class I-like orientation
is colored in blue, while the SH3A that recognizes the Cbl-b peptide in a class II-like orientation is shown
in grey.
Therefore, the recognition of an arginine in each extreme of the Cbl-b
peptide by the acidic pocket of each SH3 domain provides a different recognition
orientation to each SH3. As seen in Figure V.42, Arg909 interacts with both domains
simultaneously, occupying the position of a conserved proline in both hydrophobic
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pockets I and II from SH3 I and SH3 II respectively. The other hydrophobic pockets
establish typical hydrophobic contacts that have been described for canonical
binding. Therefore, we refer to the binding of SH3 I as class I-like binding, and class
II-like binding to the peptide recognition of SH3 II.
The peptide is thus sandwiched by the two SH3 domains in the ternary
complex and there are no significant direct SH3:SH3 contacts in the CIN85-
SH3A:Cbl-b structure. Only aspartic acid from the n-Src loop of each SH3 domain
(Asp33) and Arg54 establish Van der Wals contacts, that don’t interfere in the
peptide binding and this indicates that the heterotrimer formation is mediated almost
exclusively by the peptide binding.
Figure V.42. Schematic representation of
the protein-peptide contacts between the
Cbl peptide and CIN85-SH3A. The Cbl-b
peptide is represented in blue, and residues
from CIN85-SH3A in black. Black dashed
lines denote hydrogen bonds and black
rays, hydrophobic interactions. The SH3
domain which the residue belongs to is
indicated in parentheses: A stands for class
I-like SH3 and B for class II-like SH3.
Complex formation between the Cbl-b peptide and either SH3 domain buries
928Å2 (SH3 I) or 715Å2 (SH3 II). These values are comparable to those of other
SH3 domain:peptide structures. Specific interactions via peptide side chains are only
made by Arg904 and Arg911 from Cbl-b at the extreme N and C termini of the
peptide with Asp16 and Glu17 of each RT loop of each CIN85-SH3A molecule (see
Figure V.42). Argines 904 and 911 are thus responsible for the binding orientation of
each SH3 domain in the ternary complex.
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Figure V.43. Detail of the CIN85-SH3A:Cbl-b heterotrimeric structure. Prolines 906 (A) and 910 (B)
from the Cbl-b peptide make hydrophobic contacts with phenylalanines 8 and 52 in SH3 II (left) and SH3 I
(right). The peptide is shown in white with oxygen atoms in red and nitrogen atoms in blue, and SH3 I and
II are shown in blue and grey, respectively.
Hydrophobic contacts are made by Pro906 and Pro910 from Cbl-b with
conserved phenyalalnine residues 8 and 52 from hydrophobic pocket I of each SH3
domain (SH3 II and SH3 I, respectively; see Figure V.43), whereas Pro908 is
surrounded by hydrophobic residues from hydrophobic pocket II of SH3 II in the
CIN85-SH3A:Cbl-b complex (Tyr10, Trp36, Pro49 and Phe52; see Figure V.44).
Figure V.44. Detail of the hydrophobic pocket II in SH3
II of the CIN85-SH3A:Cbl-b heterotrimeric structure.
Proline 908 from the Cbl-b peptide makes hydrophobic
contacts with Tyr10, Trp36, Pro49 and Phe52 from CIN85-
SH3ASH3 II. The peptide is shown in white with oxygen
atoms in red and nitrogen atoms in blue, and SH3 II is
represented with grey sticks.
Several hydrogen bonds are formed by
backbone carbonyl oxygens of the peptide to
side chains of either SH3 domain. The indole
rings from Trp36 from each SH3 domain
hydrogen bonds the carbonyl oxygen from Cbl-
b Pro905 in the class I-like recognition, and the
carbonyl oxygen from Arg909 in the class II-
like orientation (see Figure V.42).
Interestingly, Lys907 from the Cbl peptide plays a central role since it is the
only residue that makes simultaneous contacts with both SH3 domains through
hydrogen bonds from its backbone carbonyl to the side chain amides of each Asn51
in CIN85-SH3A (see Figure V.42). These contacts are pseudo-symmetrical and the
backbone carbonyl of Lys907 constitutes the pseudo dyad axis of these interactions.
Accordingly, equivalent interactions are established by Arg904 and Arg911 as well
as Pro905 and Arg909 from Cbl-b (Figure V.45).
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Figure V.45. Comparison of the SH3 I:Cbl-b and SH3 II:Cbl-b interfaces from the CIN85-SH3A:Cbl-b
heterotrimer complex. Surfaces of CIN85-SH3A domains engaging the Cbl-b peptide in a class I-like
orientation (blue, left) and in a class II-like orientation (grey, right) are shown. The Cbl-b peptide is
represented in sticks, and its residues are indicated. Binding pockets are indicated with arrows.
We therefore observe that essential residues in the interaction appear to
mantain a symmmetrical distribution. Key to the CIN85-SH3A recognition are Cbl-b
arginines 904 and 911 that are recognized by the RT loops of each SH3 domain,
and which are determinant for the SH3 orientation in this novel heterotrimer
arrangement.
Validation of the quality of the model of the CIN85-SH3A:Cbl-b complex was
undertaken with the program PROCHECK from the CCP4 program suite and web-
based tool MolProbity (Lovell, Davis et al. 2003). Analysis in both programs
indicated that 98.3% of the residues were in the allowed regions of Φ and ψ 
conformational space, with Glu32 and Asn42 from SH3 II as outliers (see Figure
V.46). These residues are located in the n-Src loop, which shows alternate
conformation probably due to its flexible nature. All the other geometrical parameters
were considered to have acceptable values.
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Figure V.46. Ramachandran plot of CIN85-
SH3A:Cbl-b structure validation in MolPrpb.
Asparagine 42 in the flexible n-Src loop from one of
the SH3A molecules (SH3A II, chain B) is in a
disallowed region, and Glu32 in the same SH3 and
Asn42 from the other SH3 molecule are in the
generously allowed regions. All the other residues
(97%) are in the favored and allowed regions.
V.1.1.3.1.1. Crystallization and structure of the
CIN85-SH3A2-58:CD2324-333 complex
All CIN85/CMS SH3 domains can recognize the only atypical PxxxPR
proline-arginine motif present in the C-terminal region of Cbl and Cbl-b (Kowanetz,
Szymkiewicz et al. 2003; Kurakin, Wu et al. 2003). Additional cellular proteins, such
as CD2 receptor (CD2), BLNK, AIP1/Alix or ZO2 contain this consensus sequence
and have been reported to be CMS/CIN85 natural partners in mammalian cells
(Dikic 2002; Kowanetz, Szymkiewicz et al. 2003). However, except for ZO2, they all
lack the N-terminal arginine responsible for class I-like recognition of Cbl-b by
CIN85-SH3A (Arg904Cbl-b), and hence, class I-like recognition of the peptide in the
interaction of the N-terminal SH3 of CIN85 with these partners would not happen in
the same manner as we observed in the CIN85-SH3A:Cbl-b complex.
Analysis of the CIN85-SH3A:Cbl-b structure has identified key component
residues in the peptide that might help predict binding of other peptides. The study
of the molecular recognition of the CIN85-SH3A domain and other binding partners
might shed light to the differences of the multiprotein complex formation and their
functional biological consequences in the cell. Therefore, we wanted to explore the
molecular interaction of the SH3A domains from CIN85 and a CD2 derived peptide
containing the already identified PxxxPR motif, which differs from the recently
extended CIN85 binding motif in Cbl.
Both N-terminal CIN85 and CMS homologue SH3A domains have a
stronger affinity for CD2 with similar dissociation constants (KD 100μM) than the rest
of CIN85 and CMS SH3 domains (Dustin, Olszowy et al. 1998; Hutchings, Clarkson
et al. 2003).
The N-terminal SH3 domain from CIN85 was crystallized in complex with a
CD2 derived peptide in order to compare its structure with the one previously solved
in the laboratory of CMS-SH3A:CD2 complex. It would also help us analyze the
effect of the absence of the N-terminal arginine of the Cbl motif on the molecular
recognition of CIN85.
Crystals were obtained with a 1:3 purified CIN85-SH3A2-58 tga protein:CD2324-
333 peptide mix, by the sitting drop vapor diffusion method in 200:100nl drops
(protein solution:reservoir solution) set with a Cartesian liquid handling robot, and
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grown at 22ºC. Very big and twinned crystals were obtained in three conditions (see
Figure V.47), so surgery had to be practiced on them to be able to separate
manageable sized single crystals feasible for crystal diffraction. Best diffraction was
measured with a crystal grown in 0.1M CHES pH 9.5, 1M Na Citrate in the reservoir
solution.
Figure V.47. Crystals of CIN85-SH3A2-58 tga:CD2324-333 complex. Crystals were grown by the sitting drop
vapor diffusion method in (A) 30% (w/v) PEG-3000, 0.1M CHES pH 9.5, (B) 2.0M (NH4)2SO4, 0.1M
Cacodylate pH 6.5, 0.2M NaCl and (C) 1M Na Citrate, 0.1M CHES pH 9.5.
Crystals were flash cooled in the reservoir solution, since it did not form ice
and no additive was needed in the reservoir solution for cryo protection. They were
stored in a liquid nitrogen container to be diffracted in a synchrotron radiation
source, at the ID23-1 beamline at the ESRF facility in Grenoble, France. Initial
diffraction pattern showed resolution beyond 1.0Å, but the rapid crystal decay only
allowed us to collect a final dataset up to 1.2Å resolution to ensure good quality
data. A dataset of 180 images of 1º rotation in phi, with 0.05 seconds exposure was
collected (Figure V.48).
Figure V.48. Diffraction Image
from the crystal of the complex
of CIN85-SH3A2-58 tga:CD2324-333.
This image corresponds to a
diffraction exposure of 0.05
seconds in a 1º oscillation in phi,
with maximum resolution at 1.2Å.
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Data reduction was carried out with Scala
software. Tails correction with width of 0.1 and a
slope of 10 was applied and standard deviation
correction values of 0.045 for full reflections and
0.035 for partials. Self rotation Function showed
peaks for three binary axes (see Figure V.49),
indicating that the data were of a P222 space group.
Systematic absences were detected every two
reflections in the k and l axes. Accordingly, data was
re-indexed with an “l, -k, h” transformation matrix,
following the IUCr (International Union of
Crystallography) convention (Figure V.50).
Figure V.49. Self Rotation function of data from CIN85-
SH3A:CD2 crystal. Peaks corresponding to three binary axes
(one perpendicular to the plane, and two on the plane), all related
by 90º rotation, can be observed.
Figure V.50. Plotted I/σ vs each reflection
axis: (A) h, (B) k, (C) l. Systematic
absences are detected every two reflections
in the k and l axes. This condition is not
contemplated in any orthogonal space
group condition. In order to fullfil the IUCr
convention of P222 space group, a
transformation with an l, -k, h matrix should
be applied, so that systematic absences are
in the h and k axes.
Structure was solved by molecular replacement using Phaser (ccp4), and a
pdb file containing only an SH3 domain from the CIN85-SH3A:Cbl-b complex (PDB
2BZ8, chain B). Then, automated model building was carried out with ARP/wARP. A
very defined electron density area was already observable in this model, where the
peptide should bind (see Figure V.50). After a quick refinement with Refmac5,
superposition of the CMS-SH3A:CD2 dimeric complex (PDB 2J7I), previously solved
in the laboratory by Gabriel Moncalián, allowed the positioning of the CD2 peptide in
the CIN85 model (see Figure V.53). The peptide did not adopt the same
88 Results
conformation as in the CMS-SH3A:CD2 model, which was corrected after some
cycles of manual (with Coot v0.1.2-pre-1) and automatic refinement (with Refmac5).
Figure V.51. Preliminary model of the CIN85-SH3A:CD2 complex after automatic rebuilding in
ARP/wARP. A difference map contoured at 1.0 around the peptide is shown in a blue mesh, where
residues from the CD2 peptide can readily be deduced (ie. Arg332 and Pro331 side chains become
evident at the bottom of the picture). The CIN85-SH3A molecule is shown in sticks.
Extensive refinement was carried out in Coot and Refmac5 until R and R-
free factors reached values of 20.8% and 20.9%, respectively. Pdb and mtz files
were transformed into ins and hkl files (the latter conserving the same Free-flags)
using ShelxPro to continue the refinement in Shelxl.
First refinement in Shelxl (Sheldrick, Schneider et al. 1997) was performed
without the addition of water molecules and only up to 2.5Å, resolution was then
increased to 1.5Å and finally to 1.2Å.
Due to the differences in the bulk solvent model used in SHELXL, the
difference between the R and the R-free values increased, compared to the values
obtained in Refmac5 (Sheldrick, Schneider et al. 1997) (Table V.3).
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Table V.3. Crystallographic data collection and analysis of CIN85-
SH3A2-58 tga:CD2324-333 structure
CIN85-SH3A2-58 tga:CD2324-333
Space group P212121
Unit Cell Dimensions (Å) a=26.9, b=39.6, c=65.5
α=β=γ=90º
Data range (Å) 39.6-1.2
Observations (unique) 153684 (22657)
Completeness (%) (last shell) 100 (99.8)
Rsym
a (last shell) 0.076 (0.652)
Reflections F>0 (cross validation) 21498 (1159)
Non-hydrogen atoms (solvent molecules) 657 (89)
Rcryst
b (Rfree
c) 0.207 (0.228)
R.m.s. bond length (Å) 0.010
R.m.s. bond angles (o) 1.391
a Rsym is the unweighted R value on I between symmetry mates.
b Rcryst = Σhkl[[Fobs(hkl)]-[Fcalc(hkl)]]/Σhkl[Fobs(hkl)]
c Rcryst is the crossvalidation R factor for 5.1% of reflections against which
the model was not refined.
Validation of the geometric parameters in MolProbity (Lovell, Davis et al.
2003) showed all residues in the favored residues with Asn42 as an outlier, which is
highly exposed to the solvent (Figure V.52). Lys58 and Gln11 were identified as
rotamer outliers differing slightly from the standard values.
Figure V.52. Ramachandran plot of CIN85-
SH3A:CD2 structure validation in MolProbity
webtool. 98.6% of the residues are in the favored
regions, with only Asn42 from the n-Src loop as an
outlier.
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Figure V.53. Overall structure of the CIN85-SH3A:CD2 heterodimeric complex. The electron density
map around the peptide is contoured at 1.0σ. The secondary structural elements are indicated. CIN85-
SH3A, which binds the CD2 peptide in a class II-like orientation is colored in grey.
Not surprisingly, the structure of the complex showed a 1:1 recognition of
the peptide, where the SH3 recognizes the CD2 peptide in a class II-like recognition
mode (Figure V.53). The first proline in the motif, Pro327, occupies the hydrophobic
pocket II, and Arg330 occupies the position in hydrophobic pocket I, usually filled by
a proline in a classical class II recognition (Figure V.54).
Figure V.54. CIN85-
SH3A:CD2 interface. Surface
of CIN85-SH3A domain is
colored in grey, and the CD2
peptide is shown in green
sticks. Peptide residues are
indicated and SH3 binding
pockets are pointed out with
arrows.
Arginine 332 in the C-terminal end of the CD2 peptide hydrogen bonds
Asp16 and Glu17 in the CIN85-SH3A RT loop, similarly to Cbl-b Arg911 in the
CIN85-SH3A:Cbl-b complex. Hydrogen bonds with carboxylic oxygens from the
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peptide main chain are found between Arg330 and the Trp36 indole ring, and
Leu328 and Asn51 side chain, as Cbl-b Lys907 and Pro910, respectively, in the
SH3 II from the CIN85-SH3A:Cbl-b structure. Hydrophobic interactions described in
the hydrophobic pocket II from the class II-like SH3 domain in the heterotrimeric
structure are found as well with Pro329 in the dimeric complex with the CD2 peptide.
CD2 proline 327 also establishes hydrophobic interactions with CIN85
phenylalanines 8 and 52.
We therefore observe that recognition of the CD2 peptide by CIN85-SH3A is
equivalent to class II-like recognition of the Cbl-b peptide. Such that interacting
residues CD2 Arg332, Pro329 and Pro327 play the same role as Cbl-b Arg911,
Pro908 and Pro906 in the class II-like interaction in the heterotrimer complex of
CIN85-SH3A:Cbl-b complex.
2. CMS
CIN85 and CMS are homologous proteins that have a similar domain
distribution in which the main difference is the presence of several putative actin
binding sites in CMS, that are absent in CIN85. They share 40% sequence identity
(according to sequence alignment with ClustalW), and conserved residues are
contained in the SH3 domains, in the proline-rich region and in the CC domain,
which has led to the assumption that these proteins are members of the same family
and share similar functions.
However, they display a differential expression pattern. CIN85 have been
reported to be ubiquiotiously expressed, mainly in brain, whereas the mouse
ortholog of CMS, CD2AP, isn’t expressed in either brain, kidney nor lung (Kirsch,
Georgescu et al. 1999; Take, Watanabe et al. 2000). They also seem to have
different affinities for their different partners. It has been observed that c-Cbl binds
preferentially to SH3B in CMS and binding to its SH3C is not detected. However, all
SH3 domains from CIN85 bind c-Cbl, being the N-terminal domain the preferred one
(see Figure V.55).
Figure V.55. Binding of c-Cbl peptide to CMS-SH3A
and CMS-SH3B monitored by collisional
quenching of CMS SH3 fluorescence. The change
in the fluorescence intensity of CMS-SH3A upon c-Cbl
binding () is larger than that of CMS-SH3B (●). An
equimolar mixture of CMS SH3A and SH3B ()
showed and average of SH3A and SH3B binding to c-
Cbl.
In order to understand the molecular details of the different members of the
CIN85/CMS family of adaptor molecules we wanted to compare the interaction of
these two adaptor molecules with Cbl.
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2.1. The N-terminal SH3 domain of CMS is the
closest to CIN85-SH3A
Alignment of CIN85-SH3A and CMS-SH3A domain sequences shows a
68% identity, and 20% strong similarity (according to Clustal alignment results; see
alignment in Figure V.56). SH3 domains B and C share 68% identity with 14%
strong similarity and 54% identity with 18% strong similarity, respectively. Hence,
SH3A was the best candidate for comparison of complexes.
Figure V.56. Sequence alignment of the N-terminal SH3 domains from CMS and CIN85. Identical
residues are shown in blue and conserved hydrophobic residues in light blue.
2.1.1. CMS-SH3A:Cbl-b complex
2.1.1.1. CMS-SH3A:Cbl-b902-912 structrure refinement
The structure of the CMS-SH3A domain in complex with the short Cbl-b
peptide was solved in the laboratory by Gabriel Moncalián at the end of his
postdoctoral stay and could not be completed.
Additional refinement was carried out with cycles of manual refinement in
Coot v0.1.2-Pre-1 and automatic refinement in Refmac5. In order to do so, the .cv
structure factor file used for refinement in CNS had to be transformed to an mtz file,
being very cautious on conserving the Free-flags from the .cv file. This way, we
would be able to continue the refinement from the last CNS model with unbiased
statistics. Refinement converged with 30 cycles using Babinet scaling and 10
previous TLS cycles with a TLS model containing only the SH3 domain and setting
the initial temperature factors to 25.
Final R and R-free values were improved to 19% and 21.8% respectively
(see Table V.4), and no significant geometry problems were detected under the
Procheck and the Whatcheck tests. All residues (68/68) were located in favored
regions of the Ramachandran plot (see Figure V.57). Other geometric parameters
showed acceptable values. Structure files were deposited in the Protein Data Bank
database with PDB code 2J6F.
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Table V.4. Crystallographic data collection and analysis
CMS-SH3A:Cbl-b902-912 (PDB 2J6F)
Space group I422
Unit Cell Dimensions (Å) a=66.51, b=66.51, c=67.78
α=β=γ=90º
Data range (Å) 20.0-1.7
Observations (unique) 205566 (8696)
Completeness (%) (last shell) 100.0 (99.9)
Rsym
a (last shell) 0.034 (0.269)
Reflections F>0 (cross validation) 8534 (465)
Non-hydrogen atoms (solvent molecules) 547 (49)
Rcryst
b (Rfree
c) 0.243 (0.277)
R.m.s. bond length (Å) 0.0055
R.m.s. bond angles (o) 1.58
a Rsym is the unweighted R value on I between symmetry mates.
b Rcryst = Σhkl[[Fobs(hkl)]-[Fcalc(hkl)]]/Σhkl[Fobs(hkl)]
c Rcryst is the crossvalidation R factor for 5% of reflections against which the
model was not refined.
Figure V.57. Ramachandran plot of CMS-SH3A:Cbl-b
structure complex validation in MolProb program. There
are no residues in disallowed regions and 96.2% of them are
in the favored regions and 2 residues in the allowed regions.
Figure V.58. Self Rotation function of data from CMS-
SH3A:Cbl-b crystal. Peaks corresponding to two binary axes
and a quaternary axis can be observed.
This crystal showed an I422 symmetry (see rotation function in Figure V.58),
and the structure of the complex displays one CMS-SH3A molecule bound to a
single Cbl-b peptide in the asymmetric unit. However, we observed that the peptide
lies perpendicular to a crystallographic 2-fold axis. Thus, electron density maps
show an average of two orientations for the peptide (Figure V.59). Final refined B
factors for the peptide, considering occupancy of 0.5 for each orientation, do not
differ significantly from the B factors of the CMS-SH3A interacting residues (~25Å2).
The double orientation of the peptide is possible, because crystallographic contacts
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are exclusively established by CMS-SH3A molecules. The model could not be
constructed for CMS-SH3A residues 1 and 59–62, since they were disordered and
thus not visible in the electron density maps. Cbl-b residues 902, 903, and 904 were
also disordered, meaning that they did not participate directly in the interaction with
the CMS-SH3A domain.
Figure V.59. Stereo view of symmetrically related peptides from the CMSA:Cbl-b heterotrimeric
complex shows the double orientation of the peptide. In this representation one of the symmetrically
related peptides is colored in grey and the other one is colored in light blue. SigmaA weighted electron
density map around them is contoured at 1.0σ.
A deeper anlalysis of the structure showed us that a heterotrimer can be
formed by symmetry. As we observed in the CIN85-SH3A:Cbl-b complex, the
structure of the CMS-SH3A:Cbl-b complex consists on a ternary complex composed
of two CMS-SH3A molecules binding,
in opposite orientations, to a single
Cbl-b peptide molecule (Figure V.60).
However, in contrast to CIN85-
SH3A:Cbl-b complex, one CMS SH3A
domain recognizes Lys907 in the N-
terminus of the peptide (as opposed to
Arg904 in the case of CIN85-SH3A),
similarly resembling a classical class I
orientation, and the second SH3
domain recognizes Arg911 in the C
terminus, resembling class II binding
(the same way that it was described
for the CIN85-SH3A:Cbl-b complex;
Figure V.61).
Figure V.60. Overall structure of the CMS-
SH3A:Cbl-b heterotrimeric complex. CMS-
SH3ASH3 I binds the peptide in a class I-like
orientation (shown in purple), and CMS-SH3ASH3
II recognizes the peptide in class II-like
orientation (shown in gray). The Cbl-b peptide is
shown in light blue. The σA-weighted electron
density map around it is contoured at 1.0σ.
Elements of secondary structure and the
positions of the RT, n-Src, and distal loops are
indicated.
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The structure of the CMS-SH3A molecule also displays the typical SH3
domain folding of a five-stranded β-barrel. Such β-barrel is stabilized by the
hydrophobic nucleus, which is formed by the same residues as in CIN85-SH3A,
except that the conserved tryptophan (CIN85 Trp37) is a leucine in CMS (CMS
Leu38). The peptide, on the other hand, does not display a typical polyproline helix
but adopts an extended conformation instead.
The structure shows that CMS also has the ability to form heterotrimeric
complexes with a Cbl-b derived peptide, as we observed in the CIN85-SH3A
complex. In the heterotrimer arrangement, the interactions of theCMS-SH3ASH3 I
(class I-like orientation) and CMS-SH3ASH3 II (class II-like orientation) with the Cbl-b
peptide are almost identical with 941 and 827Å2 of buried surface, respectively.
However, the interacting surface of the two CMS-SH3A molecules is negligible. Only
54Å2 of the 3918Å2 total surface of each SH3 is shared, corresponding mainly to
side chains of Glu35 (from both CMS-SH3ASH3 I and CMS-SH3ASH3 II).
In this case, hydrophilic specific interactions via side chains are only made
by Lys907 and Arg911 at the N and C termini of the Cbl-b peptide with both Asp16
and Glu17 from CMS-SH3ASH3 I andCMS-SH3ASH3 II, respectively and Arg909 with
Glu35 from both CMS-SH3A molecules. Hydrophobic contacts in the class I-like
orientation are made by Cbl-b Pro910 with conserved residues of hydrophobic
pocket II. Hydrophobic pocket I in the class I-like binding is empty due to the limited
extension of the peptide. In turn, Cbl-b Pro906 and 908 are embedded within
hydrophobic pockets I and II, respectively in the class II-like orientation. Thus, Cbl-b
Pro908 and 910 occupy equivalent positions in the opposed SH3 domains of the
heterotrimer, as observed in the CIN85-SH3A:Cbl-b heterotrimer.
Figure V.61. Schematic representation
of contacts between CMS-SH3A and
the Cbl-b peptide (light blue). Residues
902, 903, and 904 from the Cbl-b peptide
were disorderer, and hence not visible at
the electron density map. Interactions and
residues from SH3 I are shown in purple
and in gray for SH3 II. Dashed lines show
hydrogen bonds (labeled with peptide-
protein distances in Å), and purple and
gray rays designate hydrophobic
interactions.
Additionally, there are
sequence-unspecific contacts
with peptide main chain atoms,
such as Pro910 and Lys907
carboxylic oxygens interacting,
respectively, with Asn52 from
each CMS-SH3ASH3 I and CMS-
SH3ASH3 II. Similarly, Pro908 and
Arg909 carboxylic oxygens
interact with Trp37 from each
CMS-SH3A.
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2.1.1.2. CMS-SH3A:YCbl-b903-914 structure
The crystal structure of the CMS-SH3A:Cbl-b902-912 complex called our
attention on the difference in the class I-like recognition of the Cbl-b peptide in
comparison with the CIN85 complex. The different orientation of the SH3 domains
did not allow any peptide residue to interact with the hydrophobic pocket I from the
SH3 I. Therefore, we aimed to study the full interaction of the SH3A from CMS with
a longer Cbl-b peptide extended in the C-terminal end.
Figure V.62. Crystals of the CMS-SH3A:YCbl-b903-914. These crystals were grown at 20ºC with 35%
PEG 3k, 0.1M Tris pH 6.5, 0.2M NaCl reservoir solution.
We crystallized the N-terminal SH3 domain of CMS in complex with the Cbl-
b derived peptide, two residues longer in the C-terminal end than the one used for
the crystallization of the CIN85-SH3A:Cbl-b902-912 and CMS-SH3A:Cbl-b902-912
complexes. As it was the case for CIN85-SH3A, CMS-SH3A was expressed
untagged and purified by ammonium sulfate precipitation. Crystals were obtained at
20ºC by hanging vapor diffusion method, with 1μl drops of a 1:1 protein mix at
8.1mM (60mg/ml) concentration and reservoir solution with 30% PEG 3kD, 0.1M
Tris pH 7, 0.2M NaCl (Figure V.62). Crystals diffracted to a 1.65Å resolution and
belonged to the I422 space group with a unit cell similar to the one calculated for the
previous CMS-SH3A:Cbl-b model, defined by a = b = 66.47, c = 68.06 and angles α
= β = γ = 90º (see Table V.5).
Figure V.63. Crystal of CMS-SH3A:YCbl-b903-914 complex, diffracted in the synchrotron radiation
source at the ESRF facility at beamline ID-14.
Two datasets were collected with a 0.934Å beam in the synchrotron
radiation source at the ESRF facility from a single crystal (Figure V.63), one with a
high resolution limit of 1.4Å and a second one to ensure complete collection of low
resolution diffraction (Figure V.64). Each image was of a 1º rotation with 1 second of
exposure. Data reduction was undertaken with Mosflm software, and scaled limiting
the resolution to 1.65Å for better statistics, with isotropic B-factors and standard
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correction protocol with SDadds of 0.03 for full reflections and 0.02 for partial
reflections (Scala, ccp4). A 99.9% completeness (with a maximum of 8 overloads
and bad spots in two images) was achieved with the processing of the high
resolution data, so that merging with the low resolution data was not necessary.
Figure V.64. Images of data collection of the crystal of the CMS-SH3A:YCbl-b903-914 complex with a
high resolution limit of 1.4Å (left) and 3.5Å (right).
In the 1.69-1.60Å shell, the Rsym increased from 44 to 70%, and the I/
decreased from 1.8 to 1.1. By limiting the resolution to 1.65Å we obtained
acceptable values of Rsym (56%) and I/ (1.4) in the last shell, and still reached a
99.9% completeness.
Molecular replacement using the CMS-SH3A:Cbl-b902-912 structure (PDB
2J6F) as a search model in Molrep gave an R-factor of 57% and a correlation
coefficient of 56.2%. A rigid body refinement in Molrep improved R values to 47.6%
for the R-factor and 69.8% for the correlation coefficient (with a contrast of 10.87
with the following best solution).
Refinement was carried out following the same refinement protocol that was
used for the solution of the complex with the CIN85-SH3A:Cbl-b902-912 complex.
Given that both crystals are isomorphous with only an extra 3% of the residues in
the new crystal, free flags were maintained from the previous CMS-SH3A:Cbl-b
structure. This was done so that the new model would not be flawed and,
additionally, comparison of the cross-validation of each structure would be
consistent.
The model converged after 110 cycles resulting in an R-factor of 22% and a
free R-factor of 27% (see Table V.5).
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Table V.5. Crystallographic data collection and analysis of CMS-
SH3A:YCbl-b903-914 structure.
CMS-SH3A:YCbl-b903-914
Space group I422
Unit Cell Dimensions (Å) a=b=66.471, c=68.058
α=β=γ=90º
Data range (Å) 47.57-1.65
Observations (unique) 118888 (3783)
Completeness (%) (last shell) 99.9 (98.3)
Rsym
a (last shell) 0.059 (0.056)
Reflections F>0 (cross validation) 8955 (519)
Non-hydrogen atoms (solvent molecules) 646 (519)
Rcryst
b (Rfree
c) 0.218 (0.270)
R.m.s. bond length (Å) 0.014
R.m.s. bond angles (o) 1.597
a Rsym is the unweighted R value on I between symmetry mates.
b Rcryst = Σhkl[[Fobs(hkl)]-[Fcalc(hkl)]]/Σhkl[Fobs(hkl)]
c Rcryst is the crossvalidation R factor for 5.5% of reflections against which the
model was not refined.
Validation of the structure with the MolProbity tool showed no outliers for
rotamers and neither in the Ramachandran plot (see Figure V.65). All other
geometrical parameters showed acceptable values.
Figure V.65. Ramachandran plot of CMS-SH3A:YCbl-
b903-914 structure complex validation with the
MolProbity web-based tool. All residues are in the
allowed regions, with 97.2% of them in the favored
regions.
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Figure V.66. CMS-SH3A:YCbl-b903-914 structure. The SH3 molecule is shown as a purple surface and
sticks. The Cbl-b peptide is represented in grey sticks in the class II-like orientatation only, with the
electron density map around it contoured at 1.0σ.A zoomed view of Arginine 912 from the peptide is
shown with a 40º rotation, where it can be readily observed that it is very disordered in the structure, and
no continuity in the electron density is detected.
Not enough electron density was observed for the C-terminal residues of the
peptide, disorder was detected starting in arginine 912 (see Figure V.66). Peptide
was constructed for the same number of residues that for the previous structure,
implying that interactions that take place in the first hydrophobic pocket of the class
I-like recognition are not essential for the heterotrimer formation.
2.1.1.3. CMS-SH3A binding to different length Cbl-b
derived peptides
Despite results obtained by the solution of the CMS-SH3A:Cbl-b
heterotrimeric structures, ITC experiments were performed to compare binding
affinity of CMS-SH3A to Cbl-b peptides of different lengths (YCbl-b903-912 and YCbl-
b903-914, performed twice for each of them).
Our results showed a marginal increase in the affinity of 3.25-fold with the
Cbl-b derived peptide two residues longer in its carboxy terminus (YCbl-b903-914).
Association constants (KAs) were calculated to be of 5.42x10
4 and 1.76x105 in a
one-site binding system. These values correspond to dissociation constants (KDs) of
18.4μM and 5.7μM for the short (YCbl-b903-912) and the long (YCbl-b903-914) Cbl-b
peptides, respectively. Both assays displayed a stoichiometry of 1:0.8 and the
enthalpic contributions to ΔG were practically the same in both cases (ΔH was
calculated to be -14.17 ± 1.23kcal/mol for the short peptide, and -12.08 ±
0.5kcal/mol for the long Cbl-b peptide).
These results show that the binding mechanism might not be affected by the
length of the peptide, since the stoichiometry and enthalpic contribution are the
same in both cases, and the affinity increase for the longer peptide is marginal the
contribution of the extra C-terminal residues to the interaction is hence considered to
be negligible.


DISCUSSION
"Science is the great antidote to the poison of enthusiasm and superstition."
Adam Smith
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VI. Discussion
1. CIN85
A grown interest in the study of CIN85 has arisen with new discoveries on its
implication in the regulation of important processes such as cell apoptosis, TKR
downregulation or lysosomal degradation. As mentioned before, EGFR
downregulation takes place upon CIN85-Cbl recognition.
We hoped that structural studies of CIN85:Cbl complexes would give us clues
on the regulatory mechanism that governs the endocytosis of the EGFR. All CIN85
SH3 domains interact with an atypical motif in Cbl proteins and other cellular
partners with different affinities (Kurakin, Wu et al.; Tibaldi and Reinherz 2003). This
suggests intrinsic structural signatures in the SH3 responsible for the divergence in
the affinities and selectivities.
1.1. CIN85 SH3 domains
Despite our efforts and other’s on the crystallization of multiple CIN85 SH3
domain protein constructs in complex with Cbl derived peptides (Katrin Rittinger’s
personal communication) as well as multiprotein complexes with different CIN85
partners, the only suitable fragments for structural studies do not go further than the
SH3 domains.
We have observed that crystallization of the individual SH3 domains of CIN85
depends directly on a low content of flexible fragments and high protein
concentration. We proved that removal of large flexible fragments together with a
drastic increment of the protein concentration (~10mM ≈ 90mg/ml) favored the ready
crystallization of the SH3 domains, individually or in complex with the short
polyproline peptides.
Sequence and structural alignment of the individual CIN85 SH3 domains shows
a high degree of conservation in the residues that form the hydrophobic core and
suggests a common fold. The structure of the individual CIN85 SH3 domains solved
in the laboratory (SH3A and SH3C) show that all conserved core residues (leu18,
Ile20 (usually Phe), Ile26, Ile29 (usually Val), Trp37, Gly39, Phe48 and Val538),
have the same side chain orientation in both SH3A and SH3C from CIN85.
Residues that have been identified as highly conserved and critical for peptide
binding in SH3 domains, such as Phe8, Tyr10, Trp36, Pro49, Asn51 and Phe52 are
totally conserved in sequence and structural conformation in bothFigure V.19 domains.
Additional residues involved in peptide binding but with lower positional entropy
adopt the same conformation in the hydrophobic pockets as well (Figure VI.1).
8 Residue numbering corresponds to CIN85-SH3A.
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Figure VI.1. Sequence alignment of all CIN85 and CMS SH3 domains. Sequence alignment of CIN85
SH3A and SH3C are shown with residue numbers indicated. Secondary structural elements are
illustrated on the top according to the CIN85 SH3 solved structures, where blue arrows represent β-
strands, the yellow helix represents the 310 helix, and grey lines represent the loops. CIN85-SH3B and
CMS SH3 domains sequence alignment is shown at the bottom, colored by hydrophobic conservation.
In the overall structures of CIN85 SH3A and SH3C domains we observe a high
conformational difference between the n-Src loops (Figure VI.2). A low sequence
and structural conservation observed in the n-Src loop of SH3 domains in general
correlates with a high variability in peptide conformation upon binding to the acidic
pocket of SH3 domains, as reported by Larson and Davidson (Larson and Davidson
2000). This is explained by the fact that acidic residues of the RT and n-Src loops
are responsible for binding specificity. Therefore, a higher variability among the SH3
sequence length and sequence conservation, as well as in structural arrangement,
has been repeatedly reported.
Figure VI.2. Structural alignment of CIN85-SH3A and CIN85-SH3C domains. CIN85 SH3A (blue) and
SH3C (green) are superposed and represented in cartoons. The 310 helix and the loops are indicated.
Main structural differences are located in the n-Src loop.
The difference in the n-Src loop sequence and conformation between CIN85
SH3A and SH3C (see Figs. Figure VI.1 and Figure VI.2) might be the reason for the
binding affinity divergence to the Cbl peptides observed in the fluorescence and ITC
studies, along with IP and TAIS (Target-Assisted Iterative Screening) studies
reported by Tibaldi and Reinherz (Tibaldi and Reinherz 2003) and Kurakin and co-
workers (Kurakin, Wu et al. 2003), respectively.
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1.2. CIN85-SH3A:Cbl-b structure
It has become evident that the interaction of c-Cbl or Cbl-b with adaptor
proteins such as CIN85 and β-PIX is an important mechanism to modulate and fine-
tune RTK endocytosis and degradation (Dikic and Giordano 2003; Lin, Yang et al.
2006; Schmidt, Husnjak et al. 2006). The same proline-arginine motif in the C-
terminal portion of c-Cbl or Cbl-b is recognized by SH3 domains present in CIN85
and β-Pix proteins, suggesting that they may act in a competitive fashion with
respect to Cbl. We reported in NSMB the crystal structure of the complex between a
Cbl-b proline-arginine peptide and the N-terminal SH3 domain of CIN85 (CIN85-
SH3A) described in the Results section V.1.1.3.1 (PDB ID 2BZ8), together with
Daniela Jozic and Katrin Rittinger’s structure of the complex between the Cbl-b
peptide and β-PIX (Jozic, Cardenes et al. 2005) (PDB ID 2AK5). Notably, the Cbl-b
peptide induces formation of a heterotrimeric complex consisting of two SH3
domains and one peptide molecule in both structures. Such heterotrimer formation
appears to be mediated solely by the peptide binding, forming a structure
arrangement that had not been described previously for SH3 domains.
Interactions made by the Cbl-b peptide with CIN85-SH3A and β-PIX are very
similar and the peptide binds simultaneously resembling a class I and a class II
orientations. Key to this unusual arrangement is the pseudo-symmetry of the peptide
sequence. Such pseudo-symmetry allows two arginines, Arg904 and Arg911, to
make equivalent hydrogen bonds with acidic residues in each SH3 domain from the
heterotrimer, and it is also preserved in c-Cbl owing to the presence of the
equivalent arginine residues, Arg822 and Arg829. Additionally, we observe that
prolines 906 and 910 in the Cbl-b peptide make equivalent hydrophobic contacts
with CIN85 phenylalanines 8 and 52 (β-Pix Phe15 and Tyr59) from each SH3 in the
heterotrimer. Some unspecific interactions with carboxylic oxygens in the main chain
are also found to be symmetrically related. We find hydrogen bonds established
between the tryptophans 36 of each SH3 domain (β-Pix Trp43) and carboxylic
oxygens of Pro905 and Arg909, which occupy the same position with respect to
each SH3. Moreover, asparagines 51 from each CIN85-SH3A in the heterotrimer (β-
Pix Asn58) hydrogen bond the Lys907 main chain oxygen, which occupies a central
position in the pseudo-symmetric peptide.
Thanks to the analysis of the high resolution structure of the CIN85-SH3A:Cbl-b
heterotrimer, the previously detected requirement of Arg911 for the CIN85:Cbl-b
binding (Kowanetz, Szymkiewicz et al. 2003; Kurakin, Wu et al. 2003) can be
rationalized by the extensive interactions between this residue and the SH3 domain.
Such interactions include a series of hydrogen bonds between the carboxylic
moieties of the acidic residues in the RT-loop of one of the SH3 domains (Asp16SH3 II
and Glu17SH3 II) and the guanidinium side chain of the C-terminal arginine, as well as
the stacking of its aliphatic portion against Trp36 in CIN85. Arg904, by contrast, has
not been previously recognized as important for complex formation with CIN85. Its
presence seems to define the multimerization state of the SH3:peptide complexes
and hence reveals why other ligands that also contain the PxxxPR motif, but lack the
N-terminal arginine, for instance Pak2 or CD2, bind with a 1:1 stoichiometry (Jozic,
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Cardenes et al. 2005). This was shown for CD2 in the CIN85-SH3A:CD2324-333
structure (Results Section V.1.1.3.1.1). Furthermore, it suggests that other targets of
CIN85 that lack the N-terminal arginine such as BLNK, the p85α subunit of PI3K,
ZO-2, TAFII70 or ASAP1 should preferentially bind in a 1:1 fashion (Figure VI.3).
Figure VI.3. Alignment of interacting sequences from CIN85
natural partners. Several polyproline-rich sequences containing
the PxxxPR motif from CIN85/CMS interacting molecules are
aligned. Hydrophobic residues are shown in conservation gradient
from blue to red. The prolines that interact with the hydrophobic
pockets I in the CIN85-SH3A:Cbl-b heterotrimer (Cbl-b Pro906 and
Pro910), and the C-terminal arginine responsible for the class II-
like interaction with the RT-loop (Cbl-b Arg911) are totally
conserved in all the partners. The N-terminal arginine responsible
for the CIN85:Cbl-b heterotrimerization is only present in c-Cbl and
Cbl-b proteins and two regions of the ZO-2 sequence.
Notably, ITC assays performed in collaboration
with Katrin Rittinger showed that mutation of this Cbl-b N-terminal arginine (Arg904)
does not appreciably change the apparent affinity of the peptide for CIN85-SH3A
(2.5±1.0 and 4.4±1.1μM for the Cbl-b wild type and R904A mutant peptides,
respectively), but changes the relative enthalpic and entropic contributions to ΔG (-
14.25±0.5 and -7.9±1.6kcal/mol) (Jozic, Cardenes et al. 2005). In contrast, binding
to β-PIX-SH3C-term is weakened ten-fold upon mutation of Arg904Cbl-b (from 14.0±3.5
to 140.0±30.0μM), indicating that, despite the similarity between the two structures,
there must be differences in the mechanism of complex formation.
Our results suggest that Cbl proteins may additionally contribute to the
formation of complexes needed for efficient EGF-receptor downregulation
(Bartkiewicz, Houghton et al. 1999) by simultaneously interacting with two CIN85
SH3 domains.
Experiments in collaboration with Yonathan L. Deribe and Ivan Dikic showed
that, in vivo, neither mutation of Cbl-b Arg904 nor that of Cbl-b Arg911 (or c-Cbl
equivalent residues Arg822 and Arg829) abolished heterotrimerization (see Fig. 4 in
Jozic et al. (Jozic, Cardenes et al. 2005); Appendix III, page 145 in this thesis). This
was done by immunoprecipitation (IP) of a Flag-tagged CIN85 construct containing
the three SH3 domains (FLAG-CIN85-3SH3), co-transfected together with wild type
(WT) CIN85 and different c-Cbl or Cbl-b mutants, all of them impaired in their ability
to homodimerize. Cbl-b-927 R904A mutant was impaired in its ability to mediate
formation of a complex between full-length CIN85 and Flag-CIN85-3SH3.
Moreover, N- and C-terminal arginines in the c-Cbl/Cbl-b CIN85 binding motifs
were mutated separately to determine their functionality in the binding to CIN85 and
receptor downregulation. Additionally, they mutated both arginines simultaneously.
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The amount of CIN85 co-precipitated with c-Cbl and Cbl-b proteins was quantified
and showed that mutation of the C-terminal arginines, Arg829 and Arg911, reduced
the interaction with CIN85 by approximately 80 and 60%, respectively, whereas
mutation of Arg822 or Arg904 reduced binding by ~25% (see Fig. 4 in Jozic et al.
(Jozic, Cardenes et al. 2005); Appendix III, page 145 in this thesis).
We know that efficient receptor endocytosis requires the formation of large
protein complexes surrounding activated receptors (Dikic 2003; Szymkiewicz,
Shupliakov et al. 2004). In order to investigate the role of these Cbl arginines
essential for the binding to CIN85, the downregulation rate of EGF receptors in cells
transfected with different Cbl mutants was measured. Mutation of either of the two
arginine residues resulted in a substantial decrease of the degradation of EGF
receptors, indicating that both play important roles in pathways controlling EGF-
receptor downregulation (see Fig. 4 in Jozic et al. (Jozic, Cardenes et al. 2005);
Appendix III, page 145 in this thesis).
These findings, together with biochemical and structural data on
heterotrimerization of CIN85 by c-Cbl and Cbl-b, pointed to an important and
previously unaccounted role of Cbl-b Arg904 and c-Cbl Arg822 in Cbl-mediated
clustering of CIN85 and controlling endocytic trafficking of EGF receptors.
It has already been shown that CIN85 contributes to receptor internalization by
clustering Cbl proteins via its three SH3 domains (Kowanetz, Szymkiewicz et al.
2003). However, our findings revealed yet another mechanism by which Cbl proteins
can contribute to the formation of signal competent complexes implicated in receptor
endocytosis.
Biochemical studies in cells clearly indicate that the proline-arginine motif in Cbl
can simultaneously accommodate two SH3 domains from separate CIN85
molecules and could thereby promote the formation of higher-order Cbl:CIN85
complexes. At present we cannot exclude that adjacent SH3 domains in CIN85 may
act in a similar manner and cooperate to bind a single ligand. Nevertheless, the
identification of Arg904 in Cbl-b as an additional binding surface for SH3 domains
explains how Cbl-mediated multimerization of CIN85 proteins occurs in vivo.
The physiological importance of these Cbl functions is likely to be relevant in
the assembly of multiprotein complexes during receptor downregulation
(Bartkiewicz, Houghton et al. 1999; Watanabe, Take et al. 2000; Kowanetz,
Szymkiewicz et al. 2003). Notably, the β-PIX-SH3 domain binds in the same manner
to Cbl proteins than CIN85. Thus, the competition of β-PIX and CIN85 for binding to
the same surface of Cbl may represent the basis for dissociation of Cbl away from
the activated EGF receptor upon activation of Cdc42:PIX complexes (Wu, Tu et al.
2003).
1.3. CIN85-SH3A:CD2 structure
Comparison of interactions of the N-terminal SH3 domain from CIN85 with
peptides derived from other natural partners was necessary to have a deeper
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knowledge of the interaction mode of this family of proteins, and the clustering
mechanism promoted by SH3:ligand complex formation.
Analysis of the CIN85-SH3A:Cbl-b structure predicted a 1:1 stoichiometry in
the CIN85-SH3A:CD2 binding, given that the N-terminal arginine participating in the
class I-like binding is missing in the CD2 motif. We crystallized the same CIN85 SH3
with a CD2 derived peptide (CD2324-333) containing the proline-rich PxxxPR binding
motif (KGPPLPRPRV, residues belonging to the motif are underlined) but lacking
the N-terminal arginine (where there is a glycine instead, shown in italics in the
peptide sequence).
The crystal structure showed a dimeric complex formed by an SH3 domain
that recognized the CD2 peptide in a Class II-like orientation, as expected. The CD2
peptide adopts the same conformation that the Cbl-b peptide in the trimeric complex,
except for the non-interacting N-terminal end, where it differs slightly. Interactions
with the peptide are equivalent to those observed in the CIN85-SH3A:Cbl-b Class II-
like interface. We observe that Arg332 in CD2 plays essentially the same role as
Arg911 in Cbl-b, establishing hydrogen bonds with the conserved acidic residues
Asp16 and Glu17 in the n-Src loop of the CIN85-SH3A.
This results further suggest that the N-terminal arginine found in the Cbl
proteins and others such as the ZO-2 tumor suppressor, can play an important role
in the heterotrimer formation. Hence, the multimeric complexes formed with these
partners that do not contain the N-terminal arginine will be different than those in
which the heterotrimer complex is formed. This differential complex formation might
yield different or modulated biological responses of the proteins involved.
2. CMS
In order to understand the molecular details of the different members of the
CIN85/CMS family of adaptor molecules we wanted to compare the interaction and
crystal complexes of these two adaptor molecules with Cbl and CD2 peptides.
2.1. CMS-SH3A:Cbl-b forms a heterotrimeric complex
with a differential recognition from CIN85-
SH3A:Cbl-b
The CMS-SH3A:Cbl-b crystal structures were used for comparative analysis
with the CIN85-SH3A structures. Superposition of CMS-SH3A:Cbl-b and CIN85-
SH3A:Cbl-b structures revealed that the overall structure of CMS-SH3A:Cbl-b (PDB
ID 2J6F) resembles the heterotrimer reported for CIN85-SH3A:Cbl-b (Jozic,
Cardenes et al. 2005), where one SH3 domain binds the Cbl-b peptide in a class I-
oriented fashion, whereas the second SH3 recognizes the peptide in the opposite
orientation (class II). Such similarity in the overall structures of the ternary
complexes provides a molecular explanation for a common role of Cbl in the
molecular mechanism of CIN85/CMS-mediated down-regulation of RTKs. Cbl might
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also participate in the clustering of CMS as reported for CIN85 and β-PIX (Jozic,
Cardenes et al. 2005). The Cα of the SH3 individual domains overlapped well with
one another (root mean square deviation, r.m.s.d., of 0.70Å for 57 residues). Main
differences were located within the n-Src and Distal loops. Nevertheless, the overall
CMS-SH3A:Cbl-b heterotrimer showed some important differences with respect to
CIN85-SH3A:Cbl-b. In particular, the orientation of the SH3 domains in CMS-
SH3A:Cbl-b differs from that of the SH3 orientations in CIN85-SH3A:Cbl-b with a
56.4º shift with respect to each other, revealing a distinctive recognition of the Cbl-b-
derived peptide for CMS or CIN85 (Figure VI.4).
Figure VI.4. Comparison of the CIN85-SH3A:Cbl-b and CMS-SH3:Cbl-b ternary complexes. A ribbon
representation of the SH3A domains of CIN85 (blue) and CMS (purple) in complex with the Cbl-b derived
peptide (represented in sticks). The SH3A from CMS binding in a class II-like fashion was generated
applying crystal symmetry operators. Complexes were superposed on SH3 II (class II-like; left). On the
left panel, the complex is oriented with the peptides in a vertical position, with the N-terminus at the top.
The complexes are rotated 90º towards the viewer to give the image on the right panel. Conformation of
side chains of the peptide residues that bind in a class II-like orientation is essentially the same in both
complexes.
The interactions corresponding to the class II-like orientation of the peptide
(CMS-SH3ASH3 II:Cbl-b) are conserved with respect to CIN85 (CIN85-SH3ASH3 II:Cbl-
b). As we have mentioned previously, Arg-911 determines the class II-like
orientation, and its importance in (CMS/CIN85):Cbl interaction has already been
described and proven (Kowanetz, Szymkiewicz et al. 2003; Kurakin, Wu et al. 2003).
The conserved heterotrimeric arrangement suggests it also plays a critical role in
CMS-SH3A:Cbl-b class II-like interaction. The only difference in the class II-like
recognition between both structures concerns Cbl-b Arg-909, which hydrogen bonds
with Glu35 from CMS and Asp33 in CIN85. However, significant differences in the
interaction surface between Cbl-b and CMS-SH3A or CIN85-SH3A are observed in
the class I-like orientation.
Residues forming the two hydrophobic binding pockets are highly conserved
between CMS-SH3A and CIN85-SH3A, yet the peptide residues interacting with
their SH3 I domains (class I-like) are different. Most differences are found in the
acidic pocket formed by the n-Src and RT loops. Comparison of the CMS-SH3A
(PDB code 2J6K, crystal structure solved in the laboratory by Mercedes Spínola-
Amilibia) and CIN85-SH3A uncomplexed crystal structures show no conformational
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changes in the n-Src and RT loops upon peptide binding (r.m.s.d. 0.3 and 0.7Å,
respectively, according to the DaliLite web-based tool (Holm and Park 2000)).
Therefore, differences observed between CMS-SH3A:Cbl-b and CIN85-SH3A:Cbl-b
are not due to conformational changes induced upon peptide binding.
When compared to the CIN85-SH3A:Cbl-b structure, we observe that the N-
terminus of the Cbl-b peptide adopts a different conformation that mostly reflects
changes in the class I binding orientation. A significant three-residue shift of the Cbl-
b peptide is observed (see Figure VI.5 and sections V.1.1.3.1 and V.2.1.1.1 for
details).
Figure VI.5. Comparison of the SH3 I:Cbl-b (class I-like) interface from CIN85-SH3A and CMS-
SH3A. Electrostatic potential surfaces of SH3 domains from CIN85-SH3A:Cbl-b (left) and CMS-
SH3A:Cbl-b (right) complexes that bind the peptide in a class I-like orientation are shown. The Cbl-b
peptides are represented in sticks, and their residues are indicated. Binding pockets are indicated with
arrows.
In CIN85, Asp16 and Glu17 from the RT loop hydrogen bond with Cbl-b
Arg904, (critical in the formation of the CIN85-SH3A:Cbl-b ternary complex);
however, in CMS-SH3A:Cbl-b, Arg904 does not participate in the interaction, and it
is Lys907 that interacts with the RT loop in the acidic pocket (Figure VI.5).
In addition, Cbl-b Arg909 in CIN85-SH3A:Cbl-b occupies a similar position to
Cbl-b Arg912 in the CMS-SH3A:Cbl-b structure, and hydrophobic pocket I is empty
in CMS-SH3ASH3 I, because the synthesized peptide ended at Arg912. Therefore, we
tested the affinity of a longer peptide (YCbl-b903-914) by microcalorimetry, and we
observed a marginal increase in the binding affinity. Even though there is certainly
room for accommodation of the next residue in the Cbl-b sequence (Thr913), no
electron density corresponding to Thr913 was observed in a 1.2Å refined CMS-
SH3A:Cbl-b complex structure with YCbl-b903-914 used as ligand. This might indicate
that, although these extra residues might favor the binding and gently increase the
affinity, the interaction with the SH3 domain is not strong and stable enough to be
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observed in the crystal. It also suggests that hydrophobic pocket I does not play an
important role in SH3A CMS mediated heterotrimer formation.
This three-residue shift in the class I orientation can be rationalized by
sequence and structural differences within the respective n-Src loops, which have
been reported to account for binding selectivity (Mayer 2001).With respect to the
CIN85 sequence, a leucine is inserted in CMS at position 32 that significantly
changes the overall conformation of the n-Src loop. In addition, Glu35 (Gly34 in
CIN85) hydrogen bonds Arg909 from the peptide. The N-terminal end of the peptide
faces opposite directions in each structure, and such displacement might be due to
the change in the conformation of the n-Src loop, given that Glu34 in CMS does not
allow the peptide to adopt a conformation similar to the one displayed in the CIN85-
SH3A:Cbl-b complex.
From the analysis of the CMS-SH3A:Cbl-b structures we were again able to
identify the importance of Cbl-b Lys907 and Arg911 for the interaction between the
SH3 domain and its ligand. Biochemical experiments, similar to those performed for
the CIN85:Cbl-b study, were carried out by Yonathan L. Derive in I. Dikic’s group to
see the importance of these residues in the context of full-length proteins expressed
in cells and the formation of the heterotrimeric complex in vivo.
To this end, HA-tagged Cbl-b wt, Cbl-b K907A, Cbl-b R911A, and Cbl-b
K907A/R911A point mutant proteins were overexpressed in HEK293T cells. We
observed that both Cbl-b Lys907 and Arg911 play important roles in the interaction
with CMS-SH3A, although the Cbl-b K907A mutation abrogated binding to a much
lesser extent than Arg911. Double mutation of both Cbl-b Lys907 and Arg911
abolished the binding almost completely (see Fig. 2 in Moncalián et al. (Moncalian,
Cardenes et al. 2006); Appendix III, page 154 in this thesis). Interaction through
equivalent residues in c-Cbl was also checked with equivalent mutant proteins (c-
Cbl K825A and c-Cbl R829A). Interestingly, a very similar profile of binding to Cbl-b
was observed (see Fig. 2 in Moncalián et al. (Moncalian, Cardenes et al. 2006);
Appendix III, page 154 in this thesis). The same effect was observed in the context
of the full length proteins through precipitation of Cbl-b and c-Cbl wt and mutant
proteins and detection of CMS (see Fig. 2 in Moncalián et al. (Moncalian, Cardenes
et al. 2006); Appendix III, page 154 in this thesis). These experiments reproducibly
showed the vital importance of these residues in binding to CMS.
The crystal structure of CMS-SH3A:Cbl-b suggested a different interaction
pattern in class I recognition compared with CIN85-SH3A:Cbl-b. Cbl-b Lys907 in
CMS-SH3A:Cbl-b occupies an equivalent position to Arg904 in the CIN85-
SH3A:Cbl-b structure. Therefore, we wanted to compare the relative importance of
Cbl-b Arg904 and Cbl-b Lys907 residues in binding to N-terminal SH3 domains from
CMS and CIN85. Immunoprecipitation assays showed that GST/CMS-SH3A was
able to bring down Cbl-b R904A as potently as wild type but pulled down Cbl-b
K907A only weakly. In sharp contrast, GST/CIN85-SH3A was able to pull down both
wild type Cbl-b and Cbl-b K907A mutant equally potently, with a slight reduction with
respect to Cbl-b R904A in accordance with a previous observation (Jozic, Cardenes
et al. 2005) (see Fig. 2 in Moncalián et al. (Moncalian, Cardenes et al. 2006);
Appendix III, page 154 in this thesis).
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The structure of CMS-SH3A:Cbl-b showed the formation of heterotrimers
involving two CMS N-terminal SH3 domains and one Cbl peptide in vitro. To check
whether the formation of CMS-SH3A:Cbl heterotrimers could also take place in vivo,
co-immunoprecipitation studies similar to those carried out for CIN85 were
performed, in which HEK293T cells were transfected with a FLAG-tagged construct
of CMS containing only the three SH3 domain regions, Myc-tagged full-length CMS,
and either c-Cbl-849 or Cbl-b-927 constructs that lack the ability to homodimerize.
Cells overexpressing c-Cbl-849 or Cbl-b-927 showed the ability to co-precipitate full-
length CMS using a FLAG antibody, indicating that Cbl is mediating the formation of
the heterotrimer in cells, as it was shown for CIN85. Point mutants of c-Cbl or Cbl-b
were otherwise significantly impaired in binding to CMS, corroborating the
importance of Lys907 and Arg911 for the CMS:Cbl-b interaction that was inferred
from the trimeric structure.
The importance of Cbl-b Lys907 is revealed by the fact that it is not conserved
for other CMS ligands. CD2 displays a leucine (Leu328) at the equivalent position,
which suggests that at least the class I type of interaction could be compromised
upon CD2 binding to CMS-SH3A. In fact, crystals of a dimeric form of a 1:1 CMS-
SH3A:CD2 complex on a class II type of interaction were obtained in the laboratory
by Gabriel Moncalián. Accordingly, ITC studies of the binding of CMS-SH3A and a
CD2 derived peptide showed a stoichiometry of 1:0.9 and a KD constant of 26.6μM
(data not shown, see Supplemental Materials). Unexpectedly, an additional
heterotrimeric crystal was also obtained in an independent crystal form. The
existence of the two molecular arrangements suggests a minimal energy difference
between the heterotrimeric and dimeric states that might have some biological
consequences in contrast to the predominant heterotrimeric complex formed by
CMS-SH3A:Cbl-b (PDB ID 2J6F).
3. CIN85 and CMS SH3 binding consensus motifs
Biochemical studies performed in collaboration with Ivan Dikic’s group
provided in vivo confirmations for the observed structures and the residues involved
in the binding between the SH3 domains and their ligands. Furthermore, we have
shown a differential binding for SH3 domains of CMS and CIN85 to Cbl-b. This is in
such a way that Cbl-b Arg904 is more important for binding and heterotrimer
formation with CIN85-SH3A than for CMS-SH3A, whereas the opposite holds true
for Cbl-b Lys907. In addition, it was also shown that Cbl mediates the formation of
heterotrimers in the context of full-length CMS. Cbl-mediated multimerization of
CMS and CIN85 proteins occurring in vivo suggests similar roles between both of
them, contributing to the formation of large protein complexes required for receptor
down-regulation. In spite of this, the differential Cbl molecular recognition between
the two adaptor molecules brings about severe consequences in the arrangement of
the SH3 domains. This distinct molecular arrangement might determine the overall
clustering of the various proteins implicated in the endocytosis of the receptor with
different implications in the biological roles.
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The CMS and CIN85 SH3A complexed structures unambiguously indicate that
residues involved in class I-like recognition are different from those involved in class
II-like. Taken together, these results indicate that consensus sequences should
indeed be considered independent for class I-like and class II-like recognition types.
Prolines not involved in binding of one of the orientations may though help in
providing the polyproline type II helix character by interaction of their δ carbons with
the preceding residue and hence hindering that residue from adopting helical ψ
angles (Bochicchio and Tamburro 2002). Nevertheless, the overall motif is similar to
the one described by Kowanetz et al. (Kowanetz, Szymkiewicz et al. 2003)
(PxP/AxPR), and another structure of CMS-SH3A:Cbl-b P908A at 1.9Å resolution
solved by Gabriel Moncalián (unpublished results) confirmed that the same
heterotrimerization is possible with Pro908 replaced by an alanine. It has been
shown that some other hydrophobic residues could be present at this position
without significantly affecting the interaction, such as isoleucine, found in the Pak
polyproline motif (Hoelz, Janz et al. 2006). Thus, a more specific consensus motif for
the heterotrimer formation could be narrowed down to RxPKxRPR in the case of
CIN85 (where the lysine and the first arginine could most probably be substituted by
a proline or a polar residue), and to PKxRPR for CMS (here the lysine and the
second arginine are probably interchangeable) (see Figure VI.6).
Figure VI.6. Cbl-b residues implicated in Class I-like and
Class II-like recognition by SH3A from CIN85 and CMS.
Cbl-b peptide residues observed in the CIN85-SH3A:Cbl-b
and CMS-SH3A:Cbl-b ternary structures are sequence
aligned and colored by hydrophobicity conservation, in a
purple to blue gradient. Residues implicated in class II-like
binding are indicated with black boxes. The positions that they
occupy in the SH3 (Hydrophobic pocket I, (I), Hydrophobic
pocket II (II) and Acidic pocket (A)) are indicated with arrows,
black for class II-like and red for class I-like.
Analysis of the CIN85 and CMS binding motifs and the interactions that take
place in each binding surface suggests that class II-like might be more stable than
class I-like binding. Firstly, class II-like binding is conserved among most of the
CIN85 and CMS natural partners (see Figure VI.3), and the interactions that are
responsible for binding in this orientation are totally conserved in all of the structures
presented in this study. Secondly, the number of interactions regarding class I-like
recognition is lower than those of class II-like, as a matter of fact, hydrophobic
pocket I is empty in the SH3 I from CMS-SH3A.
Additionally, we can predict from the peptide sequence if the formation of the
ternary complex will take place. It has been demonstrated by mutagenesis studies
that the presence of basic residues in the motifs determines the formation of the
heterotrimer. As seen for the CIN85-SH3A:CD2 structure, the absence of the N-
terminal arginine in the motif of a specific partner predicts a 1:1 binding in a class II-
like orientation. Similarly, the absence of a basic residue in the position
corresponding to Cbl-b Lys907 might hamper the class I-like recognition in CMS.
However, the requirement of the basic residue for class I-like binding in CMS might
be of less importance, as shown for CMS-SH3A:CD2 by G. M (PDB IDs 2J6O and
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2J6I). This is also in agreement with the results obtained in the in vivo experiments,
where the quantification of the contribution of each basic residue in the motif
suggests a more predominant role of the arginine involved in the class II binding.
This effect has also been observed in binding to other partners that bear a
+xPxxxP+ motif. Mutation of R309 to alanine in the KVPTVPPR motif from Sprouty2,
which would correspond to the basic residue in the class II orientation, prevents
interaction with CIN85 (Haglund, Schmidt et al. 2005).
4. Other examples of Ligand Induced SH3
Oligomerization (LISO)
At the time we solved the trimeric structures, the CIN85:Cbl and β-PIX:Cbl
complexes were the only reported examples of ternary SH3-domain:peptide
complexes in which the peptide induces trimerization and potentially oligomerization
of its targets. Later on, we searched the database for possible examples of other
SH3 ternary complexes to compare them with ours.
A few months after our report, another heterotrimeric SH3:polyproline complex
in which two SH3 domains recognize the same polyproline peptide in opposite
orientations was reported. An AMAP1 derived peptide (AMAP1823-837;
skKRPPPPPPGhkrt) was found to mediate heterotrimerization with two Cortactin
SH3 domains (PDB ID 2DX1) (Hashimoto, Hirose et al. 2006).
Cortactin is a known CMS binding partner (Lynch, Winata et al. 2003), and this
complex has been found to link the EGFR endocytosis and the Actin cytoskeleton.
Moreover, AMAP1 mouse ortholog, ASAP1, was identified as a CIN85 effector
interacting through an ASAP1 PxxxPR motif. Such interaction enhances the EGFR
recycling and is believed to participate in the invasive machinery of several breast
cancer cells (Kowanetz, Husnjak et al. 2004).
In contrast to the CIN85-SH3A:Cbl-b complex, the SH3 domains of Cortactin
are related by a non-crystallographic twofold symmetry axis, positioning them
antiparallely to each other but displaced 53.9º in respect to the CMS-SH3A:Cbl-b
complex. The AMAP1 peptide adopts a left handed poplyproline type II (PPII) helix,
in which a classical class I binding motif can be deduced (RxxPxxP). However, in
the SH3 domain that recognizes the peptide in a class I orientation we find that both
Arg826 and Lys825 form hydrogen bonds with the conserved acidic residues in the
n-Src loop of Cortactin (Asp20 and Glu21), being the lysine the basic residue
interacting more strongly instead of the predicted Arginine.
The authors found that, in the Cortactin-SH3:AMAP1 complex, two residues
interact with both SH3 domains simultaneously. Pro829 is not only forming part of
the Class I interface but also of the Class II-like contacts through interaction with
Pro53 of both SH3 domains. Furthermore, Arg826, apart from the contact with the n-
Src loop of the Class I oriented SH3, establishes an atypical interaction with the
hydrophobic pocket I of the Class II-like recognizing SH3 by hydrogen bonding to
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Tyr56. This peculiarity is what explains the anti-parallel orientation of the SH3
domains.
In the other hand, the Class II recognition of the AMAP1 peptide is not a typical
one, since there is no basic residue in the C-terminus of the polyproline binding
motif, unlike CIN85-SH3A Class II-like Cbl-b recognition.
As we have seen for CMS-SH3A:Cbl-b, the heterotrimeric crystal structure can
be occluded by the crystallographic symmetry. It is possible that only through the
generation of the crystallographically related molecules in the model, the biological
heterotrimer is detected.
A fine search through the PDB database brings out another example of an SH3
heterotrimer that can only be generated by crystallographic symmetry, the Fyn-
SH3:3BP-2 complex (PDB 1Fyn), in which the crystallographic axis is located
perpendicular to the peptide.
The complex itself is atypical, since the peptide does not contain a classical
RxxPxxP motif, instead, the peptide does not contain a basic residue to interact with
the n-Src loop of the Fyn SH3. Unexpectedly, the residue interacting with the acidic
pocket is a proline (3BP-2 Pro202).
The 3BP-2 peptide itself adopts a general PPII structure with a kink at Ala203
(Musacchio, Saraste et al. 1994) that allows Pro202 to fit in the acidic groove.
Strikingly, if we compare the Fyn SH3 domain with the N-terminal SH3 domains from
CIN85 and CMS, there are not many residue changes that would provide the n-Src
loop from Fyn with a much higher hydrophobic character that would explain the
contact with a proline (see Figure VI.8). Nonetheless, conserved glutamic and
aspartic residues responsible for hydrogen bonding to the basic residue usually
present in the polyproline motif are also present in Fyn-SH3.
In the case of the Class II-like recognition, the acidic pocket is not interacting
with any residue from the peptide. Hydrophobic pockets I and II establish typical
contacts with prolines 205 and 208 respectively.
In the case of the Myosin tail region-interacting protein MTI1 (BBC1) SH3
domain complexed structure with the Proline-rich protein Las17 derived peptide, a
heterotrimeric structure is also observed. However, the orientation of the SH3
domains, and thus, the recognition of the peptide, differs highly from the CIN85 and
CMS SH3 heterotrimeric structures.
The structure of the peptide does adopt a PPII helix conformation and class II
recognition corresponds to the canonical, since Las17 R360 is hydrogen bonding
Asp23 in the n-Src loop, and hydrophobic grooves I and II are occupied by prolines
355 and 358 respectively.
On the other hand, Class I binding can be detected by the recognition of the
Las17 Arg350 by the Asp23 in SH3 I. In this case, it is virtually a classical class I
binding, except that there is an extra alanine residue in the motif (RxxxPxxP) that
allows arginine to bend towards the n-Src loop.
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4.1. Comparison of all LISO arrangements
Comparison of all ternary complexes shows that none of them superpose
perfectly (Figure VI.7). We wanted to identify sequence and structural features
common among all of the trimeric structures.
Class II binding motifs are the most conserved among the peptide sequences
(see bottom of Figure VI.8). Most important difference is that hydrophobic groove II
in CIN85 and CMS holds an arginine (instead of the proline or alanine typically found
in SH3:peptide binding) that is facing the n-Src loop and hydrogen bonds Glu35 in
CMS. We still refer to it as a hydrophobic pocket because it is comprised of several
conseved hydrophobic residues and for historical reasons. If we inspect CIN85 and
CMS SH3A structures, we observe that this is possible thanks to the fact that there
is a non-bulky residue at the top of the n-Src loop, CIN85 Gly35 and CMS Gly36.
This glycine is conserved among all SH3 domains of the CIN85/CMS family and it is
also present in the Cortactin SH3 sequence (Figure VI.1 and Figure VI.8).
Additionally, there are no interactions in the acidic pocket of Fyn and Cortactin SH3
II (Class II oriented SH3) domains, given that their binding peptides do not bear a
basic residue at their C-termini.
Most diversity is found in the class I binding. Here, all SH3 recognize an N-
terminal basic residue (Figure VI.8) except for Fyn-SH3. The presence of a tyrosine
residue in Fyn-SH3 n-Src loop (Tyr132) allows Pro202 from 3BP2 to establish
hydrophobic contacts, atypical in the SH3:peptide recognition. The most sticking
abnormality is the substitution of the proline residue by Cbl-b Lys907 in hydrophobic
pocket II of CIN85-SH3A. We could not find any structural difference that would
justify the preference of this amino acid at this position. The only difference in the
sequence with respect to the other SH3 domains that could affect binding of this
lysine residue is the presence of CIN85 Gln13 (Figure VI.1), which weakly hydrogen
bonds lysine Nz (3.9Å). However, this does not seem to affect the specificity of the
recognition of this residue, given that β-Pix-SH3 interacts with Cbl-b in the same
manner and holds a threonine residue at this position.
The hydrophobic pocket I in the class I binding, is interacting with a proline in all
cases, except for CMS, which is empty as discussed previously. Moreover, only two
residues typically separate n-Src and hydrophobic groove II interacting residues in
class I peptides. This is the case only for CIN85 and CMS SH3A. However, all other
peptides in the LISO structures hold four and three residues between the positive
residue (or 3BP2 Pro202) and the first consensus proline (see bottom of Figure
VI.8). In the case of Fyn and BBC1, this is possible provided that the second
residues in the motif sequence are very small (3BP2 Ala203 and Las17 Gly351) and
allows bending of the N-termini towards the acidic pocket. As discussed earlier,
AMAP1 Arg826 is also interacting with the acidic residues of the SH3 n-Src loop.
It appears to be evident that in order for the peptide-mediated heterotrimer to be
formed, the peptide needs to embed motifs resembling a classical class I and a
classical class II in its sequence. This is possible only if the peptide sequence is
pseudosymmetric. We have seen though, that class II is more stable in some cases
(CIN85 and CMS) and class I in others (Fyn, Cortactin and BBC1).
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Inspection of the SH3 sequences does not reveal any feature that provides an
explanation for the potentiality for the Ligand Induced SH3 Oligomerization, given
that important residues involved in peptide binding are all conserved, such as Tyr10,
n-Src acidic residues (Asp16 and Glu17 in CIN85), Trp36, Pro499 . In spite of this,
we have observed that variation in the sequence might tolerate interaction with
residues that differ from the consensus sequence motif, as discussed for Gly35 in
CIN85 or Gly36 in CMS, and Tyr132 in Fyn.
Figure VI.7. Comparison of SH3:polyproline heterotrimers. Ternary complexes of CIN85-SH3A:Cbl-b
(blue), CMS-SH3A:Cbl-b (purple), Fyn-SH3:3BP-2 (yellow), Cortactin-SH3:AMAP1 (red) and BBC1:Las17
(green) are superposed on the SH3 binding the peptide in a class I-like orientation (left) or in a class II-
like orientation (right). SH3 domains and polyproline peptides are represented as backbones. Two views
of a 90º rotation are shown.
9 Residues are numberer according to CIN85 sequence.
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Class I Class II
Figure VI.8. Sequence comparison of SH3:polyproline heterotrimer components. On the top,
structural sequence alignment is shown for SH3 domains and for peptides in their class I and class II
interfaces in the bottom. Residues are colored in a gradient of percent identity conservation. Basic amino
acids interacting with the acidic pocket (A) are indicated with red boxes, and residues interacting with
hydrophobic grooves I (I) and II (II) are indicated with black boxes. Black arrows indicate peptide residues
at positions in the hydrophobic pockets not classical for class I and class II binding respectively.
In summary, we can predict the possibility of SH3 heterotrimerization from
analysis of the peptide sequence, as we did for CIN85-SH3:CD2. Nevertheless,
there are no clear SH3 sequence features that can help us predict the formation of
such a molecular arrangement.
CONCLUSIONS
"Science knows no country, because knowledge belongs to humanity, and is the
torch which illuminates the world"
Louis Pasteur
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VII.a Conclusions
 Taken together, we have identified a novel molecular recognition mechanism for
SH3 domains where the same peptide is simultaneously recognized as Class I
and Class II. Such molecular arrangement suggests that separate consensus
motifs should be considered for each class orientation.
 This novel mechanism of Cbl mediated multimeric complex formation has
provided Cbl with a new molecular functional role in the EGFR downregulation.
Cbl acts as an adaptor that can accommodate multiple CIN85 molecules and
consequently promote the formation of higher-order Cbl-CIN85 complexes.
 We have detected crucial residues in the proline-arginine motif of c-Cbl and Cbl-
b involved in the formation of the ternary complex with the adaptor proteins
CIN85 and CMS and the assembly of the endocytic machinery that governs
downregulation of activated receptor tyrosine kinases.
 We have identified molecular features that might explain the slight differences in
CIN85/CMS recognition of Cbl.
 Our analysis of the structures of other ligand induced SH3 heterotrimers has
shown that formation of the trimeric complex in other cases is independent of
the PxxxPR motif in the ligand.
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VII.bConclusiones
 Hemos identificado un novedoso mecanismo de reconocimiento molecular para
los dominios SH3 donde el mismo péptide es reconocido simultáneamente
como clase I y clase II. Dicha disposición molecular sugiere que se deben
considerar diferentes motivos consenso de unión para cada orientación.
 Este novedoso mecanismo para la formación de complejos multiproteicos
mediados por Cbl ha proporcionado una nueva función a Cbl en su papel en la
regulación negativa del receptor EGFR. Cbl actúa entonces como una molécula
adaptadora que puede acomodar varias moléculas de CIN85 y
consequentemente promover la formación de complejos Cbl-CIN85 de mayor
magnitud.
 Hemos detectado residuos cruciales en el motivo de poliprolina-arginina en c-
Cbl y Cbl-b para la formación del complejo ternario con las proteínas
adaptadoras CIN85 y CMS, y para el ensamblaje de la maquinaria endocítica
que controla la regulación negativa de los receptores de tirosín-quinasa
activados.
 Hemos identificado características moleculares que podrían explicar las
diferencias diferencias en el reconocimiento de Cbl por CIN85 y CMS.
 Nuestro análisis de otras estructuras de heterotrímeros de SH3 inducidos por el
ligando (LISO: Ligand Induce SH3 Oligomerization) ha mostrado que la
formación de complejos ternarios en otros casos es independiente del motivo
PxxxPR en el ligando.
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X. Appendix II: Abbreviations
2xTY Two times Tryptone-Yeast broth
Amp Ampicillin
Ap Ampicillin
Cbl Cas-Br-M (murine) ecotropic retroviral transforming sequence
Cbl-b Cas-Br-M (murine) ecotropic retroviral transforming sequence b
CD Circular dicroism
CD2AP CD2-associated protein
cDNA Coding desoxyribonucleic acid
CIN85 Cbl-interacting protein of 85 kDa
CMS Cas ligand with multiple SH3 domains
DNA Desoxyribonucleic acid
E. coli Escherichia coli
EGF Epidermal Growth Factor
EGFR Epidermal Growth Factor Receptor
ESRF European Synchrotron Radiation Facility
IPTIG Isopropyl β-D-1-thiogalactoside
ITC Isothermal titration calorimetry
Kan Kanamycin
Kn Kanamycin
LB Lysogeny broth
MR Molecular replacement
NMR Nuclear magnetic resonance
o/n Over night
OD Optical density
ORF Open reading frame
PAGE Polyacrylamide gel electrophoresis
PDB Protein Data Bank
ppt Precipitate
rpm Revolutions per minute
s/n Supernatan
SDS Sodium Dodecyl Sulfate
SH3 Src Homology 3
SH3KBP1 SH3-domain kinase binding protein 1
TB Terrific broth
TCP Total cell pellet
TKR Tyrosine kinase receptor
UV Ultriviolet light
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w/v Weight to volume
β-MeOH β-Mercapto ethanol
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XI. Appendix III: Articles
“Scientific papers are important because without them scientists cannot get money
from the government or from universities.”
E. R. Schulman
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